CA2161230A1 - Novel peptide nucleic acids - Google Patents
Novel peptide nucleic acidsInfo
- Publication number
- CA2161230A1 CA2161230A1 CA002161230A CA2161230A CA2161230A1 CA 2161230 A1 CA2161230 A1 CA 2161230A1 CA 002161230 A CA002161230 A CA 002161230A CA 2161230 A CA2161230 A CA 2161230A CA 2161230 A1 CA2161230 A1 CA 2161230A1
- Authority
- CA
- Canada
- Prior art keywords
- site
- modified
- heterocycle
- group
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.
Description
094/~5477 PCT/~94/0014 NOVEL PEPTIDE NUCLEIC ACIDS
RELATED APPLICATION
This patent application is a continuation-in-part of application PCT EP92/01219, filed May 19, 1992. The entire contents of this application, which published November 26, 1992 as WO 92/20702, is incorporated herein by reference.
FIELD OF THE lNV~NllON
This invention is directed to compounds that are not polynucleotides yet which bind to comp]ementary DNA and RNA strands. In particular, the invention concerns compounds wherein naturally-occurring nucleobases or other nucleobase-binding moieties are covalently bound to a polyamide backbone.
BACRGROUND OF THE lNV~NllON
Oligodeoxyribonucleotides as long as 100 base pairs (bp) are routinely synthesized by solid phase methods using commercially available, fully automatic synthesis machines.
The chemical synthesis of oligoribonucleotides, however, is far less routine. Oligoribonucleotides also are much less stable than oligodeoxyribonucleotides, a fact which has contributed to the more prevalent use of oligodeoxyribo-nucleotides in medical and biological research directed to, for example, gene therapy or the regulation of transcription or translation.
The function of a gene starts by transcription of its information to a messenger RNA (mRNA) which, by interaction with the ribosomal complex, directs the synthesis W094/2~477 ~ 3 ~ PCT~B94/00142 of a protein coded for by its sequence. The synthetic process is known as translation. Translation requires the presence of various co-factors and building blocks, the amino acids, and their transfer RNAs (tRNA), all of which are 5 present in normal cells.
Transcription initiation requires specific recognition of a promoter DNA sequence by the RNA-synthesizing enzyme, RNA polymerase. In many cases in prokaryotic cells, and probably in all cases in eukaryotic cells, this recognition is preceded by sequence-specific binding of a protein transcription factor to the promoter.
Other proteins which bind to the promoter, but whose binding prohibits action of RNA polymerase, are known as repressors.
Thus, gene activation typically is regulated positively by transcription factors and negatively by repressors.
Most conventional drugs function by interaction with and modulation of one or more targeted endogenous proteins, e.g., enzymes. Such drugs, however, typically are not specific for targeted proteins but interact with other 20 proteins as well. Thus, a relatively large dose of drug must be used to effectively modulate a targeted protein. Typical daily doses of drugs are from 10-5-10-1 millimoles per kilogram of body weight or 10-3-10 millimoles for a 100 kilogram person. If this modulation instead could be 25 effected by interaction with and inactivation of mRNA, a dramatic reduction in the necessary amount of drug necessary could likely be achieved, along with a corresponding reduction in side effects. Further reductions could be effected if such interaction could be rendered site-specific. Given that a functioning gene continually producesmRNA, it would thus be even more advantageous if gene tran-scription could be arrested in its entirety.
Oligodeoxynucleotides offer such opportunities.
For example, synthetic oligodeoxynucleotides could be used as antisense probes to block and eventually lead to the breakdown of mRNA. Thus, synthetic DNA could suppress translation i~ vivo. It also may be possible to modulate the
RELATED APPLICATION
This patent application is a continuation-in-part of application PCT EP92/01219, filed May 19, 1992. The entire contents of this application, which published November 26, 1992 as WO 92/20702, is incorporated herein by reference.
FIELD OF THE lNV~NllON
This invention is directed to compounds that are not polynucleotides yet which bind to comp]ementary DNA and RNA strands. In particular, the invention concerns compounds wherein naturally-occurring nucleobases or other nucleobase-binding moieties are covalently bound to a polyamide backbone.
BACRGROUND OF THE lNV~NllON
Oligodeoxyribonucleotides as long as 100 base pairs (bp) are routinely synthesized by solid phase methods using commercially available, fully automatic synthesis machines.
The chemical synthesis of oligoribonucleotides, however, is far less routine. Oligoribonucleotides also are much less stable than oligodeoxyribonucleotides, a fact which has contributed to the more prevalent use of oligodeoxyribo-nucleotides in medical and biological research directed to, for example, gene therapy or the regulation of transcription or translation.
The function of a gene starts by transcription of its information to a messenger RNA (mRNA) which, by interaction with the ribosomal complex, directs the synthesis W094/2~477 ~ 3 ~ PCT~B94/00142 of a protein coded for by its sequence. The synthetic process is known as translation. Translation requires the presence of various co-factors and building blocks, the amino acids, and their transfer RNAs (tRNA), all of which are 5 present in normal cells.
Transcription initiation requires specific recognition of a promoter DNA sequence by the RNA-synthesizing enzyme, RNA polymerase. In many cases in prokaryotic cells, and probably in all cases in eukaryotic cells, this recognition is preceded by sequence-specific binding of a protein transcription factor to the promoter.
Other proteins which bind to the promoter, but whose binding prohibits action of RNA polymerase, are known as repressors.
Thus, gene activation typically is regulated positively by transcription factors and negatively by repressors.
Most conventional drugs function by interaction with and modulation of one or more targeted endogenous proteins, e.g., enzymes. Such drugs, however, typically are not specific for targeted proteins but interact with other 20 proteins as well. Thus, a relatively large dose of drug must be used to effectively modulate a targeted protein. Typical daily doses of drugs are from 10-5-10-1 millimoles per kilogram of body weight or 10-3-10 millimoles for a 100 kilogram person. If this modulation instead could be 25 effected by interaction with and inactivation of mRNA, a dramatic reduction in the necessary amount of drug necessary could likely be achieved, along with a corresponding reduction in side effects. Further reductions could be effected if such interaction could be rendered site-specific. Given that a functioning gene continually producesmRNA, it would thus be even more advantageous if gene tran-scription could be arrested in its entirety.
Oligodeoxynucleotides offer such opportunities.
For example, synthetic oligodeoxynucleotides could be used as antisense probes to block and eventually lead to the breakdown of mRNA. Thus, synthetic DNA could suppress translation i~ vivo. It also may be possible to modulate the
2 ~ ~
094/25477 PCTnB94/00142 genome of an animal by, for example, triple helix ~ormation using oligonucleotides or other DNA recognizing agents.
However, there are a number of drawbacks associated with triple helix formation. For example, it can only be used for 5 homopurine sequences and it requires unphysiologically high ionic strength and low pH.
Furthermore, unmodified oligonucleotides are unpractical both in the antisense approach and in the triple helix approach because they have short in vivo half-lives, they are difficult to prepare in more than milligram quantities and, thus, are prohibitively costly, and they are poor cell membrane penetrators.
These problems have resulted in an extensive search for improvements and alternatives. For example, the problems arising in connection with double-stranded DNA (dsDNA) recognition through triple helix formation have been diminished by a clever "switch back" chemical linking whereby a sequence of polypurine on one strand is recognized, and by "switching back", a homopurine sequence on the other strand can be recognized. See, e.g., McCurdy, Moulds, and Froehler, Nucleosides, in press. Also, good helix formation has been obtained by using artificial bases, thereby improving binding conditions with regard to ionic strength and pH.
In order to improve half life as well as membrane 25 penetration, a large number of variations in polynucleotide backbones has been undertaken, although so far not with the desired results. These variations include the use of methylphosphonates, monothiophosphates, dithiophosphates, phosphoramidates, phosphate esters, bridged 30 phosphoroamidates, bridged phosphorothioates, bridged methylenephosphonates, dephospho internucleotide analogs with siloxane bridges, carbonate bridges, carboxymethyl ester bridges, acetamide bridges, carbamate bridges, thioether, sulfoxy, sulfono bridges, various "plastic" DNAs, ~-anomeric 35 bridges, and borane derivatives.
The great majority of these backbone modifications led to decreased stability for hybrids formed between the W094/25477 ~ 3 ~ PCTnB94/00142 modified oligonucleotide and its complementary native oligonucleotide, as assayed by measuring Tm values.
Conse~uently, it is generally understood in the art that backbone modifications destabilize such hybrids, i. e., result in lower Tm values, and should be kept to a minimum.
OBJECTS OF THE INVENTION
It is one object of the present invention to provide compounds that bind ssDNA and RNA strands to form stable hybrids therewith.
It is a further object of the invention to provide compounds that bind ssDNA and RNA strands.
It is another object to provide compounds wherein naturally-occurring nucleobases or other nucleobase-binding moieties are covalently bound to a peptide backbone.
It is yet another object to provide compounds other than RNA that can bind one strand of a double-stranded polynucleotide, thereby displacing the other strand.
It is still another object to provide therapeutic, diagnostic, and prophylactic methods that employ such compounds.
SUMMARY OF THE INVENTION
The present invention provides a novel class of compounds, known as peptide nucleic acids (PNAs), that bind complementary ssDNA and RNA strands. The compounds of the invention generally comprise ligands linked to a peptide backbone. Representative ligands include either the four main naturally occurring DNA bases (i.e., thymine, cytosine, adenine or guanine) or other naturally occurring nucleobases ( e . g., inosine, uracil, 5-methylcytosine or thiouracil) or artificial bases (e.g., bromothymine, azaadenines or azaguanines, etc. ) attached to a peptide backbone through a suitable linker.
In WO 92/20702, we described PNAs wherein such ligands are linked to a polyamide backbone solely through aza 35 nitrogen atoms. The PNAs of the invention differ from those ~ 094l25477 21~ 1 ~ 3 ~ PCT~B94/00142 disclosed in WO 92/20702 principally in that their recognition moieties are linked to the polyamide backbone additionally through amido and/or ureido tethers.
In certain preferred embodiments, the peptide 5 nucleic acids of the invention have the general formula (I):
l L2 tn A 2 A "
Q ~B 1 1 ~G 1 2~B ~D 2-G ~~~~~~-- C n' ~D n (I) wherein:
n is at least 2, each of L1-~n is independently selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of C1-Cn is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R5 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and Rs is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each of Dl-Dn is (CR5R7)z where R5 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
30each of G1-Gn-1 is -NR3Co-, -NR3CS -, -NR3So- or -NR3So2-, in either orientation, where R3 is as defined above W094/25477 2~ ~ 23~ PCT~B94/OOln ~
each pair of Al-An and Bl-Bn are selected such that:
(a) A is a group of formula (IIa), (IIb) or (IIc) and B i s N or R3N+; or (b) A is a group of formula (IId) and B is CH;
R~ Rl ~1 R1 X
c r c c r ~ c _ _ p _l _ q `2 r 2 s (IIa) (IIb) R1 ~1 ~3 R1 Rf X R3 1l l 11 l --C Y C l C-- C Y C C--N--2 r 2 5 ~2 ~ 2 s (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each Rl and R2 is independently selected from the group consisting of hydrogen, (Cl-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen;
each of Gl-Gn-l is -NR3Co-, -NR3CS-, -NR3So- or -0 NR3So2-, in either orientation, where R3 is as defined above;
Q i s - CO2H, - CONR ' R ' ', - SO3H or -SO2NR' R ' ' or an activated derivative of -CO2H or -SO3H; and I is -NHR' ' 'R' ' ' ' or -NR' ' ' C (O) R' ' ' ', where R', R", R' ' ' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, ~ 094/2~477 2 ~ 6 ~ 2 3 ~ PCT~B94/00142 reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.
In certain embodiments, at least one A is a group 5 of formula (IIc) and B is N or R3N+. In other embodiments, A
is a group of formula (IIa) or (IIb), B is N or R3N+, and at least one of y or z is not 1 or 2.
Preferred peptide nucleic acids have general formula (IIIa) or (IIIb):
L L ~
( C H 2 ) I ( C H
R3N ~0 0 R3N/~o R h~( C H 2 ) ( C H 2~)N~L ( C H 2 ) k , ~ N mH - R
R7' R7 (IIIa) L L ~
( C H 2 ) I ( C H 2 ) I
o~N R 3 o~N R 3 R h ~( C H 2 )~ N ( C H 2~) ",lL ( C H 2 ) k N ~( ~ N H - R
_ _P n - -(IIIb) wherein:
each L is independently selected rom the group consisting of hydrogen, phenyl, heterocyclic moieties, 15 naturally occurring nucleobases, and non-naturally occurring nucleobases;
W094/25477 ~ 2 3 ~ PCT~B94/00142 each R7 is independently selected from the group consisting of hydrogen and the side ch~ n~ of naturally occurring alpha amino acids;
n is an integer from 1 to 60;
each of k, l, and m is independently zero or an integer from 1 to 5;
p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
Particularly preferred are compounds having formula (IIIa) or tIIIb) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), cytosine (C), guanine (G) and uracil (U), k and m are zero or 1, and n is an integer from 1 to 30, in particular from 4 to 20.
The peptide nucleic acids of the invention are synthesized by adaptation of standard peptide synthesis procedures, either in solution or on a solid phase. The synthons used are specially monomer amino acids or their activated derivatives, protected by standard protecting groups. The oligonucleotide analogs also can be synthesized by using the corresponding diacids and diamines.
Thus, the novel monomer synthons according to the invention are selected from the group consisting of amino acids, diacids and diamines having general formulae:
L L . L
A
E~c~B~D~F O r E~c/B~c/E O r F~C~B~D~F
( IV) (V) (VI ) wherein L, A, B, C and D are as defined above, except that any amino groups therein may be protected by amino protecting groups; E is COOH, CSOH, SOOH, SO2OH or an activated derivative thereof; and F is NHR3 or NPgR3, where R3 is as defined above and Pg is an amino protecting group.
~ 094/25477 ~ PCT~B94/00142 g Preferred monomer synthons according to the invention have formula (VIIIa)-(VIIIc):
o~/ CH2 ) I
HO~ CH2~N~CH2 O p7 (VIIIa) ( CH2 ) I
R 3 N /~0 HO,f~CH ` I CH2~NH2 (VIIIb) ( CH2 ) O~N R 3 HO~ CH2~N~CH
Op7 p (VIIIc) W094/2~477 ~ 3 ~ PCT~B94/00142 ~
or amino-protected and/or acid terminal activated derivatives thereof, wherein L is selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases; and R7 is selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids.
Unexpectedly, these compounds also are able to recognize duplex DNA by displacing one strand, thereby presumably generating a double helix with the other one.
Such recognition can take place to dsDNA sequences 5-60 base pairs long. Sequences between 10 and 20 bases are of interest since this is the range within which unique DNA
sequences of prokaryotes and eukaryotes are found. Reagents which recognize 17-18 bases are of particular interest since this is the length of unique sequences in the human genome.
The compounds of the invention are able to form triple helices with dsDNA and double helices with RNA or ssDNA. The compounds of the invention also are able to form triple helices wherein a first PNA strand binds with RNA or ssDNA
and a second PNA strand binds with the resulting double helix or with the first PNA strand.
Whereas the improved binding of the compounds of the invention should render them efficient as antisense agents, it is expected that an extended range of related reagents may cause strand displacement, now that this surprising and unexpected new behavior of dsDNA has been discovered.
Thus, in one aspect, the present invention provides methods for inhibiting the expression of particular genes in the cells of an organism, comprising administering to said organism a reagent as defined above which binds specifically to sequences of said genes.
Further, the invention provides methods for inhibiting transcription and/or replication of particular genes or for inducing degradation of particular regions of 094/25477 ~ PCTnB94100142 double stranded DNA in cells of an organism by administering to said organism a reagent as defined above.
Still further, the invention provides methods for killing cells or virus by contacting said cells or virus with a reagent as defined above which binds specifically to sequences of the genome of said cells or virus.
DET~TT-~n DESCRIPTION OF THE lNv~NllON
In the oligonucleotide analogs and monomer synthons according to the invention, ligand L is primarily a naturally occurring nucleobase attached at the position found in nature, i.e., position 9 for adenine or guanine, and position l for thymine or cytosine. Alternatively, L may be a non-naturally occurring nucleobase (nucleobase analog), another base-binding moiety, an aromatic moiety, (Cl-C4)alkanoyl, 15 hydroxy or even hydrogen. It will be understood that the term nucleobase includes nucleobases bearing removable protecting groups. Some typical nucleobase ligands and illustrative synthetic ligands are shown in Figure 2 of WO
92/20702. Furthermore, L can be a DNA intercalator, a reporter ligand such as, for example, a fluorophor, radio label, spin label, hapten, or a protein-recognizing ligand such as biotin. In monomer synthons, L may be blocked with protecting groups, as illustrated in Figure 4 of WO 92/20702.
Linker A can be a wide variety of groups such as CRlR2CO- -CRlR2CS- -CRlR2CSe-, -CRlR2CNHR3-, -CRlR2C=CH2- and -CRlR2C=C(CH3)2-, where Rl, R2 and R3 are as defined above.
Preferably, A is methylenecarbonyl (-CH2CO-), amido (-CoNR3-), or ureido (-NR3CoNR3-). Also, A can be a longer chain moiety such as propanoyl, butanoyl or pentanoyl, or corresponding derivative, wherein O is replaced by another value of X or the chain is substituted with RlR2 or is heterogenous, containing Y. Further, A can be a (C2-C6)alkylene chain, a (C2-C6)alkylene chain substituted with 2~ ~ 23~
W094/25477 PCT~B94/00142 RlR2 or can be heterogenous, containing Y. In certain cases, A can just be a single bond.
In one preferred form of the invention, B i8 a nitrogen atom, thereby presenting the possibility of an achiral backbone. B can also be R3N+, where R3 is as defined above, or CH.
In the preferred form of the invention, C is -CR5R7-, but can also be a two carbon unit, i.e. -CHR6CHR7- or -CR6R7CH2-, where R6 and R7 are as defined above. R6 and R7 also can be a heteroaryl group such as, for example, pyrrolyl, furyl, thienyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, or can be taken together to complete an alicyclic system such as, for example, l,2-cyclobutanediyl, l,2-cyclopentanediyl or l,2-cyclohexanediyl.
In the preferred form of the invention, E in the monomer synthon is COOH or an activated derivative thereof, and G in the oligomer is -CoNR3-. As defined above, E may also be CSOH, SOOH, SO2OH or an activated derivative thereof, whereby G in the oligomer becomes -CSNR3-, -SONR3-and -So2NR3-, respectively. The activation may, for example, be achieved using an acid anhydride or an active ester derivative, wherein hydrogen in the groups represented by E is replaced by a leaving group suited for generating the growing backbone.
The amino acids which form the backbone may be identical or different. We have found that those based on 2-aminoethylglycine are especially well suited to the purpose of the invention.
In some cases it may be of interest to attach ligands at either terminus (Q, I) to modulate the binding characteristics of the PNAs. Representative ligands include DNA intercalators which will improve dsDNA binding or basic groups, such as lysine or polylysine, which will strengthen the binding of PNA due to electrostatic interaction. To 35 decrease negatively charged groups such as carboxy and sulfo 094/25J77 _ l3 _ PCT~B94/0014 groups could be used. The design of the synthons further allows such other moieties to be located on non-terminal positions.
In a further aspect of the invention, the PNA
5 oligomers are conjugated to low molecular effector ligands such as ligands having nuclease activity or alkylating activity or reporter ligands (fluorescent, spin labels, radioactive, protein recognition ligands, for example, biotin or haptens). In a further aspect of the invention, the PNAs are conjugated to peptides or proteins, where the peptides have signaling activity and the proteins are, for example, enzymes, transcription factors or antibodies. Also, the PNAs can be attached to water-soluble or water-insoluble polymers.
In another aspect of the invention, the PNAs are conjugated to oligonucleotides or carbohydrates. When warranted, a PNA
oligomer can be synthesized onto some moiety (e.g., a peptide chain, reporter, intercalator or other type of ligand-containing group) attached to a solid support.
Such conjugates can be used for gene modulation (e.g., gene targeted drugs), for diagnostics, for biotechnology, and for scientific purposes.
As a further aspect of the invention, PNAs can be used to target RNA and ssDNA to produce both antisense-type gene regulating moieties and hybridization probes for the identification and purification of nucleic acïds.
Furthermore, the PNAs can be modified in such a way that they can form triple helices with dsDNA. Reagents that bind sequence-specifically to dsDNA have applications as gene targeted drugs. These are foreseen as extremely useful drugs for treating diseases like cancer, AIDS and other virus infections, and may also prove effective for treatment of some genetic diseases. Furthermore, these reagents may be used for research and in diagnostics for detection and isolation of specific nucleic acids.
wo 94/2s477 2 ~ ~ ~ .7~ 3 ~ PCTnB94/00142 ~
The triple helix principle is believed to be the only known principle in the art for sequence-specific recognition of dsDNA. However, triple helix formation is largely limited to recognition of homopurine-homopyrimidine sequences. Strand displacement is superior to triple helix recognition in that it allows for recognition of any sequence by use of the four natural bases. Also, in strand displacement recognition readily occurs at physiological conditions, that is, neutral pH, ambient (20-40 C) temperature and medium (100-150 mM) ionic strength.
Gene targeted drugs are designed with a nucleobase sequence (containing 10-20 units) complementary to the regulatory region (the promoter) of the target gene.
Therefore, upon administration of the drug, it binds to the 15 promoter and block access thereto by RNA polymerase.
Consequently, no mRNA, and thus no gene product (protein~, is produced. If the target is within a vital gene for a virus, no viable virus particles will be produced. Alternatively, the target could be downstream from the promoter, causing the 20 RNA polymerase to terminate at this position, thus forming a truncated mRNA/protein which is nonfunctional.
Sequence-specific recognition of ssDNA by base complementary hybridization can likewise be exploited to target specific genes and viruses. In this case, the target sequence is contained in the mRNA such that binding of the drug to the target hinders the action of ribosomes and, consequently, translation of the mRNA into protein. The peptide nucleic acids of the invention are superior to prior reagents in that they have significantly higher affinity for complementary ssDNA. Also, they possess no charge and water soluble, which should facilitate cellular uptake, and they contain amides of non-biological amino acids, which should make them biostable and resistant to enzymatic degradation by, for example, proteases.
094/25477 PCTnB94/00142 genome of an animal by, for example, triple helix ~ormation using oligonucleotides or other DNA recognizing agents.
However, there are a number of drawbacks associated with triple helix formation. For example, it can only be used for 5 homopurine sequences and it requires unphysiologically high ionic strength and low pH.
Furthermore, unmodified oligonucleotides are unpractical both in the antisense approach and in the triple helix approach because they have short in vivo half-lives, they are difficult to prepare in more than milligram quantities and, thus, are prohibitively costly, and they are poor cell membrane penetrators.
These problems have resulted in an extensive search for improvements and alternatives. For example, the problems arising in connection with double-stranded DNA (dsDNA) recognition through triple helix formation have been diminished by a clever "switch back" chemical linking whereby a sequence of polypurine on one strand is recognized, and by "switching back", a homopurine sequence on the other strand can be recognized. See, e.g., McCurdy, Moulds, and Froehler, Nucleosides, in press. Also, good helix formation has been obtained by using artificial bases, thereby improving binding conditions with regard to ionic strength and pH.
In order to improve half life as well as membrane 25 penetration, a large number of variations in polynucleotide backbones has been undertaken, although so far not with the desired results. These variations include the use of methylphosphonates, monothiophosphates, dithiophosphates, phosphoramidates, phosphate esters, bridged 30 phosphoroamidates, bridged phosphorothioates, bridged methylenephosphonates, dephospho internucleotide analogs with siloxane bridges, carbonate bridges, carboxymethyl ester bridges, acetamide bridges, carbamate bridges, thioether, sulfoxy, sulfono bridges, various "plastic" DNAs, ~-anomeric 35 bridges, and borane derivatives.
The great majority of these backbone modifications led to decreased stability for hybrids formed between the W094/25477 ~ 3 ~ PCTnB94/00142 modified oligonucleotide and its complementary native oligonucleotide, as assayed by measuring Tm values.
Conse~uently, it is generally understood in the art that backbone modifications destabilize such hybrids, i. e., result in lower Tm values, and should be kept to a minimum.
OBJECTS OF THE INVENTION
It is one object of the present invention to provide compounds that bind ssDNA and RNA strands to form stable hybrids therewith.
It is a further object of the invention to provide compounds that bind ssDNA and RNA strands.
It is another object to provide compounds wherein naturally-occurring nucleobases or other nucleobase-binding moieties are covalently bound to a peptide backbone.
It is yet another object to provide compounds other than RNA that can bind one strand of a double-stranded polynucleotide, thereby displacing the other strand.
It is still another object to provide therapeutic, diagnostic, and prophylactic methods that employ such compounds.
SUMMARY OF THE INVENTION
The present invention provides a novel class of compounds, known as peptide nucleic acids (PNAs), that bind complementary ssDNA and RNA strands. The compounds of the invention generally comprise ligands linked to a peptide backbone. Representative ligands include either the four main naturally occurring DNA bases (i.e., thymine, cytosine, adenine or guanine) or other naturally occurring nucleobases ( e . g., inosine, uracil, 5-methylcytosine or thiouracil) or artificial bases (e.g., bromothymine, azaadenines or azaguanines, etc. ) attached to a peptide backbone through a suitable linker.
In WO 92/20702, we described PNAs wherein such ligands are linked to a polyamide backbone solely through aza 35 nitrogen atoms. The PNAs of the invention differ from those ~ 094l25477 21~ 1 ~ 3 ~ PCT~B94/00142 disclosed in WO 92/20702 principally in that their recognition moieties are linked to the polyamide backbone additionally through amido and/or ureido tethers.
In certain preferred embodiments, the peptide 5 nucleic acids of the invention have the general formula (I):
l L2 tn A 2 A "
Q ~B 1 1 ~G 1 2~B ~D 2-G ~~~~~~-- C n' ~D n (I) wherein:
n is at least 2, each of L1-~n is independently selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of C1-Cn is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R5 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and Rs is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each of Dl-Dn is (CR5R7)z where R5 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
30each of G1-Gn-1 is -NR3Co-, -NR3CS -, -NR3So- or -NR3So2-, in either orientation, where R3 is as defined above W094/25477 2~ ~ 23~ PCT~B94/OOln ~
each pair of Al-An and Bl-Bn are selected such that:
(a) A is a group of formula (IIa), (IIb) or (IIc) and B i s N or R3N+; or (b) A is a group of formula (IId) and B is CH;
R~ Rl ~1 R1 X
c r c c r ~ c _ _ p _l _ q `2 r 2 s (IIa) (IIb) R1 ~1 ~3 R1 Rf X R3 1l l 11 l --C Y C l C-- C Y C C--N--2 r 2 5 ~2 ~ 2 s (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each Rl and R2 is independently selected from the group consisting of hydrogen, (Cl-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen;
each of Gl-Gn-l is -NR3Co-, -NR3CS-, -NR3So- or -0 NR3So2-, in either orientation, where R3 is as defined above;
Q i s - CO2H, - CONR ' R ' ', - SO3H or -SO2NR' R ' ' or an activated derivative of -CO2H or -SO3H; and I is -NHR' ' 'R' ' ' ' or -NR' ' ' C (O) R' ' ' ', where R', R", R' ' ' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, ~ 094/2~477 2 ~ 6 ~ 2 3 ~ PCT~B94/00142 reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.
In certain embodiments, at least one A is a group 5 of formula (IIc) and B is N or R3N+. In other embodiments, A
is a group of formula (IIa) or (IIb), B is N or R3N+, and at least one of y or z is not 1 or 2.
Preferred peptide nucleic acids have general formula (IIIa) or (IIIb):
L L ~
( C H 2 ) I ( C H
R3N ~0 0 R3N/~o R h~( C H 2 ) ( C H 2~)N~L ( C H 2 ) k , ~ N mH - R
R7' R7 (IIIa) L L ~
( C H 2 ) I ( C H 2 ) I
o~N R 3 o~N R 3 R h ~( C H 2 )~ N ( C H 2~) ",lL ( C H 2 ) k N ~( ~ N H - R
_ _P n - -(IIIb) wherein:
each L is independently selected rom the group consisting of hydrogen, phenyl, heterocyclic moieties, 15 naturally occurring nucleobases, and non-naturally occurring nucleobases;
W094/25477 ~ 2 3 ~ PCT~B94/00142 each R7 is independently selected from the group consisting of hydrogen and the side ch~ n~ of naturally occurring alpha amino acids;
n is an integer from 1 to 60;
each of k, l, and m is independently zero or an integer from 1 to 5;
p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
Particularly preferred are compounds having formula (IIIa) or tIIIb) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), cytosine (C), guanine (G) and uracil (U), k and m are zero or 1, and n is an integer from 1 to 30, in particular from 4 to 20.
The peptide nucleic acids of the invention are synthesized by adaptation of standard peptide synthesis procedures, either in solution or on a solid phase. The synthons used are specially monomer amino acids or their activated derivatives, protected by standard protecting groups. The oligonucleotide analogs also can be synthesized by using the corresponding diacids and diamines.
Thus, the novel monomer synthons according to the invention are selected from the group consisting of amino acids, diacids and diamines having general formulae:
L L . L
A
E~c~B~D~F O r E~c/B~c/E O r F~C~B~D~F
( IV) (V) (VI ) wherein L, A, B, C and D are as defined above, except that any amino groups therein may be protected by amino protecting groups; E is COOH, CSOH, SOOH, SO2OH or an activated derivative thereof; and F is NHR3 or NPgR3, where R3 is as defined above and Pg is an amino protecting group.
~ 094/25477 ~ PCT~B94/00142 g Preferred monomer synthons according to the invention have formula (VIIIa)-(VIIIc):
o~/ CH2 ) I
HO~ CH2~N~CH2 O p7 (VIIIa) ( CH2 ) I
R 3 N /~0 HO,f~CH ` I CH2~NH2 (VIIIb) ( CH2 ) O~N R 3 HO~ CH2~N~CH
Op7 p (VIIIc) W094/2~477 ~ 3 ~ PCT~B94/00142 ~
or amino-protected and/or acid terminal activated derivatives thereof, wherein L is selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases; and R7 is selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids.
Unexpectedly, these compounds also are able to recognize duplex DNA by displacing one strand, thereby presumably generating a double helix with the other one.
Such recognition can take place to dsDNA sequences 5-60 base pairs long. Sequences between 10 and 20 bases are of interest since this is the range within which unique DNA
sequences of prokaryotes and eukaryotes are found. Reagents which recognize 17-18 bases are of particular interest since this is the length of unique sequences in the human genome.
The compounds of the invention are able to form triple helices with dsDNA and double helices with RNA or ssDNA. The compounds of the invention also are able to form triple helices wherein a first PNA strand binds with RNA or ssDNA
and a second PNA strand binds with the resulting double helix or with the first PNA strand.
Whereas the improved binding of the compounds of the invention should render them efficient as antisense agents, it is expected that an extended range of related reagents may cause strand displacement, now that this surprising and unexpected new behavior of dsDNA has been discovered.
Thus, in one aspect, the present invention provides methods for inhibiting the expression of particular genes in the cells of an organism, comprising administering to said organism a reagent as defined above which binds specifically to sequences of said genes.
Further, the invention provides methods for inhibiting transcription and/or replication of particular genes or for inducing degradation of particular regions of 094/25477 ~ PCTnB94100142 double stranded DNA in cells of an organism by administering to said organism a reagent as defined above.
Still further, the invention provides methods for killing cells or virus by contacting said cells or virus with a reagent as defined above which binds specifically to sequences of the genome of said cells or virus.
DET~TT-~n DESCRIPTION OF THE lNv~NllON
In the oligonucleotide analogs and monomer synthons according to the invention, ligand L is primarily a naturally occurring nucleobase attached at the position found in nature, i.e., position 9 for adenine or guanine, and position l for thymine or cytosine. Alternatively, L may be a non-naturally occurring nucleobase (nucleobase analog), another base-binding moiety, an aromatic moiety, (Cl-C4)alkanoyl, 15 hydroxy or even hydrogen. It will be understood that the term nucleobase includes nucleobases bearing removable protecting groups. Some typical nucleobase ligands and illustrative synthetic ligands are shown in Figure 2 of WO
92/20702. Furthermore, L can be a DNA intercalator, a reporter ligand such as, for example, a fluorophor, radio label, spin label, hapten, or a protein-recognizing ligand such as biotin. In monomer synthons, L may be blocked with protecting groups, as illustrated in Figure 4 of WO 92/20702.
Linker A can be a wide variety of groups such as CRlR2CO- -CRlR2CS- -CRlR2CSe-, -CRlR2CNHR3-, -CRlR2C=CH2- and -CRlR2C=C(CH3)2-, where Rl, R2 and R3 are as defined above.
Preferably, A is methylenecarbonyl (-CH2CO-), amido (-CoNR3-), or ureido (-NR3CoNR3-). Also, A can be a longer chain moiety such as propanoyl, butanoyl or pentanoyl, or corresponding derivative, wherein O is replaced by another value of X or the chain is substituted with RlR2 or is heterogenous, containing Y. Further, A can be a (C2-C6)alkylene chain, a (C2-C6)alkylene chain substituted with 2~ ~ 23~
W094/25477 PCT~B94/00142 RlR2 or can be heterogenous, containing Y. In certain cases, A can just be a single bond.
In one preferred form of the invention, B i8 a nitrogen atom, thereby presenting the possibility of an achiral backbone. B can also be R3N+, where R3 is as defined above, or CH.
In the preferred form of the invention, C is -CR5R7-, but can also be a two carbon unit, i.e. -CHR6CHR7- or -CR6R7CH2-, where R6 and R7 are as defined above. R6 and R7 also can be a heteroaryl group such as, for example, pyrrolyl, furyl, thienyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, or can be taken together to complete an alicyclic system such as, for example, l,2-cyclobutanediyl, l,2-cyclopentanediyl or l,2-cyclohexanediyl.
In the preferred form of the invention, E in the monomer synthon is COOH or an activated derivative thereof, and G in the oligomer is -CoNR3-. As defined above, E may also be CSOH, SOOH, SO2OH or an activated derivative thereof, whereby G in the oligomer becomes -CSNR3-, -SONR3-and -So2NR3-, respectively. The activation may, for example, be achieved using an acid anhydride or an active ester derivative, wherein hydrogen in the groups represented by E is replaced by a leaving group suited for generating the growing backbone.
The amino acids which form the backbone may be identical or different. We have found that those based on 2-aminoethylglycine are especially well suited to the purpose of the invention.
In some cases it may be of interest to attach ligands at either terminus (Q, I) to modulate the binding characteristics of the PNAs. Representative ligands include DNA intercalators which will improve dsDNA binding or basic groups, such as lysine or polylysine, which will strengthen the binding of PNA due to electrostatic interaction. To 35 decrease negatively charged groups such as carboxy and sulfo 094/25J77 _ l3 _ PCT~B94/0014 groups could be used. The design of the synthons further allows such other moieties to be located on non-terminal positions.
In a further aspect of the invention, the PNA
5 oligomers are conjugated to low molecular effector ligands such as ligands having nuclease activity or alkylating activity or reporter ligands (fluorescent, spin labels, radioactive, protein recognition ligands, for example, biotin or haptens). In a further aspect of the invention, the PNAs are conjugated to peptides or proteins, where the peptides have signaling activity and the proteins are, for example, enzymes, transcription factors or antibodies. Also, the PNAs can be attached to water-soluble or water-insoluble polymers.
In another aspect of the invention, the PNAs are conjugated to oligonucleotides or carbohydrates. When warranted, a PNA
oligomer can be synthesized onto some moiety (e.g., a peptide chain, reporter, intercalator or other type of ligand-containing group) attached to a solid support.
Such conjugates can be used for gene modulation (e.g., gene targeted drugs), for diagnostics, for biotechnology, and for scientific purposes.
As a further aspect of the invention, PNAs can be used to target RNA and ssDNA to produce both antisense-type gene regulating moieties and hybridization probes for the identification and purification of nucleic acïds.
Furthermore, the PNAs can be modified in such a way that they can form triple helices with dsDNA. Reagents that bind sequence-specifically to dsDNA have applications as gene targeted drugs. These are foreseen as extremely useful drugs for treating diseases like cancer, AIDS and other virus infections, and may also prove effective for treatment of some genetic diseases. Furthermore, these reagents may be used for research and in diagnostics for detection and isolation of specific nucleic acids.
wo 94/2s477 2 ~ ~ ~ .7~ 3 ~ PCTnB94/00142 ~
The triple helix principle is believed to be the only known principle in the art for sequence-specific recognition of dsDNA. However, triple helix formation is largely limited to recognition of homopurine-homopyrimidine sequences. Strand displacement is superior to triple helix recognition in that it allows for recognition of any sequence by use of the four natural bases. Also, in strand displacement recognition readily occurs at physiological conditions, that is, neutral pH, ambient (20-40 C) temperature and medium (100-150 mM) ionic strength.
Gene targeted drugs are designed with a nucleobase sequence (containing 10-20 units) complementary to the regulatory region (the promoter) of the target gene.
Therefore, upon administration of the drug, it binds to the 15 promoter and block access thereto by RNA polymerase.
Consequently, no mRNA, and thus no gene product (protein~, is produced. If the target is within a vital gene for a virus, no viable virus particles will be produced. Alternatively, the target could be downstream from the promoter, causing the 20 RNA polymerase to terminate at this position, thus forming a truncated mRNA/protein which is nonfunctional.
Sequence-specific recognition of ssDNA by base complementary hybridization can likewise be exploited to target specific genes and viruses. In this case, the target sequence is contained in the mRNA such that binding of the drug to the target hinders the action of ribosomes and, consequently, translation of the mRNA into protein. The peptide nucleic acids of the invention are superior to prior reagents in that they have significantly higher affinity for complementary ssDNA. Also, they possess no charge and water soluble, which should facilitate cellular uptake, and they contain amides of non-biological amino acids, which should make them biostable and resistant to enzymatic degradation by, for example, proteases.
3 ~
W094/2~477 PCT~B94/00142 It is believed that PNA oligomers according to the invention exhibit biochemical/biological properties similar to those disclosed in WO 92/20702, and that such properties can be determined by similar means. It also is believed that the PNAs of the invention can be synthesized by similar methodology. Monomer synthons according to the invention are coupled using the standard protocols to give the desired oligomeric sequences.
One monomer synthon according to the invention is 10 prepared by reacting glycinamide hydrochloride 1 with ethyl acrylate in the presence of an acid scavenging base to give the Michael adduct, N-carboxamidomethyl-~-alanine ethyl ester 2. The adduct 2 is condensed with 1-carboxymethyl thymine 3 using diisopropylcarbodiimide and hydroxybenzotriazole to 15 give (N- carboxamidomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester 4. The primary amide of 4 is oxidized and rearranged to the Boc-protected amine with sodium hypobromite in t-butanol to provide (N-t-butyloxycarbonylaminomethyl)-N- ( 1- ( thymin-1-yl)acetyl)-~-alanine ethyl ester 5. The ethyl ester is hydrolyzed withaqueous base to provide the thymine-based monomer, (N-t-butyloxycarbonylaminomethyl)- N - ( 1- ( thymin-1-yl)acetyl)-~-alanine 6. This reaction sequence is followed to prepare the corresponding C, G, and A -based monomers, namely, N- (t-25 butyloxycarbonylaminomethyl)-N- ( 1- (N4-benzyloxycarbonyl-cytosin-l-yl)acetyl)-~-alanine, N- ( t-butyloxycarbonyl-aminomethyl -N- ( 1- ( 2 - amino-6-benzyloxy-purin-9-yl)acetyl)-~-alanine, N-(t-butyloxycarbonylaminomethyl)-N-(l-(N6-benzyloxycarbonyl-adenine-9-yl)acetyl)-~-alanine.
A further monomer synthon is prepared by reacting 1-aminothymine with triphosgene to give the carbamoyl chloride derivative, 8, which is condensed with N-(2-t-butyloxycarbonylaminoethyl)glycine ethyl ester and an acid scavenger to yield the fully protected monomer, 9. The ester is hydrolyzed to give the useful monomer, 10. This reaction W094/2~477 ~ 3 ~ - 16 - PCT~B94/00142 ~
sequence is followed to prepare the corresponding C, G, and A
-based monomers, namely, N-(t-butyloxycarbonylaminoethyl)-N-(1-N4-benzyloxycarbonyl-cytosin-1-yl)aminocarbonyl)-glycine, N-(t-butyloxycarbonylaminoethyl)-N-(1-(2-amino-6-benzyloxy-5 purin-9-yl)- aminocarbonyl)-glycine, N-(t-butyloxycarbonyl-amino ethyl)-N-(1-(N6-benzyloxycarbonyl-adenine-9-yl)aminocarbonyl)-glycine.
A further monomer synthon is prepared by converting 2-hydroxy-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester to its azido analog via the use of diphenyl phosphoryl azide, DEAD, and triphenylphosphine generally by the procedure described in Tetrahedron Letters, (1977), p. 1977.
The azido compound, 12, was converted to the iminophosphorane, 13, and used immediately in a high pressure reaction with carbon dioxide to convert it into isocyanate, 14. The isocyanate is condensed with thymine to give the fully protected monomer, 15, which is hydrolyzed to the actual monomer, 16, using hydroxide. This reaction sequence is followed to prepare the corresponding C, G, and A -based 20 monomers, namely, 5-(t-butyloxycarbonylamino)-2-((N4-benzyloxycarbonyl-cytosin-1-yl)carbonylamino-pentanoic acid ethyl ester, 5-(t-butyloxycarbonylamino-2-((2-amino-6-benzyloxy-purin-9-yl)carbonylamino)-pentanoic acid ethyl ester, 5-(t-butyloxycarbonylamino)-2-((N6-benzyloxycarbonyl-adenine-9-yl)carbonylamino)-pentanoic acid ethyl ester.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon ex~mln~tion of the following examples thereof, which are not intended to be limiting.
Example 1 N-carboxamidomethyl-~-alanine ethyl ester, 2.
Glycinamide hydrochloride (1, 11.0 g, 0.10 mol) is suspended in 500 mL of dioxane and diisopropylethylamine (12.9 g, 0.10 mol) is added and the mixture cooled to 0C.
~61~
094/25477 PCT~B94/00142 With stirring ethyl acrylate (10.0 g, 0.10 mol) is added dropwise over 15 minutes. After the addition is complete the reaction is allowed to warm to room temperature and stir for 12 hours. The reaction mixture is diluted with water 1.5 L
and the pH adjusted to 4. The solution is extracted with - diethyl ether (3X300 mL). The aqueous layer is neutralized with sodium hydroxide and extracted 5 times with dichloromethane. The dichloromethane extracts are combined, dried (Na2SO4), and the solvent removed to give a solid.
Example 2 (N-carboxamidomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester, 4.
The product from Example 1, 2, is dissolved in dichloromethane (500 mL) and to this is added 1-carboxymethyl thymine (3, 15.5 g, 0.1 mol), hydroxybenzotriazole (13.5 g, 0.1 mol) and the solution is cooled to 0C in an ice bath.
Diisopropylcarbodiimide (12.6 g, 0.1 mol) dissolved in 50 mL
of dichloromethane is added in one portion and the reaction is stirred for 12 hours. The suspended solids are removed by filtration and washed with dichloromethane. The solution is evaporated to a solid and the desired product, 4, is obtained after chromatography on silica gel using dichloromethane/ethanol as eluent.
Example 3 (N-t-butyloxycarbonylaminomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester, 5.
The product from Example 2, 4, is dissolved t-butanol/dioxane (4:1, 500 mL), cooled to 0C, and sodium hypobromite solution (0.15 mol) is added. After 6 hours the reaction mixture is evaporated to remove volatile solvents and the residue is diluted with water (500 mL) and extracted (5X200 mL) with dichloromethane. The extracts are combined, dried, and evaporated to a solid.
W094/25477 ~ 3 ~ PCT~B94/00142 Example 4 (N-t-butyloxycarbonylAm;n~methyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine, 6.
The product from Example 3, 5, is dissolved in ethanol (500 mL) and 5M sodium hydroxide (20 mL) is added.
The solution is stirred for 6 hours, then neutralized with 5N
hydrochloric acid (20 mL) and the solution evaporated to a solid. This solid is recrystallized to give the title compound.
Example 5 1-(Chlorocarbonylamino)-thymine, 8.
l-Amino thymine (7, 12.5 g, 0.1 mol) is dissolved in tetrahydrofuran (500 mL) and the solution is cooled to 0C
and a 2M solution of triphosgene in THF (150 mL) is added and the reaction is stirred for 4 hours. The solution is evaporated to a solid, which is used as is in the next reaction.
Example 6 N-(2-t-Butyloxycarbonylaminoethyl)-N-(thymin-1-yl-amino-carbonyl)glycine ethyl e~ter, 9.
The product from Example 5, 8, is dissolved in THF
(500 mL) and diisopropylethylamine (12.9 g, 0.1 mol) is added, followed by N-(2-t-butyloxycarbonylaminoethyl)glycine ethyl ester (24.6 g, 0.1 mol) and the solution stirred for 12 hours. The reaction is diluted with 1000 mL of diethyl ether and extracted 3 times with O.lN HC1 solution. The organic layer is washed with diluted sodium bicarbonate solution, dried, filtered and evaporated to give a solid.
Example 7 30 N-(2-t-Butyloxycarbonylaminoethyl)-N-(thymin-1-yl-amino-carbonyl)glycine, 10.
The product from Example 6, 9, is dissolved in ethanol (500 mL) and 2M sodium hydroxide (50 mL) is added.
The reaction is stirred for 6 hours, then neutralized with 50 ~ 094t25477 2 ~ ~ ~ 2 ~ ~ PCT~B94/00142 .
mL of 2M HC1 solution, and evaporated to remove the ethanol.
The residue is dissolved in dichloromethane (250 mL) and is extracted with water (2X50 mL), dried, filtered, and evaporated to a solid.
5 Example 8 2-Azido-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, 12.
2-Hydroxy-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, (11, 26.1 g, 0.1 mol), triphenylphosphine (26.2 10 g, 0.10 mol), diethylazodicarboxylate (17.4 g, 0.1 mol), and diphenylphosphorylazide (27.5 g, 0.1 mol) is dissolved in THF
(500 mL) and heated to reflux and maintained there for 8 hours. The reaction is cooled to room temperature, evaporated to an oil, and the product isolated by column chromatography using dichloromethane:ethanol as eluent.
Example 9 2-Iminotriphenylphosphoranyl-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, 13.
The product, 12, from Example 8 is dissolved in THF
and triphenylphosphine (26.2 g, 0.1 mol) is added and the reaction is stirred for 4 hours. This solution is used as is for the next reaction (Example 10).
Example 10 2-Isocyanato-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, I4.
The reaction solution from Fxample 9 is placed in a Parr~ bomb and carbon dioxide (22 g, 0.5 mol) is condensed into the bomb. The bomb is sealed and heated to 50C for 12 hours. The bomb is cooled and vented to atmospheric 30 pressure. The solution is transferred from the bomb to a flask and used as is in the next reaction (Example 11).
W094/25477 ~ 2 3 ~ ~ PCT~B94/00142 Example 11 2-(Thymin-l-ylcarbonylamino)-5-(t-butyloxycarbonyl ~m; no) pentanoic acid ethyl ester, 15.
The reaction solution from Example 10 i8 placed in a flask and to this is added thymine (12.6 g, 0.1 mol). The resulting solution is allowed to stir for 12 hours, then is evaporated to a solid, which is purified by column chromatography using dichlormethane:ethanol as the eluent.
Example 12 2-(Thymin-l-ylcarbonylamino)-5-(t-butyloxycarbonyl-amino)pentanoic acid, 16.
The product from Example 11, 15, is dissolved in ethanol (500 mL) and to this added 2M sodium hydroxide (50 mL) and the reaction stirred for 12 hours. The reaction is 15 neutralized with 2M HC1 solution (50 mL) and evaporated to a small volume. This residue is diluted with water (250 mL) and extracted with dichloromethane (4X100 mL), dried, filtered, and evaporated to give a solid.
Example 13 1-(2(-Thyminyl)acetyl)-1-(2-(tBoc-aminopropyl))glycine, 17 1,3-Diaminopropane (0.05 mmol) was dissolved in THF
(100 mL) and chloroacetic acid (0.045 mmol) was added and the reaction heated at reflux for 4 hours and cooled to room temperature. The solution was diluted with diethyl ether (500 mL) and extracted 3 times with lN NaOH solution. The combined water layers were acidified to pH = 4 and extracted with dichloromethane (5X50 mL). The organic layers were combined, dried, filtered and evaporated to an oil. This oil was dissolved in methanol (1000 mL) and dry HCl gas added.
30 The reaction was heated to reflux and maintained there for 8 hours. The reaction was cooled and evaporated to an oil.
This oil was dissolved in dioxane/water and p-nitrophenyl-t-butylcarbonate (0.05 mmol) was added and the pH adjusted to 10. The reaction was stirred for 4 hours, then neutralized and extracted 5 times with dichloromethane. The methyl ester 094/25477 ~ ~12 3 ~ ` PCT~B94/00142 was dissolved in 50~ DMF in dichloromethane and to this was added dicyclohexylcarbodiimide (DCC, 0.05 mmol) and hydroxbenzotriazole (0.05 mmol), and 2-thyminylacetic acid (0.05 mmol). The reaction was stirred for 18 hours then the 5 DCC was removed by filtration and the residue evaporated to an oil. The oil was purified by column chromatography.
Example 14 3-(Boc-amino)-1,2-propanediol, 18 3-Amino-1,2-propanediol (40.00 g, 0.440 mol, 1.0 eqv) was dissolved in water (1000 ml) and cooled to 0 C, and di-tert-butyl dicarbonate (115.0 g, 0.526 mol, 1.2 eqv) was added in one portion. The reaction mixture was heated to room temperature on a water bath with stirring. The pH was maintained at 10.5 with a solution of sodium hydroxide (17.56 15 g, 0.440 mol, 1.0 eqv) in water (120 ml). When the addition of aqueous sodium hydroxide was completed, the reaction mixture was stirred overnight at room temperature.
Subsequently, ethyl acetate (750 ml) was added to the reaction mixture followed by cooling to 0C and the pH was adjusted to 2.5 with 4N sulfuric acid with vigorous stirring.
The phases were separated. The water phase was washed with additional ethyl acetate (6x350 ml). The volume of the organic phase was reduced to 900 ml by evaporation under reduced pressure and washed with a saturated aqueous solution of potassium hydrogen sulfate diluted to twice its volume (lx1000 ml) and with saturated aqueous sodium chloride (lx500 ml). The organic phase was dried (MgS04) and evaporated under reduced pressure to yield 50.12 9 (60~) of the title compound. The product could be solidified by evaporation from methylene chloride and subsequent freezing. lH-NMR
(CDCl3/TMS): ~ = 1.43 (s, 9H, Me3C), 3.25 (m, 2H, CH2), 3.57 (m, 2H, CH2), 3.73 (m, lH, CH). l3C-NMR (CDCl3/TMS): ~ = 28.2 (Me3C), 42.6 (CH2), 63.5, 71.1 (CH2OH, CHOH), 79.5 (Me3C), 157.0 (C=O).
W094/25477 ~ PCT~B94/00142 Example 15 Boc-aminoacetaldehyde, 19 3-(Boc-amino)-l~2-propanediol (18, 20.76 g, 0.109 mol, 1 eqv) was suspended in water (150 ml). Potassium m-5 periodate (24.97 g, 0.109 mol, 1 eqv) was added and thereaction mixture was stirred for 2 h at room temperature under nitrogen. The reaction mixture was filtered and the water phase was extracted with chloroform (6x250 ml). The organic phase was dried (MgS04) and evaporated to afford crude Boc-aminoacetaldehyde as a golden oil. This oil was kugelrohr distilled at 80C and 0.2 mbar to yield 13.19 g (76~) of the title compound as a semicrystalline solid. lHNMR
(DMSO-d6/TMS): ~ = 1.47 (s, 9H, Me3C), 3.81 (d, J=5.6 Hz, 2H, CH2), 7.22 (b, 1 H, NH), 9.54 (s, 1 H, CHO). l3C-NMR (DMSO-d6/TMS): ~ = 28.2 (Me3C), 50.5 (CH2), 78.4 (Me3C), 156.1(carbamate C=O), 200.6 (CHO). Anal. Calcd. for C7Hl3N03: C, 52.82; H, 8.23; N, 8.80. Found: C, 52.21; H, 8.15; N, 8.46.
Example 16 (Boc-amino)ethylglycine Methyl Ester, 20 20 A. Reduction With Sodium Cyanoborohydride Boc-aminoacetaldehyde (19, 1.00 g, 6.3 mmol, 1 eqv) was dissolved in methanol (50 ml). Anhydrous sodium acetate (1.03 g, 12.6 mmol, 2 eqv), glycine methyl ester hydrochloride (Aldrich Chemical Co., 0.79 g, 6.3 mmol, 1 eqv) and sodium cyanoborohydride (1.97 g, 31.4 mmol, 5 eqv) were added to the solution in that order. The reaction mixture was stirred for 2 h at room temperature under nitrogen.
Water (50 ml) was added to the suspension and the resulting clear solution was evaporated under reduced pressure to remove the methanol. The aqueous phase was extracted with methylene chloride (3xlO0 ml). The organic phase was washed with a saturated aqueous solution of sodium chloride (lxlO0 ml), dried (Na2S04), filtered and then evaporated under reduced pressure affording 1.41 g of crude title compound as 35 a yellow oil. The crude product was kugelrohr distilled at 110C and 0.5 mbar to yield 0.49 g (34~) of 2-(Boc-W094/2~477 ~3 PCTnB94/00142 amino)ethylglycine methyl ester as a colorless liquid. lH-NMR (CDCl3/TMS): ~ = 1.36 (s, 9H, Me3C), 1.91 (s, lH, NH), 2.67 (t, J=6 Hz, 2H, NHCH2), 3.13 (q, J=6 Hz, 2H, NHCH2), 3.34 (s, 2H, CH2COO), 3.65 (s, 3H, OMe), 5.13 (b, lH, carbamate NH). l3C-NMR (CDCl3/TMS): ~ = 28.2 (Me3C), 39.9, 48.5 (NHCH2), 50.0 (CH2COO), 51.5 (OMe), 78.9 (Me3C), 155.9 (carbamate C=O), 172.6 (ester C=O). Anal. Calcd for CloH2N2O4 C, 51.71; H, 8.68; N, 12.06. Found: C, 51.55; H, 8.72; N, 11.79.
10 B. Catalytic hydrogenation Boc-aminoacetaldehyde (2.08 g, 13.1 mmol, 1 eqv) was dissolved in methanol (50 ml) and cooled to 0 C.
Palladium on activated carbon (10~, 0.4 g) was added under nitrogen and with vigorous stirring. Anhydrous sodium acetate (2.14 g, 26.1 mmol, 2 eqv) and glycine methyl ester, hydrochloride (1.64 g, 13.1 mmol, 1 eqv) each dissolved in methanol (25 ml) were added to the mixture. The reaction mixture was hydrogenated at atmospheric pressure and room temperature with vigorous stirring, until hydrogen uptake had ceased (when 287 ml, 13.1 mmol, 1 eqv had been consumed) after about 1 h. The reaction mixture was filtered and the solvent removed under reduced pressure. The residue was suspended in water (30 ml), and during vigorous stirring pH
was adjusted to 8 by dropwise addition of 0.5 N NaOH. The 25 water phase was extracted with methylene chloride (4x50 ml).
The organic phase was dried (Na2S04), filtered and evaporated under reduced pressure to yield 3.03 g of crude title compound as a golden oil. The crude product was kugelrohr distilled at 100 C and 0.2 mbar to afford 2.33 g (77~) of 2-(Boc-amino)ethylglycine methyl ester as a colorless liquid.
The analytical data were in accord with those provided above for the reduction with sodium cyanoborohydride.
PCT~B94/00142 _ W094/~477 2I~123~
Example 17 General Method for the Synthesis of PNA Oligomers Oligomers were prepared generally in accordance with the methods disclosed by WO 92/20702. Benzyhydrylamine resin (initially loaded 0.28 mmol/gm with Boc-L-Lys(2-chlorobenyloxycarbonyl)) was swollen in DMF and an excess of a monomer to be coupled was added, followed by dicyclohexyl-carbodiimide (0.15M in 509O' DMF in dichloromethane). The Boc deprotection was accomplished by trifluoroacetic acid treatment. The progress of the coupling reactions was monitored by quantitative ninhydrin analysis. The PNA was released from the resin using anhydrous HF under standard conditions. The products were purified using HPLC with acetonitrile-water (O.l~TFA) gradient and structure confirmed 15 by fast atom bombardment mass spectrometry. The following sequences have been synthesized by this method:
H-TloLysNH2 H-T4CTsLysNH2 20 H-T4cT2cT2LysNH2 H-TGTAcGTcAcAAcTA-NH2 H-CCTTCCcTT-NH2 H-lllllllllCCCCCCC-NH2 H-CCCCCC~lllllllll-NH2 H-TTcTcTcTcT-NH2 H-CCCCCACCACTTCCCCTCTC-(Lys)gNH2 H-CTTATATTCCGTCATCGCTCLys -NH2 H-TATTCCGTCATCGCTCCTCALys-NH2 ~ 094/25477 ~16 12 ~ ~ PCT~B94100142 H-CTGCTGCCTCTGTCTCAGGTLysNH2 H-T4-($-alanine)C-T5LysNH2 H-T4-(~-alanine)T-T5LysNH2 Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.
WO 94/25477 PCT1~94/00142 ~
~123~
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLI QNT: Nielsen, Peter E.
Buchardt, Ole Egholm, Michael Berg, Rolf H.
(ii) TITLE OF INVENTION: Novel Peptide Nucleic Acids (iii) NUMBER OF SEQUENCES: 24 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz, and Norris (B) STREET: One Liberty Place - 46th Floor (C) CITY: Philadelphia (D) STATE: PA
(E) COUNTRY: USA
(F) ZIP: 19103 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLI QTION DATA:
(A) APPLI Q TION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Lucci, Joseph (B) REGISTRATION NUMBER: 33,307 (C) REFERENCE/DOCKET NUMBER: ISIS1017 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 215-568-3100 (B) TELEFAX: 215-568-3439 (2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= MODIFIED-SITE
/note= "Thymine heterocycle is attached to ~IO 9412~477 2 ~ 6 ~L 2 3 0 PCT/IB94/00142 N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D~ OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label- Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
- (A) NAME~KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
WO 94/25477 21612 3 Q PCT~B94/00142 ~
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: Jlabel= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) S~QU~N~ DESCRIPTION: SEQ ID NO:1:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEAl~XE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
0 94/25477 ~ 3 0 PCT~B94/00142 (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine throuyh the N-acetyl group at postion l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 8 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 W 0 94/25477 21~1~ 3 ~ PCT~B94/00142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 l0 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: ll amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note5 "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site 0 94125477 ~ 2 3 0 PCT~B94/00142 (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)ylycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to - N-acetyl(2-aminoethyl~glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: lO
(D) OTHER INFORMATION: /label= Modified-site /note_ "Thymine heterocycle is attached to W 0 94/2~477 2 ~ 61~ 3 ~ PCTnB94/00142 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) ~u~N~ DESCRIPTION: SEQ ID NO:3:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at positlon 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site ~ 94/~5477 2 1~ 12 3 ~ PCT/IB94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note_ ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 10 (2) INFORMATION FOR SEQ ID NO:s:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids W 0 94/25477 2 ~ 3 ~ PCTnB94/00142 (B) TYPE: amino acid (C) STRANDEDNESS: sinyle (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "A~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~ ~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl 0 94/2~477 21 ~ PCT~B94/00142 group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label_ Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: lO
(D) OTEER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTEER INFORMATION: /label= Modified-site /note= "~n; n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site ~ (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site 2 ~ 3 ~
WO 94/25477 PCT~B94/00142 (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle i9 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEAlU~E:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l o~ the heterocycle."
~o 94,25477 21612 ~ i~ PCT/IB94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEA'luKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B~ LOCATION: 8 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 o~ the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 W O 94/25477 PCT~B94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
~ O 94/25477 ~161~ ~ ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle iS attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) S~Qu~N~ DESCRIPTION: SEQ ID NO:7:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa l 5 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single WO 94/25477 2 ~ PCT/IB94/00142 (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "~en;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATuKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acety(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= l~ n i n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
~1~123~
0 94/25477 PCT~B94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through th~e N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle iæ attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site - /note= "A~ni n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site WO 94/25477 21~ ~ ~ 3 ~ PCT~B94/00142 ~
/note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa l 5 l0 15 (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 2 ~ 3 ~
~VO 94/~5477 PCT/IB94/00142 (D) OTHER INFORMATION: Jlabel= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "~n; nP heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl - group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site W O 94/2~477 PCTnB94/00l42 ~
~ 3 9 44 -/note= ~ n i ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/REY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl?glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE: -(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "~nine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
0 94/25477 ~ 2 3 ~ PCT~B94/00142 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STR~N~ S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= ~'A~nine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
- (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~
WO 94/25477 2 ~ 3 ~ PCTm394/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modi~ied-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= DThymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl ~ 0 94/2~477 21~ ~. 2 3 ~ PCTnB94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine th~ough the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURB:
(A) NAME/KEY: Modi~ied-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FBATURE:
(A) NAME/KEY: Modified-site - (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.l' (ix) FEATURE:
(A) NAME/KEY: Modified-site WO 94/25477 2 ~ 3 ~ PCTnB94/00142 (B) LOCATION: 9 (D) Ol~R INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:11:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
~ 2 1 612 3 ~ PCT/IB94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: S
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /notec "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site - /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site W O 94/25477 PCT~B94/00142 ~
2 ~ 3 ~
~note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEALuKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified,site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids 0 94125477 _ 51 _ PCT~B94/00142 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site - (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
r (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl WO 94/25477 ~ ~ 6 ~ ~ 3 ~ PCT~B94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 tD) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-~ite (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note- "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site ~VO 94/2~;477 ~ 3 0 PCT/IB94/00142 (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) Sh'QUh'N~h DESCRIPTION: SEQ ID NO:13:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W O 94/2~477 ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l o~ the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 ~O 94/25477 211~1~ 3 0 PCT/IB94/00142 (D~ OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-amlnoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site L (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi) ~QU~N~ DESCRIPTION: SEQ ID NO:14:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site W O 94/25477 P~CTnnB94/00142 (B) LOCP.TION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
~A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to 0 94/2~477 % 1. 61~ 3 Q PCT~B94/00142 N-acetyl~2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) ~QU~N~ DESCRIPTION: SEQ ID NO:15:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:16:
(i) S~U~N~: CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) sTR~NnRnNRss single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)ylycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site W 0 94/25477 PCT~B94/00142 _ 2 ~ 3 ~ ~
/note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAluKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
0 94/2S477 ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= ~Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acety(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) S~QU~N~ DESCRIPTION: SEQ ID NO:1~:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 lO 15 (2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTX: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown WO 94/2~477 ~ PCT~B94/00142 (ii) MOLECULB TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine th,rough the N-acetyl group at position l of the heterocycle.'~
(ix) FEA~l~U~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEAl~KE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note- "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site '2,1~1~3~
0 94/25477 PCT~B94/00142 (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
- (A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to W O 94/25477 PCTnB94/00l42 _ 2 3 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified- 8 ite (B) LOCATION: 1~
(D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle iB attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of thr heterocycle."
(ix) FEA'l'U~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
~6~
_ W 0 94/25477 PCT~B94/00142 . .
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DBSCRIPTION: SEQ ID NO:17:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Lys LYB Lys Lys Lys Lys Lys Lys (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) sTR~Nn~N~s single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "~n ' n~ heterocycle is attached to W O 94/2~477 2 ~ ~12 3 0 PCTnB94/00142 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~
(ix) FEATURE:
D
~0 94/25477 PCT/IB94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAMB/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= ~Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LO Q TION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAluKE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site W O 94/25477 2 ~ PCT~B94/00142 /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site W 0 94/25477 ~ 1 6 12 3 0 PCT~B94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OT~ER INFORMATION: /label= Modified-site WO 94/25477 21~ O PCTnB94/00142 /note= "Cytosine heterocycle i6 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modi$ied-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modi$ied-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
2 ~ 3 ~
0 94/25477 PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl - group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "~n~ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 WO 94/2~;477 2 ~ PCT/IB94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids ~B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the haterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
O 94/25477 ~ 3 0 PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site tB) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= ~Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 WO 94/25477 2 t ~ ~ ~ 3 ~ PCTtIB94tO0142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified- 8 ite /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heteroside is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl O 94/25477 ~ 1$ 1 ~ ~ ~ PCT~B94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of thr heterocycle."
(ix) FEATURE:
(A) NAME/REY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "~ni ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:20:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:21:
(i) ~u~N~ CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 W O 94/25477 PCT~B94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n i ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site O 94/2~477 ~ 3 ~ PCT~B94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "A~n;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W 0 94/25477 ~ I ~ / 3 PCT~B94/00142 (ix) FEATU~: ~
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa ~6~3~
0 94/25477 PCT~B94/00142 Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:22:
(i) S~Qu~N~ CHARACTERISTICS:
(A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W O 94/25477 2 ~ ~12 3 0 PCT~B94/00142 ~
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' -(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: ll (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 ~ O 94l25477 ~16 12 3 ~ PCT~B94/00142 (D) OTHBR INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHBR INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site ~6~
WO 94/25477 PCT~B94/00142 /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acet group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of thr heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
2 ~ 3 ~
0 94/2~477 PCTnBg4/00l42 (A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycinr through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note5 ~Beta isoform of al ~nin~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site tnote= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl W O 94/2~477 2 ~ ~ ~ 2 3 ~ PCT~B94100142 ~
group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: ll (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 l0 (2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: 8 ingle (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /la~el= Modified-site /note= "Thymine heterocycle is attached to ~ 0 94/2~477 ~1612 3 ~ PCT~B94/00142 N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Beta isoform of alanine."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 W 0 94/25477 21~1 ~ 3 ~ PCT~B94/00142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/K~Y: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Lys
W094/2~477 PCT~B94/00142 It is believed that PNA oligomers according to the invention exhibit biochemical/biological properties similar to those disclosed in WO 92/20702, and that such properties can be determined by similar means. It also is believed that the PNAs of the invention can be synthesized by similar methodology. Monomer synthons according to the invention are coupled using the standard protocols to give the desired oligomeric sequences.
One monomer synthon according to the invention is 10 prepared by reacting glycinamide hydrochloride 1 with ethyl acrylate in the presence of an acid scavenging base to give the Michael adduct, N-carboxamidomethyl-~-alanine ethyl ester 2. The adduct 2 is condensed with 1-carboxymethyl thymine 3 using diisopropylcarbodiimide and hydroxybenzotriazole to 15 give (N- carboxamidomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester 4. The primary amide of 4 is oxidized and rearranged to the Boc-protected amine with sodium hypobromite in t-butanol to provide (N-t-butyloxycarbonylaminomethyl)-N- ( 1- ( thymin-1-yl)acetyl)-~-alanine ethyl ester 5. The ethyl ester is hydrolyzed withaqueous base to provide the thymine-based monomer, (N-t-butyloxycarbonylaminomethyl)- N - ( 1- ( thymin-1-yl)acetyl)-~-alanine 6. This reaction sequence is followed to prepare the corresponding C, G, and A -based monomers, namely, N- (t-25 butyloxycarbonylaminomethyl)-N- ( 1- (N4-benzyloxycarbonyl-cytosin-l-yl)acetyl)-~-alanine, N- ( t-butyloxycarbonyl-aminomethyl -N- ( 1- ( 2 - amino-6-benzyloxy-purin-9-yl)acetyl)-~-alanine, N-(t-butyloxycarbonylaminomethyl)-N-(l-(N6-benzyloxycarbonyl-adenine-9-yl)acetyl)-~-alanine.
A further monomer synthon is prepared by reacting 1-aminothymine with triphosgene to give the carbamoyl chloride derivative, 8, which is condensed with N-(2-t-butyloxycarbonylaminoethyl)glycine ethyl ester and an acid scavenger to yield the fully protected monomer, 9. The ester is hydrolyzed to give the useful monomer, 10. This reaction W094/2~477 ~ 3 ~ - 16 - PCT~B94/00142 ~
sequence is followed to prepare the corresponding C, G, and A
-based monomers, namely, N-(t-butyloxycarbonylaminoethyl)-N-(1-N4-benzyloxycarbonyl-cytosin-1-yl)aminocarbonyl)-glycine, N-(t-butyloxycarbonylaminoethyl)-N-(1-(2-amino-6-benzyloxy-5 purin-9-yl)- aminocarbonyl)-glycine, N-(t-butyloxycarbonyl-amino ethyl)-N-(1-(N6-benzyloxycarbonyl-adenine-9-yl)aminocarbonyl)-glycine.
A further monomer synthon is prepared by converting 2-hydroxy-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester to its azido analog via the use of diphenyl phosphoryl azide, DEAD, and triphenylphosphine generally by the procedure described in Tetrahedron Letters, (1977), p. 1977.
The azido compound, 12, was converted to the iminophosphorane, 13, and used immediately in a high pressure reaction with carbon dioxide to convert it into isocyanate, 14. The isocyanate is condensed with thymine to give the fully protected monomer, 15, which is hydrolyzed to the actual monomer, 16, using hydroxide. This reaction sequence is followed to prepare the corresponding C, G, and A -based 20 monomers, namely, 5-(t-butyloxycarbonylamino)-2-((N4-benzyloxycarbonyl-cytosin-1-yl)carbonylamino-pentanoic acid ethyl ester, 5-(t-butyloxycarbonylamino-2-((2-amino-6-benzyloxy-purin-9-yl)carbonylamino)-pentanoic acid ethyl ester, 5-(t-butyloxycarbonylamino)-2-((N6-benzyloxycarbonyl-adenine-9-yl)carbonylamino)-pentanoic acid ethyl ester.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon ex~mln~tion of the following examples thereof, which are not intended to be limiting.
Example 1 N-carboxamidomethyl-~-alanine ethyl ester, 2.
Glycinamide hydrochloride (1, 11.0 g, 0.10 mol) is suspended in 500 mL of dioxane and diisopropylethylamine (12.9 g, 0.10 mol) is added and the mixture cooled to 0C.
~61~
094/25477 PCT~B94/00142 With stirring ethyl acrylate (10.0 g, 0.10 mol) is added dropwise over 15 minutes. After the addition is complete the reaction is allowed to warm to room temperature and stir for 12 hours. The reaction mixture is diluted with water 1.5 L
and the pH adjusted to 4. The solution is extracted with - diethyl ether (3X300 mL). The aqueous layer is neutralized with sodium hydroxide and extracted 5 times with dichloromethane. The dichloromethane extracts are combined, dried (Na2SO4), and the solvent removed to give a solid.
Example 2 (N-carboxamidomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester, 4.
The product from Example 1, 2, is dissolved in dichloromethane (500 mL) and to this is added 1-carboxymethyl thymine (3, 15.5 g, 0.1 mol), hydroxybenzotriazole (13.5 g, 0.1 mol) and the solution is cooled to 0C in an ice bath.
Diisopropylcarbodiimide (12.6 g, 0.1 mol) dissolved in 50 mL
of dichloromethane is added in one portion and the reaction is stirred for 12 hours. The suspended solids are removed by filtration and washed with dichloromethane. The solution is evaporated to a solid and the desired product, 4, is obtained after chromatography on silica gel using dichloromethane/ethanol as eluent.
Example 3 (N-t-butyloxycarbonylaminomethyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine ethyl ester, 5.
The product from Example 2, 4, is dissolved t-butanol/dioxane (4:1, 500 mL), cooled to 0C, and sodium hypobromite solution (0.15 mol) is added. After 6 hours the reaction mixture is evaporated to remove volatile solvents and the residue is diluted with water (500 mL) and extracted (5X200 mL) with dichloromethane. The extracts are combined, dried, and evaporated to a solid.
W094/25477 ~ 3 ~ PCT~B94/00142 Example 4 (N-t-butyloxycarbonylAm;n~methyl)-N-(1-(thymin-1-yl)acetyl)-~-alanine, 6.
The product from Example 3, 5, is dissolved in ethanol (500 mL) and 5M sodium hydroxide (20 mL) is added.
The solution is stirred for 6 hours, then neutralized with 5N
hydrochloric acid (20 mL) and the solution evaporated to a solid. This solid is recrystallized to give the title compound.
Example 5 1-(Chlorocarbonylamino)-thymine, 8.
l-Amino thymine (7, 12.5 g, 0.1 mol) is dissolved in tetrahydrofuran (500 mL) and the solution is cooled to 0C
and a 2M solution of triphosgene in THF (150 mL) is added and the reaction is stirred for 4 hours. The solution is evaporated to a solid, which is used as is in the next reaction.
Example 6 N-(2-t-Butyloxycarbonylaminoethyl)-N-(thymin-1-yl-amino-carbonyl)glycine ethyl e~ter, 9.
The product from Example 5, 8, is dissolved in THF
(500 mL) and diisopropylethylamine (12.9 g, 0.1 mol) is added, followed by N-(2-t-butyloxycarbonylaminoethyl)glycine ethyl ester (24.6 g, 0.1 mol) and the solution stirred for 12 hours. The reaction is diluted with 1000 mL of diethyl ether and extracted 3 times with O.lN HC1 solution. The organic layer is washed with diluted sodium bicarbonate solution, dried, filtered and evaporated to give a solid.
Example 7 30 N-(2-t-Butyloxycarbonylaminoethyl)-N-(thymin-1-yl-amino-carbonyl)glycine, 10.
The product from Example 6, 9, is dissolved in ethanol (500 mL) and 2M sodium hydroxide (50 mL) is added.
The reaction is stirred for 6 hours, then neutralized with 50 ~ 094t25477 2 ~ ~ ~ 2 ~ ~ PCT~B94/00142 .
mL of 2M HC1 solution, and evaporated to remove the ethanol.
The residue is dissolved in dichloromethane (250 mL) and is extracted with water (2X50 mL), dried, filtered, and evaporated to a solid.
5 Example 8 2-Azido-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, 12.
2-Hydroxy-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, (11, 26.1 g, 0.1 mol), triphenylphosphine (26.2 10 g, 0.10 mol), diethylazodicarboxylate (17.4 g, 0.1 mol), and diphenylphosphorylazide (27.5 g, 0.1 mol) is dissolved in THF
(500 mL) and heated to reflux and maintained there for 8 hours. The reaction is cooled to room temperature, evaporated to an oil, and the product isolated by column chromatography using dichloromethane:ethanol as eluent.
Example 9 2-Iminotriphenylphosphoranyl-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, 13.
The product, 12, from Example 8 is dissolved in THF
and triphenylphosphine (26.2 g, 0.1 mol) is added and the reaction is stirred for 4 hours. This solution is used as is for the next reaction (Example 10).
Example 10 2-Isocyanato-5-(t-butyloxycarbonylamino)pentanoic acid ethyl ester, I4.
The reaction solution from Fxample 9 is placed in a Parr~ bomb and carbon dioxide (22 g, 0.5 mol) is condensed into the bomb. The bomb is sealed and heated to 50C for 12 hours. The bomb is cooled and vented to atmospheric 30 pressure. The solution is transferred from the bomb to a flask and used as is in the next reaction (Example 11).
W094/25477 ~ 2 3 ~ ~ PCT~B94/00142 Example 11 2-(Thymin-l-ylcarbonylamino)-5-(t-butyloxycarbonyl ~m; no) pentanoic acid ethyl ester, 15.
The reaction solution from Example 10 i8 placed in a flask and to this is added thymine (12.6 g, 0.1 mol). The resulting solution is allowed to stir for 12 hours, then is evaporated to a solid, which is purified by column chromatography using dichlormethane:ethanol as the eluent.
Example 12 2-(Thymin-l-ylcarbonylamino)-5-(t-butyloxycarbonyl-amino)pentanoic acid, 16.
The product from Example 11, 15, is dissolved in ethanol (500 mL) and to this added 2M sodium hydroxide (50 mL) and the reaction stirred for 12 hours. The reaction is 15 neutralized with 2M HC1 solution (50 mL) and evaporated to a small volume. This residue is diluted with water (250 mL) and extracted with dichloromethane (4X100 mL), dried, filtered, and evaporated to give a solid.
Example 13 1-(2(-Thyminyl)acetyl)-1-(2-(tBoc-aminopropyl))glycine, 17 1,3-Diaminopropane (0.05 mmol) was dissolved in THF
(100 mL) and chloroacetic acid (0.045 mmol) was added and the reaction heated at reflux for 4 hours and cooled to room temperature. The solution was diluted with diethyl ether (500 mL) and extracted 3 times with lN NaOH solution. The combined water layers were acidified to pH = 4 and extracted with dichloromethane (5X50 mL). The organic layers were combined, dried, filtered and evaporated to an oil. This oil was dissolved in methanol (1000 mL) and dry HCl gas added.
30 The reaction was heated to reflux and maintained there for 8 hours. The reaction was cooled and evaporated to an oil.
This oil was dissolved in dioxane/water and p-nitrophenyl-t-butylcarbonate (0.05 mmol) was added and the pH adjusted to 10. The reaction was stirred for 4 hours, then neutralized and extracted 5 times with dichloromethane. The methyl ester 094/25477 ~ ~12 3 ~ ` PCT~B94/00142 was dissolved in 50~ DMF in dichloromethane and to this was added dicyclohexylcarbodiimide (DCC, 0.05 mmol) and hydroxbenzotriazole (0.05 mmol), and 2-thyminylacetic acid (0.05 mmol). The reaction was stirred for 18 hours then the 5 DCC was removed by filtration and the residue evaporated to an oil. The oil was purified by column chromatography.
Example 14 3-(Boc-amino)-1,2-propanediol, 18 3-Amino-1,2-propanediol (40.00 g, 0.440 mol, 1.0 eqv) was dissolved in water (1000 ml) and cooled to 0 C, and di-tert-butyl dicarbonate (115.0 g, 0.526 mol, 1.2 eqv) was added in one portion. The reaction mixture was heated to room temperature on a water bath with stirring. The pH was maintained at 10.5 with a solution of sodium hydroxide (17.56 15 g, 0.440 mol, 1.0 eqv) in water (120 ml). When the addition of aqueous sodium hydroxide was completed, the reaction mixture was stirred overnight at room temperature.
Subsequently, ethyl acetate (750 ml) was added to the reaction mixture followed by cooling to 0C and the pH was adjusted to 2.5 with 4N sulfuric acid with vigorous stirring.
The phases were separated. The water phase was washed with additional ethyl acetate (6x350 ml). The volume of the organic phase was reduced to 900 ml by evaporation under reduced pressure and washed with a saturated aqueous solution of potassium hydrogen sulfate diluted to twice its volume (lx1000 ml) and with saturated aqueous sodium chloride (lx500 ml). The organic phase was dried (MgS04) and evaporated under reduced pressure to yield 50.12 9 (60~) of the title compound. The product could be solidified by evaporation from methylene chloride and subsequent freezing. lH-NMR
(CDCl3/TMS): ~ = 1.43 (s, 9H, Me3C), 3.25 (m, 2H, CH2), 3.57 (m, 2H, CH2), 3.73 (m, lH, CH). l3C-NMR (CDCl3/TMS): ~ = 28.2 (Me3C), 42.6 (CH2), 63.5, 71.1 (CH2OH, CHOH), 79.5 (Me3C), 157.0 (C=O).
W094/25477 ~ PCT~B94/00142 Example 15 Boc-aminoacetaldehyde, 19 3-(Boc-amino)-l~2-propanediol (18, 20.76 g, 0.109 mol, 1 eqv) was suspended in water (150 ml). Potassium m-5 periodate (24.97 g, 0.109 mol, 1 eqv) was added and thereaction mixture was stirred for 2 h at room temperature under nitrogen. The reaction mixture was filtered and the water phase was extracted with chloroform (6x250 ml). The organic phase was dried (MgS04) and evaporated to afford crude Boc-aminoacetaldehyde as a golden oil. This oil was kugelrohr distilled at 80C and 0.2 mbar to yield 13.19 g (76~) of the title compound as a semicrystalline solid. lHNMR
(DMSO-d6/TMS): ~ = 1.47 (s, 9H, Me3C), 3.81 (d, J=5.6 Hz, 2H, CH2), 7.22 (b, 1 H, NH), 9.54 (s, 1 H, CHO). l3C-NMR (DMSO-d6/TMS): ~ = 28.2 (Me3C), 50.5 (CH2), 78.4 (Me3C), 156.1(carbamate C=O), 200.6 (CHO). Anal. Calcd. for C7Hl3N03: C, 52.82; H, 8.23; N, 8.80. Found: C, 52.21; H, 8.15; N, 8.46.
Example 16 (Boc-amino)ethylglycine Methyl Ester, 20 20 A. Reduction With Sodium Cyanoborohydride Boc-aminoacetaldehyde (19, 1.00 g, 6.3 mmol, 1 eqv) was dissolved in methanol (50 ml). Anhydrous sodium acetate (1.03 g, 12.6 mmol, 2 eqv), glycine methyl ester hydrochloride (Aldrich Chemical Co., 0.79 g, 6.3 mmol, 1 eqv) and sodium cyanoborohydride (1.97 g, 31.4 mmol, 5 eqv) were added to the solution in that order. The reaction mixture was stirred for 2 h at room temperature under nitrogen.
Water (50 ml) was added to the suspension and the resulting clear solution was evaporated under reduced pressure to remove the methanol. The aqueous phase was extracted with methylene chloride (3xlO0 ml). The organic phase was washed with a saturated aqueous solution of sodium chloride (lxlO0 ml), dried (Na2S04), filtered and then evaporated under reduced pressure affording 1.41 g of crude title compound as 35 a yellow oil. The crude product was kugelrohr distilled at 110C and 0.5 mbar to yield 0.49 g (34~) of 2-(Boc-W094/2~477 ~3 PCTnB94/00142 amino)ethylglycine methyl ester as a colorless liquid. lH-NMR (CDCl3/TMS): ~ = 1.36 (s, 9H, Me3C), 1.91 (s, lH, NH), 2.67 (t, J=6 Hz, 2H, NHCH2), 3.13 (q, J=6 Hz, 2H, NHCH2), 3.34 (s, 2H, CH2COO), 3.65 (s, 3H, OMe), 5.13 (b, lH, carbamate NH). l3C-NMR (CDCl3/TMS): ~ = 28.2 (Me3C), 39.9, 48.5 (NHCH2), 50.0 (CH2COO), 51.5 (OMe), 78.9 (Me3C), 155.9 (carbamate C=O), 172.6 (ester C=O). Anal. Calcd for CloH2N2O4 C, 51.71; H, 8.68; N, 12.06. Found: C, 51.55; H, 8.72; N, 11.79.
10 B. Catalytic hydrogenation Boc-aminoacetaldehyde (2.08 g, 13.1 mmol, 1 eqv) was dissolved in methanol (50 ml) and cooled to 0 C.
Palladium on activated carbon (10~, 0.4 g) was added under nitrogen and with vigorous stirring. Anhydrous sodium acetate (2.14 g, 26.1 mmol, 2 eqv) and glycine methyl ester, hydrochloride (1.64 g, 13.1 mmol, 1 eqv) each dissolved in methanol (25 ml) were added to the mixture. The reaction mixture was hydrogenated at atmospheric pressure and room temperature with vigorous stirring, until hydrogen uptake had ceased (when 287 ml, 13.1 mmol, 1 eqv had been consumed) after about 1 h. The reaction mixture was filtered and the solvent removed under reduced pressure. The residue was suspended in water (30 ml), and during vigorous stirring pH
was adjusted to 8 by dropwise addition of 0.5 N NaOH. The 25 water phase was extracted with methylene chloride (4x50 ml).
The organic phase was dried (Na2S04), filtered and evaporated under reduced pressure to yield 3.03 g of crude title compound as a golden oil. The crude product was kugelrohr distilled at 100 C and 0.2 mbar to afford 2.33 g (77~) of 2-(Boc-amino)ethylglycine methyl ester as a colorless liquid.
The analytical data were in accord with those provided above for the reduction with sodium cyanoborohydride.
PCT~B94/00142 _ W094/~477 2I~123~
Example 17 General Method for the Synthesis of PNA Oligomers Oligomers were prepared generally in accordance with the methods disclosed by WO 92/20702. Benzyhydrylamine resin (initially loaded 0.28 mmol/gm with Boc-L-Lys(2-chlorobenyloxycarbonyl)) was swollen in DMF and an excess of a monomer to be coupled was added, followed by dicyclohexyl-carbodiimide (0.15M in 509O' DMF in dichloromethane). The Boc deprotection was accomplished by trifluoroacetic acid treatment. The progress of the coupling reactions was monitored by quantitative ninhydrin analysis. The PNA was released from the resin using anhydrous HF under standard conditions. The products were purified using HPLC with acetonitrile-water (O.l~TFA) gradient and structure confirmed 15 by fast atom bombardment mass spectrometry. The following sequences have been synthesized by this method:
H-TloLysNH2 H-T4CTsLysNH2 20 H-T4cT2cT2LysNH2 H-TGTAcGTcAcAAcTA-NH2 H-CCTTCCcTT-NH2 H-lllllllllCCCCCCC-NH2 H-CCCCCC~lllllllll-NH2 H-TTcTcTcTcT-NH2 H-CCCCCACCACTTCCCCTCTC-(Lys)gNH2 H-CTTATATTCCGTCATCGCTCLys -NH2 H-TATTCCGTCATCGCTCCTCALys-NH2 ~ 094/25477 ~16 12 ~ ~ PCT~B94100142 H-CTGCTGCCTCTGTCTCAGGTLysNH2 H-T4-($-alanine)C-T5LysNH2 H-T4-(~-alanine)T-T5LysNH2 Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.
WO 94/25477 PCT1~94/00142 ~
~123~
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLI QNT: Nielsen, Peter E.
Buchardt, Ole Egholm, Michael Berg, Rolf H.
(ii) TITLE OF INVENTION: Novel Peptide Nucleic Acids (iii) NUMBER OF SEQUENCES: 24 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz, and Norris (B) STREET: One Liberty Place - 46th Floor (C) CITY: Philadelphia (D) STATE: PA
(E) COUNTRY: USA
(F) ZIP: 19103 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (vi) CURRENT APPLI QTION DATA:
(A) APPLI Q TION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Lucci, Joseph (B) REGISTRATION NUMBER: 33,307 (C) REFERENCE/DOCKET NUMBER: ISIS1017 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 215-568-3100 (B) TELEFAX: 215-568-3439 (2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= MODIFIED-SITE
/note= "Thymine heterocycle is attached to ~IO 9412~477 2 ~ 6 ~L 2 3 0 PCT/IB94/00142 N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D~ OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label- Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
- (A) NAME~KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
WO 94/25477 21612 3 Q PCT~B94/00142 ~
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: Jlabel= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) S~QU~N~ DESCRIPTION: SEQ ID NO:1:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEAl~XE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
0 94/25477 ~ 3 0 PCT~B94/00142 (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine throuyh the N-acetyl group at postion l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 8 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 W 0 94/25477 21~1~ 3 ~ PCT~B94/00142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 l0 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: ll amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note5 "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site 0 94125477 ~ 2 3 0 PCT~B94/00142 (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)ylycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to - N-acetyl(2-aminoethyl~glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: lO
(D) OTHER INFORMATION: /label= Modified-site /note_ "Thymine heterocycle is attached to W 0 94/2~477 2 ~ 61~ 3 ~ PCTnB94/00142 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) ~u~N~ DESCRIPTION: SEQ ID NO:3:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at positlon 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site ~ 94/~5477 2 1~ 12 3 ~ PCT/IB94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note_ ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 10 (2) INFORMATION FOR SEQ ID NO:s:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids W 0 94/25477 2 ~ 3 ~ PCTnB94/00142 (B) TYPE: amino acid (C) STRANDEDNESS: sinyle (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "A~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~ ~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl 0 94/2~477 21 ~ PCT~B94/00142 group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label_ Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: lO
(D) OTEER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTEER INFORMATION: /label= Modified-site /note= "~n; n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site ~ (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site 2 ~ 3 ~
WO 94/25477 PCT~B94/00142 (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle i9 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEAlU~E:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l o~ the heterocycle."
~o 94,25477 21612 ~ i~ PCT/IB94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEA'luKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B~ LOCATION: 8 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 o~ the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 W O 94/25477 PCT~B94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
~ O 94/25477 ~161~ ~ ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle iS attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) S~Qu~N~ DESCRIPTION: SEQ ID NO:7:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa l 5 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single WO 94/25477 2 ~ PCT/IB94/00142 (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "~en;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATuKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acety(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= l~ n i n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
~1~123~
0 94/25477 PCT~B94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through th~e N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle iæ attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site - /note= "A~ni n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site WO 94/25477 21~ ~ ~ 3 ~ PCT~B94/00142 ~
/note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa l 5 l0 15 (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 2 ~ 3 ~
~VO 94/~5477 PCT/IB94/00142 (D) OTHER INFORMATION: Jlabel= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "~n; nP heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl - group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site W O 94/2~477 PCTnB94/00l42 ~
~ 3 9 44 -/note= ~ n i ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/REY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl?glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE: -(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "~nine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
0 94/25477 ~ 2 3 ~ PCT~B94/00142 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STR~N~ S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= ~'A~nine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
- (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~
WO 94/25477 2 ~ 3 ~ PCTm394/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modi~ied-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= DThymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl ~ 0 94/2~477 21~ ~. 2 3 ~ PCTnB94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine th~ough the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURB:
(A) NAME/KEY: Modi~ied-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FBATURE:
(A) NAME/KEY: Modified-site - (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.l' (ix) FEATURE:
(A) NAME/KEY: Modified-site WO 94/25477 2 ~ 3 ~ PCTnB94/00142 (B) LOCATION: 9 (D) Ol~R INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:11:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
~ 2 1 612 3 ~ PCT/IB94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: S
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /notec "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site - /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site W O 94/25477 PCT~B94/00142 ~
2 ~ 3 ~
~note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEALuKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified,site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids 0 94125477 _ 51 _ PCT~B94/00142 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site - (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
r (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl WO 94/25477 ~ ~ 6 ~ ~ 3 ~ PCT~B94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 tD) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-~ite (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note- "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site ~VO 94/2~;477 ~ 3 0 PCT/IB94/00142 (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) Sh'QUh'N~h DESCRIPTION: SEQ ID NO:13:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W O 94/2~477 ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l o~ the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 ~O 94/25477 211~1~ 3 0 PCT/IB94/00142 (D~ OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-amlnoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site L (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi) ~QU~N~ DESCRIPTION: SEQ ID NO:14:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site W O 94/25477 P~CTnnB94/00142 (B) LOCP.TION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
~A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to 0 94/2~477 % 1. 61~ 3 Q PCT~B94/00142 N-acetyl~2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(Xi ) ~QU~N~ DESCRIPTION: SEQ ID NO:15:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:16:
(i) S~U~N~: CHARACTERISTICS:
(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) sTR~NnRnNRss single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)ylycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site W 0 94/25477 PCT~B94/00142 _ 2 ~ 3 ~ ~
/note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAluKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
0 94/2S477 ~ PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= ~Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acety(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) S~QU~N~ DESCRIPTION: SEQ ID NO:1~:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 lO 15 (2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTX: 29 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown WO 94/2~477 ~ PCT~B94/00142 (ii) MOLECULB TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine th,rough the N-acetyl group at position l of the heterocycle.'~
(ix) FEA~l~U~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEAl~KE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note- "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site '2,1~1~3~
0 94/25477 PCT~B94/00142 (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
- (A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to W O 94/25477 PCTnB94/00l42 _ 2 3 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified- 8 ite (B) LOCATION: 1~
(D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle iB attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of thr heterocycle."
(ix) FEA'l'U~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
~6~
_ W 0 94/25477 PCT~B94/00142 . .
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DBSCRIPTION: SEQ ID NO:17:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Lys LYB Lys Lys Lys Lys Lys Lys (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) sTR~Nn~N~s single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "~n ' n~ heterocycle is attached to W O 94/2~477 2 ~ ~12 3 0 PCTnB94/00142 ~
N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.'~
(ix) FEATURE:
D
~0 94/25477 PCT/IB94/00142 (A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAMB/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= ~Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LO Q TION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAluKE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site W O 94/25477 2 ~ PCT~B94/00142 /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site W 0 94/25477 ~ 1 6 12 3 0 PCT~B94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 - (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OT~ER INFORMATION: /label= Modified-site WO 94/25477 21~ O PCTnB94/00142 /note= "Cytosine heterocycle i6 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modi$ied-site /note= "~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modi$ied-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
2 ~ 3 ~
0 94/25477 PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl - group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "~n~ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 WO 94/2~;477 2 ~ PCT/IB94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids ~B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n;ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the haterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
O 94/25477 ~ 3 0 PCT~B94/00142 (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site tB) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= ~Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEAlU~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 WO 94/25477 2 t ~ ~ ~ 3 ~ PCTtIB94tO0142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified- 8 ite /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heteroside is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl O 94/25477 ~ 1$ 1 ~ ~ ~ PCT~B94/00142 group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of thr heterocycle."
(ix) FEATURE:
(A) NAME/REY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "~ni ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(xi) ~Qu~N~ DESCRIPTION: SEQ ID NO:20:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:21:
(i) ~u~N~ CHARACTERISTICS:
(A) LENGTH: 20 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 W O 94/25477 PCT~B94/00142 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= ll~n i ne heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site O 94/2~477 ~ 3 ~ PCT~B94/00142 /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "A~n;n~ heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W 0 94/25477 ~ I ~ / 3 PCT~B94/00142 (ix) FEATU~: ~
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa ~6~3~
0 94/25477 PCT~B94/00142 Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO:22:
(i) S~Qu~N~ CHARACTERISTICS:
(A) LENGTH: 21 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
W O 94/25477 2 ~ ~12 3 0 PCT~B94/00142 ~
(ix) FEAlUKE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle.~' -(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= ~Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: ll (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12 ~ O 94l25477 ~16 12 3 ~ PCT~B94/00142 (D) OTHBR INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 13 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 14 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 15 (D) OTHBR INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 16 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 17 (D) OTHER INFORMATION: /label= Modified-site /note= "Adenine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: 18 (D) OTHER INFORMATION: /label= Modified-site ~6~
WO 94/25477 PCT~B94/00142 /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acet group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19 (D) OTHER INFORMATION: /label= Modified-site /note= "Guanine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 9 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of thr heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys (2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STR~Nn~nN~S: single (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
2 ~ 3 ~
0 94/2~477 PCTnBg4/00l42 (A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.'~
(ix) FEAlu~E:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycinr through the N-acetyl group at position 1 of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note5 ~Beta isoform of al ~nin~
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Cytosine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9 (D) OTHER INFORMATION: /label= Modified-site tnote= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl W O 94/2~477 2 ~ ~ ~ 2 3 ~ PCT~B94100142 ~
group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: l0 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle.
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: ll (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Lys l 5 l0 (2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: 8 ingle (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(A) NAME/ Æ Y: Modified-site (B) LOCATION: l (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position l of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3 (D) OTHER INFORMATION: /la~el= Modified-site /note= "Thymine heterocycle is attached to ~ 0 94/2~477 ~1612 3 ~ PCT~B94/00142 N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle i8 attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5 (D) OTHER INFORMATION: /label= Modified-site /note= "Beta isoform of alanine."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle.~' (ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: g (D) OTHER INFORMATION: /label= Modified-site /note= ~Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 10 W 0 94/25477 21~1 ~ 3 ~ PCT~B94/00142 ~
(D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(ix) FEATURE:
(A) NAME/K~Y: Modified-site (B) LOCATION: 11 (D) OTHER INFORMATION: /label= Modified-site /note= "Thymine heterocycle is attached to N-acetyl(2-aminoethyl)glycine through the N-acetyl group at position 1 of the heterocycle."
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Lys
Claims (23)
1. A compound having the formula:
wherein:
n is at least 2, each of L1-Ln is independently selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of C1-Cn is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R5 and R7 taken together complete an alicyclic or heterocyclic system;
each of D1-Dn is (CR6R7)z where R6 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
each of G1-Gn-1 is -NR3CO-, -NR3CS-, -NR3SO- or -NR3SO2-, in either orientation, where R3 is as defined above each of A1-An and B1-Bn are selected such that:
(a) A is a group of formula (IIa), (IIb) or (IIc), and B is N or R3N+, provided that at least one A is a group of formula (IIc); or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
Q is -CO2H, -CONR'R'', -SO3H or -SO2NR'R'' or an activated derivative of -CO2H or -SO3H; and I is -NHR'''R'''' or -NR'''C(O)R'''', where R', R", R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.
wherein:
n is at least 2, each of L1-Ln is independently selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of C1-Cn is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R5 and R7 taken together complete an alicyclic or heterocyclic system;
each of D1-Dn is (CR6R7)z where R6 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
each of G1-Gn-1 is -NR3CO-, -NR3CS-, -NR3SO- or -NR3SO2-, in either orientation, where R3 is as defined above each of A1-An and B1-Bn are selected such that:
(a) A is a group of formula (IIa), (IIb) or (IIc), and B is N or R3N+, provided that at least one A is a group of formula (IIc); or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
Q is -CO2H, -CONR'R'', -SO3H or -SO2NR'R'' or an activated derivative of -CO2H or -SO3H; and I is -NHR'''R'''' or -NR'''C(O)R'''', where R', R", R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.
2. The compound of claim 1 having the formula:
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k, 1, and m is, independently, zero or an integer from 1 to 5;
each p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k, 1, and m is, independently, zero or an integer from 1 to 5;
each p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
3. The compound of claim 1 having the formula:
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k, 1, and m is, independently, zero or an integer from 1 to 5;
each p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k, 1, and m is, independently, zero or an integer from 1 to 5;
each p is zero or 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
4. A compound having one of the following formulas:
or or wherein:
L is selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, and heterocyclic moieties, reporter ligands, wherein amino groups are, optionally, protected by amino protecting groups;
each C is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (Cl-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each D is (CR6R7)z where R5 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
A and B are selected such that:
(a) A is a group of formula (IIc) and B is N or R3N+; or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2i Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each E is COOH, CSOH, SOOH, SO2OH or an activated or protected derivative thereof; and each F is NHR3 or NPgR3, where R3 is as defined above, and Pg is an amino protecting group.
or or wherein:
L is selected from the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups, and heterocyclic moieties, reporter ligands, wherein amino groups are, optionally, protected by amino protecting groups;
each C is (CR6R7)y where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (Cl-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each D is (CR6R7)z where R5 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
A and B are selected such that:
(a) A is a group of formula (IIc) and B is N or R3N+; or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3) 2i Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each E is COOH, CSOH, SOOH, SO2OH or an activated or protected derivative thereof; and each F is NHR3 or NPgR3, where R3 is as defined above, and Pg is an amino protecting group.
5. The compound of claim 4 having the formula:
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids; and each k, 1, and m is, independently, zero or an integer from 1 to 5.
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids; and each k, 1, and m is, independently, zero or an integer from 1 to 5.
6. The compound of claim 4 having the formula:
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids; and each k, 1, and m is, independently, zero or an integer from 1 to 5.
wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, heterocyclic moieties, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids; and each k, 1, and m is, independently, zero or an integer from 1 to 5.
7. A process for preparing a compound according to claim 1, comprising the steps of:
A) providing a polymer substrate, said polymer being functionalized with a chemical group capable of forming an anchoring linkage with an amino acid;
B) coupling said polymer with a first amino acid through said anchoring linkage, said first amino acid having formula (IV):
(IV) wherein:
L is selected from the group consisting of naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA
intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, wherein amino groups are, optionally, protected by amino protecting groups;
each C is (CR6R7)y where R5 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each D is (CR6R7)2 where R6 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
A and B are selected such that:
(a) A is a group of formula (IIc) and B is N or R3N+; or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3)2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each E is COOH, CSOH, SOOH, SO2OH or an activated or protected derivative thereof; and each F is NHR3 or NPgR3, where R3 is as defined above, and Pg is an amino protecting group;
C) removing said amino protecting group from said coupled first amino acid to generate a free amino group; and D) reacting said free amino group with a second amino acid having formula (IV) to form a peptide chain.
A) providing a polymer substrate, said polymer being functionalized with a chemical group capable of forming an anchoring linkage with an amino acid;
B) coupling said polymer with a first amino acid through said anchoring linkage, said first amino acid having formula (IV):
(IV) wherein:
L is selected from the group consisting of naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA
intercalators, nucleobase-binding groups, heterocyclic moieties, and reporter ligands, wherein amino groups are, optionally, protected by amino protecting groups;
each C is (CR6R7)y where R5 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each D is (CR6R7)2 where R6 and R7 are as defined above;
each of y and z is zero or an integer from 1 to 10, the sum y + z being greater than 2 but not more than 10;
A and B are selected such that:
(a) A is a group of formula (IIc) and B is N or R3N+; or (b) A is a group of formula (IId) and B is CH; or (c) A is a group of formula (IIa) or (IIb) and B
is N or R3N+, provided at least one of y or z is not 1 or 2;
(IIa) (IIb) (IIc) (IId) where:
X is O, S, Se, NR3, CH2 or C(CH3)2;
Y is a single bond, O, S or NR4;
each of p and q is zero or an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy-or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each E is COOH, CSOH, SOOH, SO2OH or an activated or protected derivative thereof; and each F is NHR3 or NPgR3, where R3 is as defined above, and Pg is an amino protecting group;
C) removing said amino protecting group from said coupled first amino acid to generate a free amino group; and D) reacting said free amino group with a second amino acid having formula (IV) to form a peptide chain.
8. The process of claim 7 further comprising the steps of:
E) removing said amino protecting group from said second amino acid to generate a terminal free amino group on said peptide chain; and F) reacting said free amino group on said peptide chain with a further amino acid having formula (IV) to lengthen said peptide chain.
E) removing said amino protecting group from said second amino acid to generate a terminal free amino group on said peptide chain; and F) reacting said free amino group on said peptide chain with a further amino acid having formula (IV) to lengthen said peptide chain.
9. The process of claim 8 wherein steps E and F
are performed a plurality of times.
are performed a plurality of times.
10. The process of claim 8 further comprising removing at least one protecting group remaining on the amino acid moieties of the peptide chain.
11. The process of claim 7 further comprising cleaving said anchoring linkage without substantially degrading said peptide chain.
12. The process of claim 7 wherein the polymer substrate contains polystyrene, polyacrylamide, silica, a composite material, cotton, or a derivative thereof.
13. The process of claim 8 wherein the chemical group capable of forming said anchoring linkage is chloro-, bromo- and iodo-substituted alkyl, amino-substituted alkyl, amino and aryl-substituted alkyl, amino- and alkylaryl-substituted alkyl, hydroxy-substituted alkyl, or a derivative thereof having a spacer group that can be cleaved substantially without degradation of said polypeptide.
14. The process of claim 13 wherein chloro-substi-tuted alkyl is chloromethyl, amino-substituted alkyl is aminomethyl, amino- and alkyl-substituted aryl is .alpha.-aminobenzyl, amino- and alkylaryl-substituted alkyl is selected from the group consisting of .alpha.-amino-3- and .alpha.-amino-4-methylbenzyl, and hydroxy-substituted alkyl is hydroxymethyl.
15. The process of claim 13 wherein:
the chemical group is derived from an amino-containing moiety selected from amino-substituted alkyl, amino- and aryl substituted alkyl, and amino- and alkylaryl-substituted alkyl; and the chemical group includes a spacer group derived from the group consisting of 4-(haloalkyl)aryl-lower alkanoic acids, Boc-aminoacyl-4-(oxymethyl)aryl-lower alkanoic acids, N-Boc-p-acylbenzhydrylamines, N-Boc-4'-(lower alkyl)-p-acylbenzhydrylamines, N-Boc-4'-(lower alkoxy)-p-acylbenzhydrylamines, and 4-hydroxymethylphenoxy-lower alkanoic acids.
the chemical group is derived from an amino-containing moiety selected from amino-substituted alkyl, amino- and aryl substituted alkyl, and amino- and alkylaryl-substituted alkyl; and the chemical group includes a spacer group derived from the group consisting of 4-(haloalkyl)aryl-lower alkanoic acids, Boc-aminoacyl-4-(oxymethyl)aryl-lower alkanoic acids, N-Boc-p-acylbenzhydrylamines, N-Boc-4'-(lower alkyl)-p-acylbenzhydrylamines, N-Boc-4'-(lower alkoxy)-p-acylbenzhydrylamines, and 4-hydroxymethylphenoxy-lower alkanoic acids.
16. A process for sequence-specific recognition of a double-stranded polynucleotide, comprising contacting said polynucleotide with a compound that is different from natural RNA and that binds to one strand of the polynucleotide, thereby displacing the other strand, said being the compound of claim 1.
17. A process for modulating the expression of a gene in an organism, comprising administering to said organism a compound according to claim 1 that specifically binds to DNA or RNA deriving from said gene, said compound being the compound of claim 1.
18. The process of claim 17 wherein said modulation includes inhibiting transcription of said gene.
19. The process of claim 17 wherein said modulation includes inhibiting replication of said gene.
20. A process for treating conditions associated with undesired protein production in an organism, comprising contacting said organism with an effective amount of a compound according to claim 1 that specifically binds with DNA or RNA deriving from a gene controlling said protein production.
21. A process for inducing degradation of DNA or RNA in cells of an organism, comprising administering to said organism a compound according to claim 1 that specifically binds to said DNA or RNA.
22. A process for killing cells or virus, comprising contacting said cells or virus with a compound according to claim 1 that specifically binds to a portion of the genome of said cells or virus.
23. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically effective carrier, binder, thickener, diluent, buffer, preservative, or surface active agent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/054,363 US5539082A (en) | 1993-04-26 | 1993-04-26 | Peptide nucleic acids |
| US08/054,363 | 1993-04-26 | ||
| PCT/IB1994/000142 WO1994025477A2 (en) | 1993-04-26 | 1994-04-25 | Novel peptide nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2161230A1 true CA2161230A1 (en) | 1994-11-10 |
Family
ID=21990528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002161230A Abandoned CA2161230A1 (en) | 1993-04-26 | 1994-04-25 | Novel peptide nucleic acids |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5539082A (en) |
| EP (2) | EP0699208A1 (en) |
| JP (2) | JP3210672B2 (en) |
| KR (1) | KR100195290B1 (en) |
| AU (1) | AU680253B2 (en) |
| CA (1) | CA2161230A1 (en) |
| WO (1) | WO1994025477A2 (en) |
Families Citing this family (1254)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US20040142899A1 (en) * | 1990-01-11 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
| US6414112B1 (en) * | 1991-05-24 | 2002-07-02 | Ole Buchardt | Peptide nucleic acids having 2,6-diaminopurine nucleobases |
| DK51092D0 (en) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
| US7223833B1 (en) * | 1991-05-24 | 2007-05-29 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
| US6451968B1 (en) * | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
| US6713602B1 (en) * | 1991-05-24 | 2004-03-30 | Ole Buchardt | Synthetic procedures for peptide nucleic acids |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
| US6277603B1 (en) * | 1991-12-24 | 2001-08-21 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
| US6117847A (en) * | 1992-03-16 | 2000-09-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides for enhanced modulation of protein kinase C expression |
| US6770738B1 (en) * | 1992-05-22 | 2004-08-03 | Isis Pharmaceuticals, Inc. | Higher order structure and binding of peptide nucleic acids |
| US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| US7825215B1 (en) | 1993-04-26 | 2010-11-02 | Peter E. Nielsen | Substituted nucleic acid mimics |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| AU679566B2 (en) | 1993-09-03 | 1997-07-03 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
| DE4331011A1 (en) * | 1993-09-13 | 1995-03-16 | Bayer Ag | C-branched oligomers that bind nucleic acids for therapy and diagnostics |
| US6710164B1 (en) * | 1993-11-22 | 2004-03-23 | Peter E. Nielsen | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| GB2284208A (en) * | 1993-11-25 | 1995-05-31 | Pna Diagnostics As | Nucleic acid analogues with a chelating functionality for metal ions |
| GB2285445A (en) * | 1993-12-06 | 1995-07-12 | Pna Diagnostics As | Protecting nucleic acids and methods of analysis |
| DE4408534A1 (en) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituted N-ethyl-glycine derivatives for the production of PNA and PNA / DNA hybrids |
| DE4408533A1 (en) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | PNA synthesis using a base-labile amino protecting group |
| DE4427980A1 (en) * | 1994-08-08 | 1996-02-15 | Bayer Ag | Nucleic acid binding oligomers for therapy and diagnostics |
| WO1996015143A1 (en) * | 1994-11-14 | 1996-05-23 | Chiron Corporation | SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH |
| US5844110A (en) * | 1995-02-01 | 1998-12-01 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compound precursors |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| EP0871770A1 (en) * | 1995-05-18 | 1998-10-21 | Abbott Laboratories | Polymeric peptide probes and uses thereof |
| ATE362546T1 (en) | 1995-10-12 | 2007-06-15 | Lansdorp Peter M | METHOD FOR DETECTING MULTIPLE COPIES OF A REPEAT SEQUENCE IN A NUCLEIC ACID MOLECULE |
| US5874532A (en) * | 1997-01-08 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for solution phase synthesis of oligonucleotides and peptides |
| US6001966A (en) * | 1995-10-19 | 1999-12-14 | Proligo Llc | Method for solution phase synthesis of oligonucleotides and peptides |
| AU7016096A (en) * | 1995-10-20 | 1997-05-07 | Trustees Of Boston University | Nucleic acid clamps |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| CA2190430A1 (en) * | 1995-12-12 | 1997-06-13 | Margret Barbara Basinski | Method for measuring genetic messages |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| EP0885236A1 (en) * | 1996-01-26 | 1998-12-23 | Codon Pharmaceuticals, Inc. | Oligonucleotide analogs |
| JP2001508643A (en) * | 1996-03-26 | 2001-07-03 | ラズバン ティー． ラドゥレシュ | Peptides with antiproliferative properties |
| US5763424A (en) * | 1996-03-26 | 1998-06-09 | Gilead Sciences, Inc. | Composition and method for storing nucleotide analogs |
| DE19653445C1 (en) * | 1996-03-26 | 1997-12-11 | Razvan T Dr Med Radulescu | Peptides with antineoplastic properties |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US5821060A (en) * | 1996-08-02 | 1998-10-13 | Atom Sciences, Inc. | DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA |
| US5849196A (en) * | 1996-10-07 | 1998-12-15 | Immune Modulation Maximum | Composition containing peptides and nucleic acids and methods of making same |
| US6528098B2 (en) * | 1996-10-22 | 2003-03-04 | Advanced Viral Research Corp. | Preparation of a therapeutic composition |
| US6043218A (en) | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
| US6566330B1 (en) * | 1996-10-22 | 2003-05-20 | Medical University Of South Carolina Foundation Research Development | Positively charged non-natural amino acids, methods of making and using thereof in peptides |
| US6060246A (en) * | 1996-11-15 | 2000-05-09 | Avi Biopharma, Inc. | Reagent and method for isolation and detection of selected nucleic acid sequences |
| US6110676A (en) * | 1996-12-04 | 2000-08-29 | Boston Probes, Inc. | Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays |
| US7235653B2 (en) * | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US20040023917A1 (en) * | 1996-12-31 | 2004-02-05 | Bennett C. Frank | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| EP2256133B1 (en) | 1997-01-08 | 2016-12-14 | Sigma-Aldrich Co. LLC | Bioconjugation of macromolecules |
| US6893868B2 (en) * | 1997-02-20 | 2005-05-17 | Onco Immunin, Inc. | Homo-doubly labeled compositions for the detection of enzyme activity in biological samples |
| US7312302B2 (en) | 1997-02-20 | 2007-12-25 | Oncolmmunin, Inc. | Compositions for the detection of enzyme activity in biological samples and methods of use thereof |
| US6037137A (en) * | 1997-02-20 | 2000-03-14 | Oncoimmunin, Inc. | Fluorogenic peptides for the detection of protease activity |
| AU6822598A (en) * | 1997-02-24 | 1998-09-09 | Georgia Tech Research Corporation | Method for determining a nucleic acid |
| US6117973A (en) * | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| US5846729A (en) * | 1997-02-27 | 1998-12-08 | Lorne Park Research, Inc. | Assaying nucleotides in solution using a fluorescent intensity quenching effect |
| US6046004A (en) * | 1997-02-27 | 2000-04-04 | Lorne Park Research, Inc. | Solution hybridization of nucleic acids with antisense probes having modified backbones |
| US6251591B1 (en) | 1997-02-27 | 2001-06-26 | Lorne Park Research, Inc. | Quantitative method for detecting nucleotide concentration |
| US6060242A (en) * | 1997-02-27 | 2000-05-09 | Lorne Park Research, Inc. | PNA diagnostic methods |
| ATE241018T1 (en) * | 1997-02-27 | 2003-06-15 | Ingeneus Corp | INVESTIGATION OF NUCLEOTIDES IN SOLUTION USING PNA PROBE |
| US6015887A (en) * | 1997-04-11 | 2000-01-18 | Isis Pharmaceuticals, Inc. | Chiral peptide nucleic acids and methods for preparing same |
| US6716625B1 (en) | 1997-04-16 | 2004-04-06 | Claude Selitrennikoff | Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use |
| US20010039263A1 (en) * | 1997-05-02 | 2001-11-08 | Max-Delbruck-Centrum Fur Molekulare Medizin | Chimeric oligonucleotides and the use thereof |
| US6617422B1 (en) | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
| JP2001501975A (en) * | 1997-05-28 | 2001-02-13 | ペーター・エー・ニールセン | Binding peptide nucleic acids with enhanced cellular uptake |
| US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
| US6528271B1 (en) * | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
| US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| WO1998058256A1 (en) * | 1997-06-16 | 1998-12-23 | The University Of North Carolina At Chapel Hill | PEPTIDO OLIGONUCLEOTIDES (PONs) AND THEIR COMBINATORIAL LIBRARIES |
| US6893815B1 (en) * | 1997-06-30 | 2005-05-17 | Isis Pharmaceuticals, Inc. | Nucleobase heterocyclic combinatorialization |
| AU731909B2 (en) | 1997-07-01 | 2001-04-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6809193B2 (en) | 1997-08-13 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US20070149472A1 (en) * | 1997-08-13 | 2007-06-28 | Mckay Robert | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
| US6960457B1 (en) | 1997-09-04 | 2005-11-01 | Stanford University | Reversible immobilization of arginine-tagged moieties on a silicate surface |
| US6300318B1 (en) | 1997-09-16 | 2001-10-09 | Peter E. Nielsen | Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor |
| US6962778B1 (en) | 1997-09-25 | 2005-11-08 | Boston Probes, Inc. | Methods, kits and compositions for suppressing the binding of detectable probes to non-target sequences in hybridization assays |
| US20030165888A1 (en) * | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
| US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
| US6723560B2 (en) | 1998-10-08 | 2004-04-20 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
| US6472209B1 (en) | 1997-10-17 | 2002-10-29 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
| US6989270B1 (en) | 1997-10-17 | 2006-01-24 | Mayo Foundation For Medical Education And Research | Using polyamide nucleic acid oligomers to engender a biological response |
| AU1366299A (en) | 1997-10-27 | 1999-05-17 | Boston Probes, Inc. | Methods, kits and compositions pertaining to pna molecular beacons |
| US6485901B1 (en) | 1997-10-27 | 2002-11-26 | Boston Probes, Inc. | Methods, kits and compositions pertaining to linear beacons |
| US7427678B2 (en) * | 1998-01-08 | 2008-09-23 | Sigma-Aldrich Co. | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method |
| US6326479B1 (en) | 1998-01-27 | 2001-12-04 | Boston Probes, Inc. | Synthetic polymers and methods, kits or compositions for modulating the solubility of same |
| WO2000018885A1 (en) * | 1998-09-29 | 2000-04-06 | Gamida Cell Ltd. | Methods of controlling proliferation and differentiation of stem and progenitor cells |
| US6361942B1 (en) | 1998-03-24 | 2002-03-26 | Boston Probes, Inc. | Method, kits and compositions pertaining to detection complexes |
| US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
| US20040063618A1 (en) * | 2002-09-30 | 2004-04-01 | Muthiah Manoharan | Peptide nucleic acids having improved uptake and tissue distribution |
| US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
| CA2329252A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for topical delivery of oligonucleotides |
| AU745880B2 (en) | 1998-05-21 | 2002-04-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| US6255050B1 (en) | 1998-05-22 | 2001-07-03 | Lorne Park Research, Inc. | Dynamic hybridization system |
| US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
| EP1095054B1 (en) | 1998-07-09 | 2006-10-25 | Biocept, Inc. | Method of using an improved peptide nucleic acid universal library to optimize dna sequence hybridation |
| US6171794B1 (en) | 1998-07-13 | 2001-01-09 | Rosetta Inpharmatics, Inc. | Methods for determining cross-hybridization |
| US20060019878A1 (en) * | 1998-07-31 | 2006-01-26 | El Shami A S | Polynucleotide encoding autoantigens associated with endometriosis |
| US7981599B1 (en) | 1998-07-31 | 2011-07-19 | Boston Probes, Inc. | Non-nucleic acid probes, probe sets, methods and kits pertaining to the detection of individual human chromosomes X, Y, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 20 as 13/21 as a pair |
| US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| US6225293B1 (en) | 1998-09-02 | 2001-05-01 | Isis Pharmaceuticals, Inc. | Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations |
| SE9803099D0 (en) | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
| US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
| US6069243A (en) * | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US6303799B1 (en) | 1998-11-10 | 2001-10-16 | Naxcor | Polynucleotide crosslinking agents |
| US6492111B1 (en) * | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
| US6441152B1 (en) * | 1998-12-08 | 2002-08-27 | Boston Probes, Inc. | Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices |
| EP1536023B1 (en) * | 1998-12-08 | 2008-03-19 | Boston Probes, Inc. | Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices |
| DE19858440A1 (en) * | 1998-12-17 | 2000-06-21 | Deutsches Krebsforsch | Process for photolithographic biochip synthesis |
| US6656692B2 (en) | 1999-12-21 | 2003-12-02 | Ingeneus Corporation | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes |
| US6420115B1 (en) | 1999-12-21 | 2002-07-16 | Ingeneus Corporation | Cation mediated triplex hybridization assay |
| US6858390B2 (en) | 1998-12-31 | 2005-02-22 | Ingeneus Corporation | Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes |
| US6403313B1 (en) | 1999-12-21 | 2002-06-11 | Ingeneus Corporation | Fluorescent intensity assay for duplex and triplex nucleic acid hybridization solution utilizing fluorescent intercalators |
| US6300320B1 (en) | 1999-01-05 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Modulation of c-jun using inhibitors of protein kinase C |
| AU764660B2 (en) | 1999-01-08 | 2003-08-28 | Lonza Cologne Ag | Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane |
| US6432642B1 (en) * | 1999-01-15 | 2002-08-13 | Pe Corporation (Ny) | Binary probe and clamp composition and methods for a target hybridization detection |
| US6455682B1 (en) | 1999-01-20 | 2002-09-24 | Northwestern University | DNA mobility modifier |
| US6399765B1 (en) | 1999-03-17 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Methods for removing dimethoxytrityl groups from oligonucleotides |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| KR20020013519A (en) * | 1999-04-08 | 2002-02-20 | 추후제출 | Antisense Oligonucleotides Comprising Universal and/or Degenerate Bases |
| US6376186B1 (en) | 1999-05-03 | 2002-04-23 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of staphylococcus |
| AU5267800A (en) | 1999-05-03 | 2000-11-17 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of bacteria in the family enterobacteriaceae |
| EP1925678B1 (en) | 1999-05-03 | 2009-07-22 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
| CA2370123C (en) | 1999-05-03 | 2010-09-14 | Gen-Probe Incorporated | Polynucleotide probes for detection and quantitation of actinomycetes |
| US6821770B1 (en) * | 1999-05-03 | 2004-11-23 | Gen-Probe Incorporated | Polynucleotide matrix-based method of identifying microorganisms |
| US6331618B1 (en) * | 1999-05-13 | 2001-12-18 | Pe Corporation (Ny) | Compositions of solvents and high concentrations of nucleic acid analogs |
| US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| US7060432B1 (en) | 1999-06-15 | 2006-06-13 | Applera Corporation | Methods for the detection, identification, and/or enumeration of yeast, particularly in wine |
| US6645733B1 (en) | 1999-06-25 | 2003-11-11 | Ingeneus Corporation | Fluorescent intensity method for assaying binding between proteins or peptides |
| CA2377739A1 (en) | 1999-07-02 | 2001-01-11 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto |
| US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
| US20020045182A1 (en) * | 1999-07-16 | 2002-04-18 | Lynx Therapeutics, Inc. | Multiplexed differential displacement for nucleic acid determinations |
| CA2317179A1 (en) | 1999-09-01 | 2001-03-01 | Affymetrix, Inc. | Macromolecular arrays on polymeric brushes and methods for preparing the same |
| US6312956B1 (en) | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
| US6660845B1 (en) * | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
| US7309569B2 (en) | 1999-12-21 | 2007-12-18 | Ingeneus, Inc. | Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6924108B2 (en) | 1999-12-21 | 2005-08-02 | Ingeneus Corporation | Nucleic acid binding enhancement by conjugation with nucleotides, nucleosides, bases and/or their analogues |
| US6911536B1 (en) | 1999-12-21 | 2005-06-28 | Ingeneus Corporation | Triplex and quadruplex catalytic hybridization |
| US7052844B2 (en) * | 1999-12-21 | 2006-05-30 | Ingeneus, Inc. | Purification of DS-DNA using heteropolymeric capture probes and a triplex, quadruplex or homologous duplex binding mechanism |
| US20030181412A1 (en) * | 1999-12-21 | 2003-09-25 | Ingeneus Corporation | Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses |
| US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
| US6613524B1 (en) | 2000-01-24 | 2003-09-02 | Ingeneus Corporation | Amperometric affinity assay and electrically stimulated complexes of nucleic acids |
| US7220541B2 (en) * | 2000-01-24 | 2007-05-22 | Ingeneus, Inc. | Homogeneous assay of biopolymer binding by means of multiple measurements under varied conditions |
| US20030170659A1 (en) * | 2000-01-24 | 2003-09-11 | Ingeneus Corporation | Electrical treatment of binding media to encourage, discourage and/or study biopolymer binding |
| US6982147B2 (en) * | 2000-01-24 | 2006-01-03 | Ingeneus Corporation | Apparatus for assaying biopolymer binding by means of multiple measurements under varied conditions |
| JP2003525292A (en) | 2000-03-01 | 2003-08-26 | エポック・バイオサイエンシーズ・インコーポレイテッド | Modified oligonucleotides for mismatch discrimination |
| EP1944310A3 (en) | 2000-03-01 | 2008-08-06 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
| US6962906B2 (en) * | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| US20040014644A1 (en) * | 2000-03-14 | 2004-01-22 | Vladimir Efimov | Oligonucleotide analogues and methods of use for modulating gene expression |
| EP1263773A4 (en) | 2000-03-14 | 2005-08-31 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
| US20050043262A1 (en) * | 2000-03-29 | 2005-02-24 | Weiss Robert H. | Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor |
| EP2363133A1 (en) | 2000-03-31 | 2011-09-07 | Trustees of Boston University | Composition comprising DNA fragments and medical and cosmetic uses thereof |
| US6936443B2 (en) * | 2000-04-03 | 2005-08-30 | Cytyc Corporation | Detection and typing of human papillomavirus using PNA probes |
| AU2001256976A1 (en) * | 2000-04-03 | 2001-10-15 | Cytyc Corporation | Detection and typing of human papillomavirus using pna probes |
| CA2408921A1 (en) * | 2000-05-10 | 2001-11-15 | Bristol-Myers Squibb Company | Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof |
| US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
| US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
| US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
| US7105962B2 (en) * | 2000-08-03 | 2006-09-12 | Matsushita Electric Industrial Co., Ltd. | Brushless motor for partable electronic equipment with wire treatment technique of coils |
| US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| ATE414794T1 (en) | 2000-09-01 | 2008-12-15 | Gen Probe Inc | AMPLIFICATION OF HIV-1 SEQUENCES FOR DETECTION OF SEQUENCES ASSOCIATED WITH DRUG RESISTANCE MUTATIONS |
| JP2004527221A (en) | 2000-09-12 | 2004-09-09 | ジェン−プロウブ インコーポレイテッド | Compositions, methods and kits for determining the presence of Cryptosporidium organisms in a test sample |
| ATE373717T1 (en) * | 2000-09-12 | 2007-10-15 | Univ Washington | PDE8A AND ITS USE |
| ATE432994T1 (en) * | 2000-09-26 | 2009-06-15 | Boston Probes Inc | PROBE, PROBE KITS, METHODS AND KITS FOR DETECTING, IDENTIFYING AND/OR COUNTING BACTERIA |
| EP2325263B1 (en) | 2000-09-29 | 2013-01-23 | Life Technologies Corporation | Modified carbocyanine dyes and their conjugates |
| US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
| EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
| WO2002040477A2 (en) * | 2000-11-03 | 2002-05-23 | President And Fellows Of Harvard College | Saframycins, analogues and uses thereof |
| ATE544473T1 (en) * | 2000-11-09 | 2012-02-15 | Cold Spring Harbor Lab | CHIMERIC MOLECULES FOR MODULATION OF GENE EXPRESSION |
| EP1356113B1 (en) * | 2000-12-15 | 2012-07-18 | Life Technologies Corporation | Methods for determining organisms |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| AU2002246978A1 (en) * | 2001-01-10 | 2002-07-24 | Symyx Technologies, Inc. | Polymer brushes for immobilizing molecules to a surface |
| US7279324B2 (en) * | 2001-01-23 | 2007-10-09 | Duke University | Nucleic acid encoding G-protein coupled receptor with modified DRY motif |
| DE60239020D1 (en) * | 2001-03-09 | 2011-03-03 | Boston Probes Inc | Combination oligomers, methods, kits and compositions |
| US6573051B2 (en) * | 2001-03-09 | 2003-06-03 | Molecular Staging, Inc. | Open circle probes with intramolecular stem structures |
| ATE434936T1 (en) | 2001-03-14 | 2009-07-15 | Myriad Genetics Inc | TSG101-GAG INTERACTION AND THEIR USE |
| WO2002074929A2 (en) * | 2001-03-19 | 2002-09-26 | President And Fellows Of Harvard College | Evolving new molecular function |
| US8026051B2 (en) | 2001-05-18 | 2011-09-27 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the detection of Candida |
| US20030207804A1 (en) * | 2001-05-25 | 2003-11-06 | Muthiah Manoharan | Modified peptide nucleic acids |
| AU2002312059B2 (en) | 2001-05-25 | 2009-01-15 | Duke University | Modulators of pharmacological agents |
| ATE371026T1 (en) | 2001-06-20 | 2007-09-15 | Nuevolution As | A METHOD FOR SYNTHESIS OF MATTRICE-DEPENDENT MOLECULES |
| EP1992643A3 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| CA2790034A1 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US6921812B1 (en) | 2001-07-03 | 2005-07-26 | Isis Pharmaceuticals, Inc. | Methods of modulating pharmacokinetics of oligonucleotides |
| WO2003006025A1 (en) * | 2001-07-09 | 2003-01-23 | Mayo Foundation For Medical Education And Research | Methods and materials for treating bone conditions |
| US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US20030082140A1 (en) * | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| US20030124196A1 (en) | 2001-08-22 | 2003-07-03 | Susan Weinbach | Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1432826B1 (en) | 2001-09-24 | 2012-12-12 | Life Technologies Corporation | Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid |
| NZ566396A (en) | 2001-10-09 | 2009-07-31 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
| CA2457565A1 (en) | 2001-10-09 | 2003-04-17 | Genentech, Inc. | Novel acidic mammalian proteins and polynucleotides encoding the same |
| US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| US6977148B2 (en) * | 2001-10-15 | 2005-12-20 | Qiagen Gmbh | Multiple displacement amplification |
| US6617137B2 (en) | 2001-10-15 | 2003-09-09 | Molecular Staging Inc. | Method of amplifying whole genomes without subjecting the genome to denaturing conditions |
| US7297485B2 (en) * | 2001-10-15 | 2007-11-20 | Qiagen Gmbh | Method for nucleic acid amplification that results in low amplification bias |
| WO2003088808A2 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US20030124592A1 (en) * | 2001-10-24 | 2003-07-03 | Bioprofile, Llc | Methods for detecting genetic haplotypes by interaction with probes |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| EP1575571A4 (en) | 2002-01-02 | 2008-06-25 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
| WO2003057916A2 (en) | 2002-01-09 | 2003-07-17 | Riken | Cancer profiles |
| AU2003210629A1 (en) * | 2002-01-23 | 2003-09-02 | Proligo, Llc | Methods for the integrated synthesis and purification of oligonucleotides |
| IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
| WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
| ATE416183T1 (en) * | 2002-02-01 | 2008-12-15 | Univ Mcgill | OLIGONUCLEOTIDES WITH ALTERNATE SEGMENTS AND USES THEREOF |
| US7553619B2 (en) | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
| US20030191075A1 (en) * | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
| US20030182669A1 (en) * | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
| US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
| US8017758B2 (en) * | 2002-03-21 | 2011-09-13 | Boston Probes, Inc. | PNA oligomers, oligomer sets, methods and kits pertaining to the detection of Bacillus anthracis |
| US20030211509A1 (en) * | 2002-03-26 | 2003-11-13 | Wiley Steven R. | TNF-delta ligand and uses thereof |
| US7169916B2 (en) * | 2002-04-01 | 2007-01-30 | Isis Pharmaceuticals, Inc. | Chloral-free DCA in oligonucleotide synthesis |
| US7052840B2 (en) * | 2002-04-03 | 2006-05-30 | Capitol Genomix, Inc. | Reversible association of nucleic acid with a carboxylated substrate |
| WO2003086273A2 (en) * | 2002-04-08 | 2003-10-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Histone conjugates and uses thereof |
| US20030211483A1 (en) * | 2002-05-09 | 2003-11-13 | Schroeder Benjamin G. | Methods for the enrichment of low-abundance polynucleotides |
| WO2003100076A2 (en) * | 2002-05-17 | 2003-12-04 | Applera Corporation | Pna probes, probe sets, method and kits pertaining to the determination of listeria |
| US7176181B2 (en) * | 2002-05-21 | 2007-02-13 | Yeda Research And Development Co. Ltd. | Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth |
| US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
| US7290215B2 (en) * | 2002-06-03 | 2007-10-30 | Microsoft Corporation | Dynamic wizard interface system and method |
| JP2005528907A (en) * | 2002-06-07 | 2005-09-29 | ミリポア・コーポレイション | Microbial kit and method for on-site inspection of liquid samples |
| US20030228619A1 (en) * | 2002-06-10 | 2003-12-11 | Xenoport, Inc. | Peptide nucleic acids as tags in encoded libraries |
| AU2003231912A1 (en) * | 2002-06-12 | 2003-12-31 | Tel Aviv Medical Center Research Development Fund | Methods of detecting and treating prostate cancer |
| WO2003105780A2 (en) * | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
| US7038037B2 (en) | 2002-06-20 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Method for sequential support-bound synthesis of conjugated oligomeric compounds |
| AU2003280470A1 (en) * | 2002-07-01 | 2004-01-19 | Guava Technologies, Inc. | Fluorescent dyes, energy transfer couples and methods |
| US20040009899A1 (en) * | 2002-07-15 | 2004-01-15 | Mcmurray Cynthia T | Treating dominant disorders |
| AU2003257181A1 (en) | 2002-08-05 | 2004-02-23 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| JP4657919B2 (en) * | 2002-08-19 | 2011-03-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Evolving new molecular functions |
| EP1575990B1 (en) | 2002-09-08 | 2009-11-18 | Applera Corporation | Solid phase bound PNA-dimers and their synthesis |
| CA2499770A1 (en) * | 2002-09-20 | 2004-04-01 | Yale University | Riboswitches, methods for their use, and compositions for use with riboswitches. |
| WO2004031350A2 (en) | 2002-09-26 | 2004-04-15 | Amgen, Inc. | Modulation of forkhead box o1a expression |
| US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
| CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| DK1569695T3 (en) | 2002-11-13 | 2013-08-05 | Genzyme Corp | ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION |
| CA2505801A1 (en) | 2002-11-13 | 2004-05-27 | Rosanne Crooke | Antisense modulation of apolipoprotein b expression |
| US20060009378A1 (en) * | 2002-11-14 | 2006-01-12 | Itshak Golan | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| WO2004046330A2 (en) | 2002-11-15 | 2004-06-03 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
| EP2292259A3 (en) | 2002-11-15 | 2011-03-23 | MUSC Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| AU2003294462C1 (en) | 2002-11-21 | 2011-06-30 | University Of Utah Research Foundation | Purinergic modulation of smell |
| AU2003294447A1 (en) * | 2002-11-21 | 2004-06-18 | Epicentre Technologies | Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences |
| US20040259132A1 (en) * | 2002-11-22 | 2004-12-23 | Henrik Stender | Peptide nucleic acid probes for analysis of pseudomonas (sensu stricto) |
| US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| WO2004050674A2 (en) * | 2002-12-04 | 2004-06-17 | Algos Therapeutics, Inc. | Methods and materials for modulating trpm2 |
| US20040115643A1 (en) * | 2002-12-12 | 2004-06-17 | Lizardi Paul M. | Thermodynamic equilibrium extension of primers |
| US20040121338A1 (en) * | 2002-12-19 | 2004-06-24 | Alsmadi Osama A. | Real-time detection of rolling circle amplification products |
| WO2004056868A2 (en) * | 2002-12-19 | 2004-07-08 | Endocube Sas | Nf-hev compositions and methods of use |
| US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
| CA2886504C (en) | 2002-12-20 | 2019-01-08 | Celera Corporation | Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| CA2510587A1 (en) | 2002-12-20 | 2004-07-15 | Qiagen Gmbh | Nucleic acid amplification |
| US7955795B2 (en) * | 2003-06-06 | 2011-06-07 | Qiagen Gmbh | Method of whole genome amplification with reduced artifact production |
| US6977153B2 (en) * | 2002-12-31 | 2005-12-20 | Qiagen Gmbh | Rolling circle amplification of RNA |
| US7615629B2 (en) * | 2002-12-31 | 2009-11-10 | Sigma-Aldrich Co. | Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| NZ541637A (en) | 2003-02-11 | 2008-07-31 | Antisense Therapeutics Pty Ltd | Modulation of insulin like growth factor I receptor |
| US7002006B2 (en) * | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
| US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| US8017323B2 (en) * | 2003-03-26 | 2011-09-13 | President And Fellows Of Harvard College | Free reactant use in nucleic acid-templated synthesis |
| US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
| AU2003237792A1 (en) | 2003-04-01 | 2004-11-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
| WO2004098386A2 (en) * | 2003-05-01 | 2004-11-18 | Gen-Probe Incorporated | Oligonucleotides comprising a molecular switch |
| EP1624936B1 (en) * | 2003-05-16 | 2009-10-28 | Universite Laval | Cns chloride modulation and uses thereof |
| EP1633893B1 (en) | 2003-05-19 | 2012-01-25 | Gen-Probe Incorporated | Compositions, methods and kits for determining the presence of trichomonas vaginalis in a test sample |
| WO2005017181A2 (en) * | 2003-05-20 | 2005-02-24 | Investigen, Inc. | System for detecting polynucleotides |
| US7960355B2 (en) * | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
| US7897582B2 (en) * | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| US7276599B2 (en) * | 2003-06-02 | 2007-10-02 | Isis Pharmaceuticals, Inc. | Oligonucleotide synthesis with alternative solvents |
| CN1984921B (en) | 2003-06-03 | 2010-06-16 | Isis药物公司 | Modulation of survivin expression |
| US7183054B2 (en) * | 2003-06-03 | 2007-02-27 | President And Fellows Of Harvard College | Assay for identifying biological targets of polynucleotide-binding compounds |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | Compositions and methods for treating and diagnosing cancer |
| DK3604537T3 (en) | 2003-06-13 | 2022-02-28 | Alnylam Europe Ag | Double-stranded ribonucleic acid with increased efficiency in an organism |
| IL161903A0 (en) * | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| EP1668130A2 (en) | 2003-09-18 | 2006-06-14 | Isis Pharmaceuticals, Inc. | Modulation of eif4e expression |
| US20050064435A1 (en) * | 2003-09-24 | 2005-03-24 | Xing Su | Programmable molecular barcodes |
| ES2437491T3 (en) | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulation of the synthesis and degradation of hyaluronan in the treatment of disease |
| US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
| US20060199194A1 (en) * | 2003-11-10 | 2006-09-07 | Q-Rna, Inc. | Methods of detection using immuno-Q-Amp technology |
| US20050214805A1 (en) * | 2003-11-10 | 2005-09-29 | Q-Rna, Inc. | Methods of detection employing immuno-Q-Amp technology |
| EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| WO2005054516A2 (en) | 2003-11-26 | 2005-06-16 | Advandx, Inc. | Peptide nucleic acid probes for analysis of certain staphylococcus species |
| CA3050151C (en) | 2003-11-26 | 2023-03-07 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
| US8227192B2 (en) | 2003-11-26 | 2012-07-24 | Advandx, Inc. | Peptide nucleic acid probes for analysis of certain Staphylococcus species |
| EP2248895B8 (en) | 2003-12-19 | 2016-09-21 | Autotelic LLC | Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent |
| EP2363480A3 (en) | 2004-01-20 | 2015-10-07 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
| US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
| US20060147946A1 (en) * | 2004-01-27 | 2006-07-06 | Pinchas Akiva | Novel calcium channel variants and methods of use thereof |
| US7842459B2 (en) | 2004-01-27 | 2010-11-30 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
| WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| WO2005084712A2 (en) * | 2004-02-27 | 2005-09-15 | Antisense Pharma Gmbh | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| WO2005089268A2 (en) | 2004-03-15 | 2005-09-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of rna by rnase h |
| EP1737878A2 (en) | 2004-04-05 | 2007-01-03 | Alnylam Pharmaceuticals Inc. | Process and reagents for oligonucleotide synthesis and purification |
| US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
| EP1750776A2 (en) | 2004-04-30 | 2007-02-14 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| WO2005111235A2 (en) * | 2004-05-04 | 2005-11-24 | Dak Denmark A/S | Methods for detecting chromosome aberrations |
| EP1745154B1 (en) | 2004-05-07 | 2012-08-01 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof |
| JP2007537167A (en) * | 2004-05-14 | 2007-12-20 | ユニヴェルシテ ラヴァル | Regulation of phospholipase C gamma and thereby regulation of pain and nociception |
| NZ550772A (en) | 2004-05-21 | 2009-10-30 | Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
| US20050287667A1 (en) | 2004-06-01 | 2005-12-29 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
| US7700272B2 (en) * | 2004-06-09 | 2010-04-20 | Mcgill University | Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans |
| EP1766089A1 (en) * | 2004-06-30 | 2007-03-28 | Applera Corporation | Analog probe complexes |
| WO2006112818A2 (en) | 2005-04-14 | 2006-10-26 | Applera Corporation | 3' modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes |
| AU2005280162B2 (en) | 2004-08-27 | 2012-04-26 | Gen-Probe Incorporated | Single-primer nucleic acid amplification methods |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
| ES2729826T3 (en) * | 2004-09-23 | 2019-11-06 | Arc Medical Devices Inc | Pharmaceutical compositions and related methods to inhibit fibrous adhesions or inflammatory disease using low sulfate fucans |
| WO2006050999A2 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
| US20060223084A1 (en) * | 2004-12-06 | 2006-10-05 | Bioveris Corporation | Methods and compositions for detecting Bacillus anthracis |
| WO2006065724A2 (en) * | 2004-12-14 | 2006-06-22 | Regents Of The University Of Minnesota | Casein kinase 2 antisense therapy |
| US20060292586A1 (en) * | 2004-12-17 | 2006-12-28 | Schroth Gary P | ID-tag complexes, arrays, and methods of use thereof |
| US20060154285A1 (en) * | 2004-12-29 | 2006-07-13 | Robishaw Janet D | Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2) |
| US20060153745A1 (en) * | 2005-01-11 | 2006-07-13 | Applera Corporation | Fluid processing device for oligonucleotide synthesis and analysis |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US7393665B2 (en) | 2005-02-10 | 2008-07-01 | Population Genetics Technologies Ltd | Methods and compositions for tagging and identifying polynucleotides |
| CA2597673C (en) | 2005-02-11 | 2014-07-08 | Harold Varmus | Methods and compositions for detecting a drug resistant egfr mutant |
| EP2348320B1 (en) | 2005-03-10 | 2024-05-01 | Gen-Probe Incorporated | Methods and systems for detecting multiple fluorescent emission signals |
| CA2842232C (en) | 2005-03-10 | 2015-01-27 | Gen-Probe Incorporated | Systems and methods to perform assays for detecting or quantifying analytes within samples |
| CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
| WO2006099365A2 (en) | 2005-03-11 | 2006-09-21 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
| US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| WO2006110314A2 (en) | 2005-03-25 | 2006-10-19 | Ambion, Inc. | Methods and compositions for depleting abundant rna transcripts |
| US7476733B2 (en) | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
| EP1863908B1 (en) | 2005-04-01 | 2010-11-17 | Qiagen GmbH | Reverse transcription and amplification of rna with simultaneous degradation of dna |
| US8097597B2 (en) | 2005-05-05 | 2012-01-17 | Antisense Pharma Gmbh | Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors |
| WO2006124448A2 (en) | 2005-05-11 | 2006-11-23 | Vector Tobacco Inc. | Reduced risk tobacco products and methods of making same |
| US9505867B2 (en) | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
| DK2236616T3 (en) | 2005-06-02 | 2014-01-13 | Advandx Inc | Peptide nucleic acid probes for analysis of microorganisms |
| AU2005332686B2 (en) * | 2005-06-03 | 2012-09-27 | Ohr Pharmaceutical, Inc. | Methods for providing palliative care with AVR118 |
| WO2006133022A2 (en) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| US20060281121A1 (en) * | 2005-06-08 | 2006-12-14 | Ron Unger | Computing with biomolecules |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| AU2006259583A1 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| WO2007015168A2 (en) | 2005-07-01 | 2007-02-08 | Dako Denmark A/S | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances |
| WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007011722A2 (en) | 2005-07-15 | 2007-01-25 | President And Fellows Of Harvard College | Reaction discovery system |
| US7776532B2 (en) | 2005-08-11 | 2010-08-17 | Synthetic Genomics, Inc. | Method for in vitro recombination |
| AU2006281569A1 (en) | 2005-08-17 | 2007-02-22 | Medexis S.A. | Composition and method for determination of CK19 expression |
| JP5523705B2 (en) | 2005-08-29 | 2014-06-18 | レグルス・セラピューティクス・インコーポレイテッド | Method of using to modulate MIR-122A |
| EP1762627A1 (en) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Method for the activation of a nucleic acid for performing a polymerase reaction |
| JP5512125B2 (en) | 2005-09-12 | 2014-06-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Recurrent gene fusion in prostate cancer |
| US20070082351A1 (en) * | 2005-09-20 | 2007-04-12 | Advandx, Inc. | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy |
| US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for diagnosis of preeclamsia |
| WO2007041621A2 (en) * | 2005-10-03 | 2007-04-12 | Xingsheng Sean Ling | Hybridization assisted nanopore sequencing |
| US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| US8652467B2 (en) * | 2005-10-14 | 2014-02-18 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
| EP2189522A1 (en) | 2005-10-14 | 2010-05-26 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
| US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
| CN101365801B (en) | 2005-10-28 | 2013-03-27 | 阿尔尼拉姆医药品有限公司 | Compositions and methods for inhibiting expression of huntingtin gene |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| JP2009513708A (en) | 2005-10-31 | 2009-04-02 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Compositions and methods for diagnosis and treatment of cancer |
| JP5129149B2 (en) * | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Compositions and methods for treating and diagnosing cancer |
| CA2626690A1 (en) | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
| WO2007120265A2 (en) | 2005-11-14 | 2007-10-25 | Applera Corporation | Coded molecules for detecting target analytes |
| WO2007062380A2 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| EP1971371B1 (en) | 2005-12-01 | 2015-08-05 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| US8313901B2 (en) * | 2005-12-21 | 2012-11-20 | Yale University | Methods and compositions related to the modulation of riboswitches |
| WO2007073149A1 (en) | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
| EP2216339A1 (en) | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
| US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| US20080057499A1 (en) * | 2006-02-06 | 2008-03-06 | Affymetrix, Inc. | Methods for high specificity whole genome amplification and hybridization |
| US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| EP2010677A4 (en) * | 2006-02-24 | 2010-04-14 | Investigen Inc | Methods and compositions for detecting polynucleotides |
| WO2007109228A1 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apparatus for microarray binding sensors having biological probe materials using carbon nanotube transistors |
| NZ571568A (en) | 2006-03-31 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene |
| WO2007125173A2 (en) | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
| WO2007130636A2 (en) | 2006-05-03 | 2007-11-15 | Geisinger Clinic | Methods for diagnosing and predicting non-alcoholic steatohepatitis (nash) |
| CN103614375A (en) | 2006-05-11 | 2014-03-05 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting expression of PCSK9 gene |
| CA2652770A1 (en) | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
| WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
| EP2023938A4 (en) * | 2006-05-23 | 2010-11-10 | Isis Pharmaceuticals Inc | Modulation of chrebp expression |
| PL2017356T3 (en) | 2006-06-06 | 2012-03-30 | Gen Probe Inc | Tagged oliggonucleotides and their use in nucleic acid amplification methods |
| US20080050752A1 (en) | 2006-06-30 | 2008-02-28 | Applera Corporation | Methods of analyzing binding interactions |
| WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
| US8101585B2 (en) * | 2006-08-04 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of JNK proteins |
| US8586006B2 (en) | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
| US20080261216A1 (en) * | 2006-09-08 | 2008-10-23 | The Regents Of The University Of Michigan | HERV Group II Viruses In Lymphoma And Cancer |
| WO2008033866A2 (en) * | 2006-09-11 | 2008-03-20 | Yale University | Methods and compositions for the use of lysine riboswitches |
| AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
| DK2068886T3 (en) | 2006-10-03 | 2013-11-18 | Tekmira Pharmaceuticals Corp | Lipid-containing preparations |
| US20100166743A1 (en) | 2006-10-06 | 2010-07-01 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| CA2915679C (en) | 2006-10-20 | 2017-12-12 | Celera Corporation | Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof |
| US20080096193A1 (en) * | 2006-10-24 | 2008-04-24 | Charles Robert Bupp | Methods and compositions for detecting polynucleotides |
| US8779194B2 (en) | 2006-10-27 | 2014-07-15 | Metkinen Chemistry Oy | Carbamoylation of amines, thiophenols, mercaptanes and phenols employing organic azides |
| WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
| US8324359B1 (en) | 2006-12-04 | 2012-12-04 | Luminex Corporation | Oxocarbonamide peptide nucleic acids and methods of using same |
| JP2010512327A (en) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Compositions and methods for the treatment of pathological angiogenesis and vascular permeability |
| EP2857526B1 (en) | 2006-12-13 | 2016-08-17 | Luminex Corporation | Systems and methods for multiplex analysis of PCR in real time |
| US9938641B2 (en) * | 2006-12-18 | 2018-04-10 | Fluidigm Corporation | Selection of aptamers based on geometry |
| WO2008074328A2 (en) * | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| EP2113567B1 (en) | 2006-12-21 | 2019-04-03 | QIAGEN GmbH | MicroRNA target site blocking oligos and uses thereof |
| EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| EP2097448A4 (en) | 2006-12-22 | 2010-07-21 | Univ Utah Res Found | Method of detecting ocular diseases and pathologic conditions and treatment of same |
| US20080241838A1 (en) * | 2006-12-29 | 2008-10-02 | Applera Corporation, Applied Biosystems Group | Methods and systems for detecting nucleic acids |
| AU2007339793A1 (en) * | 2006-12-29 | 2008-07-10 | Applied Biosystems, Llc | Systems and methods for detecting nucleic acids |
| WO2008086529A2 (en) * | 2007-01-11 | 2008-07-17 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| US7928083B2 (en) * | 2007-01-16 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
| US7803543B2 (en) * | 2007-01-19 | 2010-09-28 | Chang Gung University | Methods and kits for the detection of nucleotide mutations using peptide nucleic acid as both PCR clamp and sensor probe |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
| WO2009045469A2 (en) | 2007-10-02 | 2009-04-09 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
| MX2009008470A (en) | 2007-02-09 | 2009-11-26 | Univ Northwestern | Particles for detecting intracellular targets. |
| EP2124996A4 (en) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
| WO2008103702A2 (en) * | 2007-02-23 | 2008-08-28 | Investigen, Inc. | Methods and compositions for rapid light-activated isolation and detection of analytes |
| US9150612B2 (en) * | 2007-02-23 | 2015-10-06 | The Research Foundation Of State University Of New York | RNA targeting compounds and methods for making and using same |
| US9260476B2 (en) | 2007-02-23 | 2016-02-16 | The Research Foundation For The State University Of New York | RNA targeting compounds and methods for making and using same |
| JP2010520749A (en) * | 2007-02-27 | 2010-06-17 | ノースウェスタン ユニバーシティ | Binding molecules to nanoparticles |
| JP2010521977A (en) | 2007-03-22 | 2010-07-01 | イェール ユニバーシティー | Methods and compositions for riboswitches that regulate alternative splicing |
| PE20090064A1 (en) | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
| AP3018A (en) | 2007-03-29 | 2014-10-31 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expressionof a gene from the ebola |
| EP1978111B1 (en) | 2007-04-02 | 2013-03-27 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of Pseudomonas aeruginosa |
| EP2162552A4 (en) | 2007-05-11 | 2010-06-30 | Univ Johns Hopkins | Biomarkers for melanoma |
| JP2010528617A (en) | 2007-05-29 | 2010-08-26 | イェール ユニバーシティー | Riboswitches and methods and compositions for using riboswitches and for use with riboswitches |
| JP2010528616A (en) * | 2007-05-29 | 2010-08-26 | イェール ユニバーシティー | Methods and compositions related to riboswitches that regulate alternative splicing and RNA splicing |
| AU2008259907B2 (en) | 2007-05-30 | 2014-12-04 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
| EP2527472B1 (en) | 2007-05-31 | 2016-09-28 | Yale University | A genetic lesion associated with cancer |
| US7807372B2 (en) * | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
| WO2008151631A2 (en) * | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
| US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| US20090324596A1 (en) | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
| EP3023436A1 (en) | 2007-07-03 | 2016-05-25 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US20100184823A1 (en) | 2007-07-05 | 2010-07-22 | Mark Aron Labow | dsRNA For Treating Viral Infection |
| EP3018216B1 (en) | 2007-07-06 | 2018-09-12 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| CN102007222A (en) * | 2007-08-13 | 2011-04-06 | 3M创新有限公司 | Methods for detecting drug-resistant microbes |
| JP2010537638A (en) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | Synthetic apolipoprotein E mimetic polypeptides and methods of use |
| WO2009032693A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| US8415455B2 (en) | 2007-09-04 | 2013-04-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| US8445217B2 (en) | 2007-09-20 | 2013-05-21 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
| WO2009039442A1 (en) * | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
| US8278047B2 (en) | 2007-10-01 | 2012-10-02 | Nabsys, Inc. | Biopolymer sequencing by hybridization of probes to form ternary complexes and variable range alignment |
| WO2009052301A1 (en) * | 2007-10-16 | 2009-04-23 | Regado Biosciences, Inc. | Steady-state subcutaneous administration of aptamers |
| US8039212B2 (en) | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| ES2641290T3 (en) | 2007-11-20 | 2017-11-08 | Ionis Pharmaceuticals, Inc | CD40 expression modulation |
| KR101026502B1 (en) | 2007-11-23 | 2011-04-01 | 주식회사 파나진 | MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same |
| ES2916498T3 (en) | 2007-12-06 | 2022-07-01 | Genalyte Inc | Method for identifying a nucleotide sequence in an unknown species of nucleic acid; and device for carrying out the method |
| EP2245159A2 (en) | 2007-12-10 | 2010-11-03 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor vii gene |
| WO2009079456A2 (en) | 2007-12-14 | 2009-06-25 | Minitube Of America, Inc. | Gender-specific separation of sperm cells and embryos |
| CA2709519A1 (en) | 2007-12-21 | 2009-07-09 | Gen-Probe Incorporated | Detection of antibiotic-resistant microorganisms |
| DE102007063102B4 (en) * | 2007-12-28 | 2022-02-10 | Robert Bosch Gmbh | Method for detecting a periodically pulsating operating parameter |
| JP5749494B2 (en) | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | Improved compositions and methods for delivery of nucleic acids |
| CA2711499C (en) | 2008-01-10 | 2018-09-25 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
| US20090221620A1 (en) | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| CA2716793A1 (en) | 2008-03-05 | 2009-09-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 and vegf genes |
| KR20090098710A (en) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | Peptide nucleic acid derivatives with good cell penetration and affinity for nucleic acid |
| KR101419980B1 (en) * | 2008-03-15 | 2014-07-15 | 홀로직, 인크. | Compositions and methods for analysis of nucleic acid molecules during amplification reactions |
| US20100113284A1 (en) * | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
| US20090326049A1 (en) * | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| EP2274425A2 (en) | 2008-04-11 | 2011-01-19 | Alnylam Pharmaceuticals Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP2982753B1 (en) | 2008-04-18 | 2018-06-06 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
| EP2806037B1 (en) | 2008-05-13 | 2016-09-21 | Gen-Probe Incorporated | Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences |
| US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
| EP3733871A1 (en) | 2008-05-27 | 2020-11-04 | Dako Denmark A/S | Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers |
| US8703421B2 (en) | 2008-05-30 | 2014-04-22 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of Salmonella |
| ATE550024T1 (en) | 2008-05-30 | 2012-04-15 | Univ Yale | TARGETED OLIGONUCLEOTIDE COMPOSITIONS FOR MODIFYING GENE EXPRESSION |
| CA2635187A1 (en) | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
| EP2310525B1 (en) | 2008-07-09 | 2014-02-26 | Celera Corporation | Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof |
| JP2011527893A (en) * | 2008-07-15 | 2011-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | Compositions and methods for inhibiting expression of TGF-β receptor gene |
| EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| EP3208337A1 (en) | 2008-09-02 | 2017-08-23 | Alnylam Pharmaceuticals, Inc. | Compositions for combined inhibition of mutant egfr and il-6 expression |
| US9650668B2 (en) | 2008-09-03 | 2017-05-16 | Nabsys 2.0 Llc | Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels |
| US8262879B2 (en) | 2008-09-03 | 2012-09-11 | Nabsys, Inc. | Devices and methods for determining the length of biopolymers and distances between probes bound thereto |
| WO2010028140A2 (en) * | 2008-09-03 | 2010-03-11 | Nabsys, Inc. | Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels |
| US10138485B2 (en) | 2008-09-22 | 2018-11-27 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
| AU2009298802A1 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| JP5529142B2 (en) | 2008-09-25 | 2014-06-25 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Lipid formulation composition and method for inhibiting expression of serum amyloid A gene |
| AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010042933A2 (en) | 2008-10-10 | 2010-04-15 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
| ES2794401T3 (en) * | 2008-10-15 | 2020-11-18 | Axolabs Gmbh | Oligonucleotide detection method |
| US8168775B2 (en) | 2008-10-20 | 2012-05-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
| US9846126B2 (en) | 2008-10-27 | 2017-12-19 | Genalyte, Inc. | Biosensors based on optical probing and sensing |
| CA2743057C (en) | 2008-11-07 | 2019-11-26 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
| AU2009315665A1 (en) * | 2008-11-17 | 2010-05-20 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of factor VII genes |
| AU2009316286B2 (en) | 2008-11-24 | 2016-05-26 | Northwestern University | Polyvalent RNA-nanoparticle compositions |
| WO2010061393A1 (en) | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
| CN102307997B (en) | 2008-12-04 | 2018-03-30 | 库尔纳公司 | By suppressing to treat the related disease of Sirtuin 1 (SIRT1) for the natural antisense transcript of Sirtuin 1 |
| US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| ES2629630T3 (en) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
| EP2633854B1 (en) | 2008-12-05 | 2015-09-16 | Yeda Research And Development Co. Ltd. | miRNA-9 or miRNA-9* for use in treating ALS |
| AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
| CA2746508A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
| AU2009335053B2 (en) | 2008-12-30 | 2013-08-01 | Gen-Probe Incorporated | Compositions, kits and related methods for the detection and/or monitoring of Listeria |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| KR101546673B1 (en) * | 2009-01-15 | 2015-08-25 | 삼성전자주식회사 | Toner for electrophotographic and process for preparing the same |
| US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
| CA2750459A1 (en) | 2009-02-03 | 2010-08-12 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of ptp1b genes |
| ES2762610T3 (en) | 2009-02-12 | 2020-05-25 | Curna Inc | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
| CN102439149B (en) | 2009-02-12 | 2018-01-02 | 库尔纳公司 | By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF) |
| US7964355B2 (en) * | 2009-02-17 | 2011-06-21 | Investigen, Inc. | Assays based on detection of photobleaching reaction products from dye catalytic complex |
| WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
| WO2010097655A1 (en) | 2009-02-26 | 2010-09-02 | Dako Denmark A/S | Compositions and methods for rna hybridization applications |
| AU2010221419B2 (en) | 2009-03-02 | 2015-10-01 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
| ES2845644T3 (en) | 2009-03-04 | 2021-07-27 | Curna Inc | Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1 |
| US20100267806A1 (en) | 2009-03-12 | 2010-10-21 | David Bumcrot | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
| MX2011009751A (en) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. |
| WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
| US20110045080A1 (en) * | 2009-03-24 | 2011-02-24 | William Marsh Rice University | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
| US8455260B2 (en) * | 2009-03-27 | 2013-06-04 | Massachusetts Institute Of Technology | Tagged-fragment map assembly |
| US20100243449A1 (en) * | 2009-03-27 | 2010-09-30 | Oliver John S | Devices and methods for analyzing biomolecules and probes bound thereto |
| US8431416B2 (en) | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
| US8309356B2 (en) * | 2009-04-01 | 2012-11-13 | Yale University | Pseudocomplementary oligonucleotides for targeted gene therapy |
| KR20170072367A (en) | 2009-04-15 | 2017-06-26 | 노오쓰웨스턴 유니버시티 | Delivery of oligonucleotide-functionalized nanoparticles |
| EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
| EP2424987B1 (en) | 2009-05-01 | 2017-11-15 | CuRNA, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
| JP5769701B2 (en) | 2009-05-05 | 2015-08-26 | テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ | Lipid composition |
| AU2010245933B2 (en) | 2009-05-05 | 2016-06-16 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
| JP6250930B2 (en) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP) |
| CN102459596B (en) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
| SG176099A1 (en) * | 2009-05-15 | 2011-12-29 | Hoffmann La Roche | Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
| US20120107331A1 (en) | 2009-05-15 | 2012-05-03 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
| CN102575251B (en) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor |
| WO2010133972A1 (en) | 2009-05-22 | 2010-11-25 | Population Genetics Technologies Ltd | Sorting asymmetrically tagged nucleic acids by selective primer extension |
| KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| US8246799B2 (en) * | 2009-05-28 | 2012-08-21 | Nabsys, Inc. | Devices and methods for analyzing biomolecules and probes bound thereto |
| CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
| WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| SG176644A1 (en) | 2009-06-03 | 2012-01-30 | Regado Biosciences Inc | Nucleic acid modulators of glycoprotein vi |
| DK2440183T3 (en) | 2009-06-10 | 2018-10-01 | Arbutus Biopharma Corp | Improved lipid formulation |
| KR101702689B1 (en) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
| WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| AU2010265889A1 (en) | 2009-06-25 | 2012-01-19 | Yale University | Single nucleotide polymorphisms in BRCA1 and cancer risk |
| CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| JP5785942B2 (en) | 2009-06-29 | 2015-09-30 | ルミネックス コーポレーション | Chimeric primer with hairpin conformation and use thereof |
| US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011011630A2 (en) | 2009-07-23 | 2011-01-27 | Codexis, Inc. | Nitrilase biocatalysts |
| IN2012DN00969A (en) | 2009-07-30 | 2015-04-10 | Antisense Pharma Gmbh | |
| WO2011017382A2 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Nanofibers and morphology shifting micelles |
| EP2462230B1 (en) * | 2009-08-03 | 2015-07-15 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
| US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
| WO2011020023A2 (en) | 2009-08-14 | 2011-02-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| WO2011022420A1 (en) | 2009-08-17 | 2011-02-24 | Yale University | Methylation biomarkers and methods of use |
| EP2467479B1 (en) | 2009-08-20 | 2016-01-06 | Population Genetics Technologies Ltd | Compositions and methods for intramolecular nucleic acid rearrangement |
| CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
| EP2473563B1 (en) * | 2009-08-31 | 2019-06-19 | Promega Corporation | Reactive cyanine compounds |
| CA2770888C (en) | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
| US9321823B2 (en) | 2009-09-02 | 2016-04-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| WO2011027218A1 (en) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of genomic copy number variations |
| WO2011027219A1 (en) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | High throughput detection of small genomic deletions and insertions |
| EP2488646B1 (en) | 2009-10-14 | 2017-12-06 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Compositions for controlling varroa mites in bees |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| BR112012009409A2 (en) | 2009-10-22 | 2017-02-21 | Genentech Inc | method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample |
| JP6147502B2 (en) | 2009-10-27 | 2017-06-14 | スウィフト バイオサイエンシーズ， インコーポレイテッド | Polynucleotide primers and probes |
| CN102666879B (en) | 2009-10-30 | 2016-02-24 | 西北大学 | Templated nanometer conjugate |
| US20110268810A1 (en) | 2009-11-02 | 2011-11-03 | Yale University | Polymeric materials loaded with mutagenic and recombinagenic nucleic acids |
| EP2496716A1 (en) | 2009-11-03 | 2012-09-12 | University Of Virginia Patent Foundation | Versatile, visible method for detecting polymeric analytes |
| US20120245041A1 (en) | 2009-11-04 | 2012-09-27 | Sydney Brenner | Base-by-base mutation screening |
| US20110112176A1 (en) * | 2009-11-09 | 2011-05-12 | John Frederick Boylan | Compositions and methods for inhibiting expression of kif10 genes |
| WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
| EP3199634A1 (en) | 2009-11-13 | 2017-08-02 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US8445228B2 (en) | 2009-11-16 | 2013-05-21 | Massachusetts Institute Of Technology | Enhancement of in vitro translation by nanoparticle conjugates |
| WO2011063403A1 (en) | 2009-11-23 | 2011-05-26 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
| AR079217A1 (en) | 2009-11-30 | 2012-01-04 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
| WO2011066504A1 (en) * | 2009-11-30 | 2011-06-03 | Physicians Reference Laboratory, Llc | Methods and compositions for detecting methicillin-resistant staphylococcus aureus |
| CA2781907C (en) | 2009-12-02 | 2019-07-16 | Dako Denmark A/S | Compositions and methods for performing hybridizations with no denaturation |
| ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
| US20110152349A1 (en) | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
| US9404160B2 (en) | 2009-12-22 | 2016-08-02 | Becton, Dickinson And Company | Methods for the detection of microorganisms |
| US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
| CA2782373C (en) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
| WO2011090740A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| ES2585829T3 (en) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63 |
| KR101878501B1 (en) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
| EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
| DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
| TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
| SG182365A1 (en) | 2010-01-12 | 2012-08-30 | Univ Yale | Structured rna motifs and compounds and methods for their use |
| US8927271B1 (en) * | 2010-01-21 | 2015-01-06 | Jack T. Johansen | Compositions and methods for detecting target analytes |
| CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| WO2011094580A2 (en) | 2010-01-28 | 2011-08-04 | Alnylam Pharmaceuticals, Inc. | Chelated copper for use in the preparation of conjugated oligonucleotides |
| WO2011097407A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| US20110196016A1 (en) | 2010-02-05 | 2011-08-11 | Anke Geick | Compositions and Methods for Inhibiting Expression of IKK2 Genes |
| EP2531612A1 (en) | 2010-02-05 | 2012-12-12 | Institute for Systems Biology | Methods and compositions for profiling rna molecules |
| CA2785529C (en) * | 2010-02-11 | 2019-01-08 | Nanostring Technologies, Inc. | Compositions and methods for the detection of small rnas |
| WO2011101744A2 (en) | 2010-02-22 | 2011-08-25 | Population Genetics Technologies Ltd. | Region of interest extraction and normalization methods |
| CN102844435B (en) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| MX2012009215A (en) | 2010-02-23 | 2012-11-23 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
| WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
| WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
| WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
| WO2011107887A2 (en) | 2010-03-02 | 2011-09-09 | Population Genetic Technologies Ltd. | Methods for replicating polynucleotides with secondary structure |
| WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
| WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
| EP2545173A2 (en) | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
| EP3210611B1 (en) | 2010-03-12 | 2019-08-21 | The Brigham and Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
| EP2548025A4 (en) | 2010-03-17 | 2013-09-25 | Univ Michigan | Using phage epitopes to profile the immune response |
| US8889350B2 (en) | 2010-03-26 | 2014-11-18 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
| ES2893199T3 (en) | 2010-03-29 | 2022-02-08 | Alnylam Pharmaceuticals Inc | dsRNA therapy for transthyretin (TTR)-related ocular amyloidosis |
| CN102971337B (en) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | FZ combines medicament and application thereof |
| WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
| RU2610661C2 (en) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| US20110269194A1 (en) | 2010-04-20 | 2011-11-03 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
| WO2011133802A1 (en) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for treatment of lysosomal storage disorders |
| US20110262406A1 (en) | 2010-04-21 | 2011-10-27 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| WO2011133876A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
| AU2011248625B2 (en) | 2010-04-26 | 2017-01-05 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase |
| JP6294074B2 (en) | 2010-04-27 | 2018-03-14 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase |
| WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
| CA2797374C (en) | 2010-04-29 | 2021-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases |
| WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
| US9068177B2 (en) | 2010-04-29 | 2015-06-30 | Atyr Pharma, Inc | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
| CA2797393C (en) | 2010-04-29 | 2020-03-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| CN103096925A (en) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases |
| CA2797978C (en) | 2010-05-03 | 2019-12-03 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
| CN107988228B (en) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT) |
| CN103096912A (en) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases |
| MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
| CN102985103A (en) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
| CA3090304A1 (en) | 2010-05-13 | 2011-11-17 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
| JP6396656B2 (en) | 2010-05-14 | 2018-09-26 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase |
| TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
| JP6027965B2 (en) | 2010-05-17 | 2016-11-16 | エータイアー ファーマ， インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase |
| US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
| WO2011150226A1 (en) | 2010-05-26 | 2011-12-01 | Landers James P | Method for detecting nucleic acids based on aggregate formation |
| AU2011257980B2 (en) | 2010-05-28 | 2016-06-30 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
| WO2011153323A2 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| WO2011156713A1 (en) | 2010-06-11 | 2011-12-15 | Vanderbilt University | Multiplexed interferometric detection system and method |
| WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
| WO2011161549A2 (en) | 2010-06-24 | 2011-12-29 | Population Genetics Technologies Ltd. | Methods and compositions for polynucleotide library production, immortalization and region of interest extraction |
| WO2012003289A1 (en) | 2010-06-30 | 2012-01-05 | Gen-Probe Incorporated | Method and apparatus for identifying analyte-containing samples using single-read determination of analyte and process control signals |
| CN107441480A (en) | 2010-06-30 | 2017-12-08 | 卡姆普根有限公司 | Polypeptide and its purposes as the medicine for treating multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
| CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
| US8623324B2 (en) | 2010-07-21 | 2014-01-07 | Aat Bioquest Inc. | Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates |
| US20130143955A1 (en) | 2010-08-09 | 2013-06-06 | Yale University | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use |
| AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
| DK2623613T3 (en) | 2010-09-21 | 2016-10-03 | Population Genetics Tech Ltd | Increasing the reliability of the allele-indications by molecular counting |
| US8715933B2 (en) | 2010-09-27 | 2014-05-06 | Nabsys, Inc. | Assay methods using nicking endonucleases |
| WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| CA2814076A1 (en) | 2010-10-14 | 2012-04-19 | Regado Biosciences, Inc. | Nucleic acid modulators of clec-2 |
| WO2012052872A2 (en) | 2010-10-17 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
| EP3434772A3 (en) | 2010-10-18 | 2019-03-20 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of rrm2 genes |
| CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| JP6073795B2 (en) | 2010-10-27 | 2017-02-01 | カッパーアールエヌエー，インコーポレイテッド | Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1) |
| US20120108651A1 (en) | 2010-11-02 | 2012-05-03 | Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) | Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof |
| EP3733866B1 (en) | 2010-11-05 | 2023-11-15 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
| CN103370054A (en) | 2010-11-09 | 2013-10-23 | 阿尔尼拉姆医药品有限公司 | Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes |
| EP2453017A1 (en) | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| US8859201B2 (en) | 2010-11-16 | 2014-10-14 | Nabsys, Inc. | Methods for sequencing a biomolecule by detecting relative positions of hybridized probes |
| CN103459599B (en) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG |
| US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
| EP2649182A4 (en) | 2010-12-10 | 2015-05-06 | Alnylam Pharmaceuticals Inc | Compositions and methods for increasing erythropoietin (epo) production |
| WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| US9045749B2 (en) | 2011-01-14 | 2015-06-02 | The General Hospital Corporation | Methods targeting miR-128 for regulating cholesterol/lipid metabolism |
| WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
| DK2670404T3 (en) | 2011-02-02 | 2018-11-19 | Univ Princeton | CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| US11274341B2 (en) | 2011-02-11 | 2022-03-15 | NABsys, 2.0 LLC | Assay methods using DNA binding proteins |
| WO2012113775A1 (en) | 2011-02-21 | 2012-08-30 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
| US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
| US8969003B2 (en) | 2011-03-23 | 2015-03-03 | Elitech Holding B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use |
| US9085800B2 (en) | 2011-03-23 | 2015-07-21 | Elitech Holding B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use |
| KR102481317B1 (en) | 2011-03-29 | 2022-12-26 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibiting expression of tmprss6 gene |
| WO2012140627A1 (en) | 2011-04-15 | 2012-10-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
| WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
| WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
| JP6188686B2 (en) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー，インコーポレイテッド | Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN) |
| US9068184B2 (en) | 2011-06-21 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
| KR102540778B1 (en) | 2011-06-21 | 2023-06-07 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibition of expression of apolipoprotein c-iii(apoc3) genes |
| MX345095B (en) | 2011-06-21 | 2017-01-17 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof. |
| EP3597750B1 (en) | 2011-06-23 | 2022-05-04 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| AU2012277376B2 (en) | 2011-06-30 | 2016-11-24 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| SG194751A1 (en) | 2011-06-30 | 2013-12-30 | Arrowhead Res Corp | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
| WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| AU2012284259A1 (en) | 2011-07-15 | 2014-03-06 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
| US20140328811A1 (en) | 2011-08-01 | 2014-11-06 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| ES2632212T3 (en) | 2011-08-04 | 2017-09-11 | Yeda Research And Development Co. Ltd. | miR-135 and compositions comprising it for the treatment of medical conditions associated with serotonin |
| CA2848753C (en) | 2011-09-14 | 2022-07-26 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| WO2013040548A2 (en) | 2011-09-17 | 2013-03-21 | Yale University | Fluoride-responsive riboswitchs, fluoride transporters, and methods of use |
| US9801948B2 (en) | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
| EP2758547B1 (en) | 2011-09-21 | 2015-09-16 | Gen-Probe Incorporated | Methods for amplifying nucleic acid using tag-mediated displacement |
| WO2013049038A1 (en) | 2011-09-28 | 2013-04-04 | Georgetown University | Assessment of risk of local recurrence of cancer using telomere health |
| US10662465B2 (en) | 2011-09-30 | 2020-05-26 | Agilent Technologies, Inc. | Hybridization compositions and methods using formamide |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| AU2012322788B2 (en) | 2011-10-11 | 2018-01-04 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| KR102102862B1 (en) | 2011-10-14 | 2020-04-22 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
| PT3597644T (en) | 2011-10-18 | 2021-11-03 | Dicerna Pharmaceuticals Inc | Amine cationic lipids and uses thereof |
| EP2768974B1 (en) | 2011-10-21 | 2017-07-19 | Dako Denmark A/S | Hybridization compositions and methods |
| WO2013061328A2 (en) | 2011-10-27 | 2013-05-02 | Yeda Research And Development Co. Ltd. | Method of treating cancer |
| KR102271212B1 (en) | 2011-11-18 | 2021-07-01 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Functionally-modified oligonucleotides and subunits thereof |
| WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
| US10465042B2 (en) | 2011-12-02 | 2019-11-05 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
| US9895451B2 (en) | 2011-12-02 | 2018-02-20 | Yale University | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof |
| HUE038369T2 (en) | 2011-12-08 | 2018-10-29 | Sarepta Therapeutics Inc | Oligonucleotide analogues targeting human lmna |
| EP2790736B1 (en) | 2011-12-12 | 2018-01-31 | Oncoimmunin, Inc. | In vivo delivery of oligonucleotides |
| KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
| AU2013216320A1 (en) | 2012-02-01 | 2014-04-03 | Compugen Ltd. | C10RF32 antibodies, and uses thereof for treatment of cancer |
| BR112014020119A2 (en) | 2012-02-13 | 2020-10-27 | Gamida-Cell Ltd | culture of mesenchymal stem cells |
| JP6329911B2 (en) | 2012-02-22 | 2018-05-23 | ブレインステム バイオテック リミテッド | MicroRNA for the production of astrocytes |
| WO2013124743A1 (en) | 2012-02-22 | 2013-08-29 | Population Genetics Technologies Ltd. | Compositions and methods for intramolecular nucleic acid rearrangement ii |
| EP3401394A1 (en) | 2012-02-22 | 2018-11-14 | Exostem Biotec Ltd | Generation of neural stem cells |
| WO2013128281A1 (en) | 2012-02-28 | 2013-09-06 | Population Genetics Technologies Ltd | Method for attaching a counter sequence to a nucleic acid sample |
| EP2825885B1 (en) | 2012-03-12 | 2021-05-12 | The Board of Trustees of the University of Illinois | Optical analyte detection systems with magnetic enhancement |
| CA2866625C (en) | 2012-03-13 | 2020-12-08 | Swift Biosciences, Inc. | Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase |
| US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
| AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| EP3563872A1 (en) | 2012-04-05 | 2019-11-06 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| EP2839005B1 (en) | 2012-04-20 | 2021-01-06 | Aptamir Therapeutics, Inc. | Mirna modulators of thermogenesis |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
| CA2873794A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating smn gene family expression |
| CN104583398A (en) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | Compositions and methods for modulating gene expression |
| EA038924B1 (en) | 2012-05-25 | 2021-11-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| ITMI20120921A1 (en) * | 2012-05-28 | 2013-11-29 | Fond Istituto Italiano Di Tec Nologia 45 | INHIBITORS OF CERAMIDASIS ACID AND THEY USE AS MEDICATIONS |
| US10077474B2 (en) | 2012-05-29 | 2018-09-18 | Abbott Molecular, Inc. | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
| US20140038182A1 (en) | 2012-07-17 | 2014-02-06 | Dna Logix, Inc. | Cooperative primers, probes, and applications thereof |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| AU2013202793B2 (en) | 2012-07-31 | 2014-09-18 | Gen-Probe Incorporated | System, method and apparatus for automated incubation |
| US20150216892A1 (en) | 2012-08-03 | 2015-08-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
| WO2014033314A1 (en) | 2012-09-03 | 2014-03-06 | Uab Bioseka | Antisense oligonucleotide targeting bacterial glucosyltransferases |
| BR112015005091B1 (en) | 2012-09-06 | 2021-07-06 | The University Of Chicago | use of an isolated antisense polynucleotide |
| CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| GB201219300D0 (en) * | 2012-10-26 | 2012-12-12 | Isis Innovation | Bifunctional organic catalysts |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| JP2016509572A (en) | 2012-11-05 | 2016-03-31 | プロナイ セラピューティクス インコーポレイテッド | Methods of using biomarkers for the treatment of cancer by modulating BCL2 expression |
| CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | Chemically modified mRNA |
| WO2014093291A1 (en) | 2012-12-10 | 2014-06-19 | Advandx, Inc. | Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest |
| US9914966B1 (en) | 2012-12-20 | 2018-03-13 | Nabsys 2.0 Llc | Apparatus and methods for analysis of biomolecules using high frequency alternating current excitation |
| BR112015015975A2 (en) | 2013-01-01 | 2018-11-06 | A. B. Seeds Ltd. | isolated dsrna molecules and methods of using them for silencing target molecules of interest. |
| CA2897941A1 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014113557A1 (en) | 2013-01-18 | 2014-07-24 | Nabsys, Inc. | Enhanced probe binding |
| US9956294B2 (en) | 2013-01-18 | 2018-05-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted sensitization of non-del(5q) malignant cells |
| CA3150658A1 (en) | 2013-01-18 | 2014-07-24 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| CN105073195A (en) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| US9289502B2 (en) | 2013-03-08 | 2016-03-22 | Emerald Therapeutics, Inc. | Preparation of oligo conjugates |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2014158628A1 (en) | 2013-03-14 | 2014-10-02 | Hologic, Inc. | Compositions and methods for analysis of nucleic acid molecules |
| KR102342916B1 (en) | 2013-03-14 | 2021-12-24 | 알닐람 파마슈티칼스 인코포레이티드 | Complement component c5 irna compositions and methods of use thereof |
| ES2708650T3 (en) | 2013-03-14 | 2019-04-10 | Andes Biotechnologies Global Inc | Antisense oligonucleotides for the treatment of tumor stem cells |
| EP2971086A1 (en) | 2013-03-14 | 2016-01-20 | ELITechGroup B.V. | Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| CN105283466A (en) | 2013-03-14 | 2016-01-27 | 安第斯生物技术股份有限公司 | Methods for detecting and treating multiple myeloma |
| WO2014143637A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2906663A1 (en) | 2013-03-15 | 2014-09-18 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
| KR102206573B1 (en) | 2013-03-15 | 2021-01-25 | 테출론 인코포레이티드 | Antisense molecules for treatment of staphylococcus aureus infection |
| CA2901293A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Detection of bisulfite converted nucleotide sequences |
| BR112015027327B1 (en) | 2013-04-29 | 2022-08-02 | Rutgers, The State University Of New Jersey | COMPOUND, CGA MODULATOR, PHARMACEUTICAL COMPOSITION INCLUDING SUCH COMPOUND OR MODULATOR |
| EP3587578A1 (en) | 2013-05-22 | 2020-01-01 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| PT2999785T (en) | 2013-05-22 | 2018-07-09 | Alnylam Pharmaceuticals Inc | Serpina1 irna compositions and methods of use thereof |
| WO2014197835A2 (en) | 2013-06-06 | 2014-12-11 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
| CA2918787A1 (en) | 2013-06-13 | 2014-12-18 | George Tachas | Combination therapy |
| DK3019619T3 (en) | 2013-07-11 | 2021-10-11 | Modernatx Inc | COMPOSITIONS INCLUDING SYNTHETIC POLYNUCLEOTIDES CODING CRISPR-RELATED PROTEINS, SYNTHETIC SGRNAs, AND USES OF USE |
| EP3044314B1 (en) | 2013-07-12 | 2019-04-10 | SeNa Research, Inc. | Methods and compositions for interference with dna polymerase and dna synthesis |
| RU2703498C2 (en) | 2013-07-19 | 2019-10-17 | Монсанто Текнолоджи Ллс | Compositions and methods for controlling leptinotarsa |
| AU2014306271A1 (en) | 2013-08-08 | 2016-03-24 | The Scripps Research Institute | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
| WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20150197534A1 (en) | 2013-09-05 | 2015-07-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3791862A1 (en) | 2013-09-11 | 2021-03-17 | Eagle Biologics, Inc. | Liquid protein formulations containing viscosity-lowering agents |
| WO2015050990A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| JP2016538829A (en) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Polynucleotide encoding low density lipoprotein receptor |
| US10119143B2 (en) | 2013-10-04 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| EP3052627B1 (en) | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
| CA3188691A1 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | 3'end caps for rnai agents for use in rna interference |
| WO2015050871A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compounds to treat hepatitis b virus |
| LT6214B (en) | 2013-10-07 | 2015-08-25 | Uab "Bioseka" | Antisense oligonucleotide for prevention of atherosclerosis and cardivascular infections |
| WO2015054451A1 (en) | 2013-10-09 | 2015-04-16 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
| WO2015057998A1 (en) | 2013-10-16 | 2015-04-23 | The University Of British Columbia | Device for formulating particles at small volumes |
| CA2928779A1 (en) | 2013-10-21 | 2015-04-30 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| CA2929630C (en) | 2013-11-03 | 2021-01-12 | The Regents Of The University Of California | Ionic liquids for transdermal drug delivery |
| AU2014341879B2 (en) | 2013-11-04 | 2020-07-23 | Beeologics, Inc. | Compositions and methods for controlling arthropod parasite and pest infestations |
| WO2015066708A1 (en) | 2013-11-04 | 2015-05-07 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna) |
| WO2015070050A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure |
| WO2015071474A2 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| WO2015126502A2 (en) | 2013-12-03 | 2015-08-27 | Northwestern University | Liposomal particles, methods of making same and uses thereof |
| US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
| CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
| EP3080266B1 (en) | 2013-12-12 | 2021-02-03 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| CN105814205B (en) | 2013-12-12 | 2019-11-19 | 阿尔尼拉姆医药品有限公司 | Complement component iRNA composition and its application method |
| JP6599334B2 (en) | 2013-12-20 | 2019-10-30 | ザ ジェネラル ホスピタル コーポレイション | Methods and assays for circulating tumor cells in the blood |
| US10450288B2 (en) | 2014-01-10 | 2019-10-22 | Glaxosmithkline Intellectual Property (No. 2) Limited | Hydroxy formamide derivatives and their use |
| DK3099799T3 (en) | 2014-01-28 | 2019-07-01 | Dice Molecules Sv Llc | ARRAYS OF MONOLITES WITH CONNECTED RECOMMENDATIONS |
| WO2015118407A2 (en) | 2014-01-29 | 2015-08-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms |
| WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
| WO2015120075A2 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
| WO2015118537A2 (en) | 2014-02-05 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
| EA201691587A1 (en) | 2014-02-11 | 2017-01-30 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS BASED ON iRNA FOR KETOGEXOKINASE (KHK) AND METHODS OF THEIR APPLICATION |
| WO2015153339A2 (en) | 2014-04-01 | 2015-10-08 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| DK3129493T3 (en) | 2014-04-09 | 2021-09-27 | Scripps Research Inst | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
| EP3140269B1 (en) | 2014-05-09 | 2023-11-29 | Yale University | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
| US11918695B2 (en) | 2014-05-09 | 2024-03-05 | Yale University | Topical formulation of hyperbranched polymer-coated particles |
| US9937270B2 (en) | 2014-05-12 | 2018-04-10 | The John Hopkins University | Engineering synthethic brain penetrating gene vectors |
| WO2015175545A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| TW201607559A (en) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | Methods and compositions for treating a SERPINC1-associated disorder |
| KR20220087576A (en) | 2014-05-22 | 2022-06-24 | 알닐람 파마슈티칼스 인코포레이티드 | Angiotensinogen (agt) irna compositions and methods of use thereof |
| WO2015187541A1 (en) | 2014-06-02 | 2015-12-10 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2015190922A1 (en) | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
| TW201620526A (en) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
| EP3161151A1 (en) | 2014-06-24 | 2017-05-03 | Abbott Molecular Inc. | Detection of single nucleotide polymorphisms in human kras |
| EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| HUE049261T2 (en) | 2014-07-15 | 2020-09-28 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Isolated polypeptides of cd44 and uses thereof |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| US9951327B1 (en) | 2014-07-17 | 2018-04-24 | Integrated Dna Technologies, Inc. | Efficient and rapid method for assembling and cloning double-stranded DNA fragments |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| RU2021123470A (en) | 2014-07-29 | 2021-09-06 | Монсанто Текнолоджи Ллс | COMPOSITIONS AND METHODS FOR COMBATING PESTS |
| AU2015298263B2 (en) | 2014-07-31 | 2020-05-14 | Anji Pharmaceuticals, Inc. | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
| US20170232109A1 (en) | 2014-08-19 | 2017-08-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
| WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| CA2959386A1 (en) | 2014-08-29 | 2016-03-03 | Lee Adam Wheeler | Methods and compositions for the treatment of cancer |
| PL3185957T3 (en) | 2014-08-29 | 2022-11-14 | Alnylam Pharmaceuticals, Inc. | Patisiran for use in treating transthyretin mediated amyloidosis |
| EP3189141B1 (en) | 2014-09-02 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antisense oligonucleotides targeting 3'utr region of a20 |
| SI3189074T1 (en) | 2014-09-05 | 2021-08-31 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| KR102617137B1 (en) | 2014-09-15 | 2023-12-27 | 칠드런'즈 메디컬 센터 코포레이션 | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
| US10556020B2 (en) | 2014-09-26 | 2020-02-11 | University Of Massachusetts | RNA-modulating agents |
| CA2961954A1 (en) | 2014-09-29 | 2016-04-07 | The Jackson Laboratory | High efficiency, high throughput generation of genetically modified mammals by electroporation |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
| EP3206751A4 (en) | 2014-10-14 | 2018-06-13 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| EP3212202B1 (en) | 2014-10-29 | 2020-05-06 | The Walter and Eliza Hall Institute of Medical Research | Mcl-1 inhibitors for use in treating diseases caused by pathological neovascularisation |
| EP3212794B1 (en) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| EP3221451A1 (en) | 2014-11-17 | 2017-09-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US10682422B2 (en) | 2014-11-18 | 2020-06-16 | Yale University | Formulations for targeted release of agents under low pH conditions and methods of use thereof |
| WO2016081621A1 (en) | 2014-11-18 | 2016-05-26 | Yale University | Formulations for targeted release of agents under low ph conditions and methods of use thereof |
| WO2016081808A1 (en) | 2014-11-20 | 2016-05-26 | The Regents Of The University Of California | Compositions and methods related to hematologic recovery |
| JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
| US10227661B2 (en) | 2014-11-21 | 2019-03-12 | GeneWeave Biosciences, Inc. | Sequence-specific detection and phenotype determination |
| JP6997623B2 (en) | 2014-12-12 | 2022-02-04 | エム． ウルフ、トッド | Compositions and Methods for Editing Intracellular Nucleic Acids Utilizing Oligonucleotides |
| US20170369872A1 (en) | 2014-12-18 | 2017-12-28 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| EP3247988A4 (en) | 2015-01-23 | 2018-12-19 | Vanderbilt University | A robust interferometer and methods of using same |
| US10421993B2 (en) | 2015-02-11 | 2019-09-24 | Paragon Genomics, Inc. | Methods and compositions for reducing non-specific amplification products |
| JP2018510621A (en) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof |
| EP3259346A4 (en) | 2015-02-20 | 2018-07-11 | Baylor College of Medicine | P63 inactivation for the treatment of heart failure |
| WO2016135559A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| US10781445B2 (en) | 2015-03-11 | 2020-09-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
| MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
| US20180064748A1 (en) | 2015-03-27 | 2018-03-08 | Yeda Research And Development Co. Ltd. | Methods of treating motor neuron diseases |
| EP3283502A4 (en) | 2015-04-07 | 2019-04-03 | The General Hospital Corporation | Methods for reactivating genes on the inactive x chromosome |
| US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
| CA2981960C (en) | 2015-04-08 | 2023-09-19 | The University Of Chicago | Compositions and methods for correcting limb girdle muscular dystrophy type 2c using exon skipping |
| US20180126014A1 (en) | 2015-04-15 | 2018-05-10 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
| AU2016252998B2 (en) | 2015-04-24 | 2021-11-04 | Atila Biosystems Incorporated | Amplification with primers of limited nucleotide composition |
| EP3291677A4 (en) | 2015-05-04 | 2019-02-13 | Monsanto Technology LLC | Compositions and methods for controlling arthropod parasite and pest infestations |
| CA2984512A1 (en) | 2015-05-06 | 2016-11-10 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
| EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| US10392607B2 (en) | 2015-06-03 | 2019-08-27 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| WO2016201301A1 (en) | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| EP3314250A4 (en) | 2015-06-26 | 2018-12-05 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| WO2017004243A1 (en) | 2015-06-29 | 2017-01-05 | Caris Science, Inc. | Therapeutic oligonucleotides |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| US11053495B2 (en) | 2015-07-17 | 2021-07-06 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| WO2017019918A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
| US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| WO2017023861A1 (en) | 2015-08-03 | 2017-02-09 | The Regents Of The University Of California | Compositions and methods for modulating abhd2 activity |
| WO2017021961A1 (en) | 2015-08-04 | 2017-02-09 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
| AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
| MX2018002090A (en) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof. |
| WO2017040078A1 (en) | 2015-09-02 | 2017-03-09 | Alnylam Pharmaceuticals, Inc. | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CA2998287A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
| JP2018535655A (en) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | ASGR inhibitor |
| JP2018530560A (en) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders |
| KR20180084782A (en) | 2015-10-14 | 2018-07-25 | 엑스-써마 인코포레이티드 | Compositions and methods for reducing ice crystal formation |
| WO2017066643A1 (en) | 2015-10-14 | 2017-04-20 | Bio-Path Holding, Inc. | P-ethoxy nucleic acids for liposomal formulation |
| JP2019507579A (en) | 2015-10-28 | 2019-03-22 | クリスパー セラピューティクス アーゲー | Materials and methods for the treatment of Duchenne muscular dystrophy |
| HUE054093T2 (en) | 2015-10-30 | 2021-08-30 | Hoffmann La Roche | Anti-htra1 antibodies and methods of use thereof |
| BR112018008971A2 (en) | 2015-11-06 | 2018-11-27 | Crispr Therapeutics Ag | Materials and Methods for Treatment of Type 1a Glycogen Storage Disease |
| WO2017081686A1 (en) | 2015-11-10 | 2017-05-18 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
| CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
| CA3005968A1 (en) | 2015-11-23 | 2017-06-01 | The Regents Of The University Of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
| WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
| WO2017099579A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
| US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
| CA3009308A1 (en) | 2015-12-23 | 2017-06-29 | Chad Albert COWAN | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
| JP7349788B2 (en) | 2016-01-06 | 2023-09-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Branch mixer and its use and manufacturing method |
| US10894985B2 (en) | 2016-01-12 | 2021-01-19 | Sitokine Limited | Methods for predicting response to treatment |
| JP2019501659A (en) | 2016-01-15 | 2019-01-24 | ザ ジャクソン ラボラトリー | Genetically modified non-human mammal by multi-cycle electroporation of CAS9 protein |
| WO2017132483A1 (en) | 2016-01-29 | 2017-08-03 | Vanderbilt University | Free-solution response function interferometry |
| US20190038771A1 (en) | 2016-02-02 | 2019-02-07 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| CA3019952A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
| WO2017143061A1 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions and methods for treatment of cystic fibrosis |
| US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| EP3416689B1 (en) | 2016-02-18 | 2023-01-18 | CRISPR Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| US11234996B2 (en) | 2016-02-25 | 2022-02-01 | The Brigham And Women's Hospital, Inc. | Treatment methods for fibrosis targeting SMOC2 |
| CN109072240A (en) | 2016-02-26 | 2018-12-21 | 耶鲁大学 | Use the composition and method of piRNA diagnosing and treating cancer |
| JP7025340B2 (en) | 2016-02-26 | 2022-02-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Multiplexed single molecule RNA visualization using a two-probe proximity ligation system |
| US11364258B2 (en) | 2016-03-04 | 2022-06-21 | Rhode Island Hospital | Methods for treating chondrosarcoma using microrna(miR) |
| WO2017158422A1 (en) | 2016-03-16 | 2017-09-21 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
| EP4339288A2 (en) | 2016-03-18 | 2024-03-20 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| JP2019512573A (en) | 2016-03-28 | 2019-05-16 | エーエーティー バイオクエスト インコーポレイテッド | Polyfluoreno [4,5-cde] oxepin conjugates and their use in analyte detection methods |
| EP3436049B1 (en) | 2016-03-31 | 2022-01-12 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
| WO2017173453A1 (en) | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
| KR102353847B1 (en) | 2016-04-14 | 2022-01-21 | 베니텍 바이오파마 리미티드 | Reagents for the treatment of oropharyngeal muscular dystrophy (OPMD) and uses thereof |
| KR102522059B1 (en) | 2016-04-18 | 2023-04-14 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene |
| US20200330609A1 (en) | 2016-04-18 | 2020-10-22 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| MA45295A (en) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM |
| KR102329187B1 (en) | 2016-04-29 | 2021-11-22 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | Oligonucleotide analogues targeting human LMNA |
| WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| CA3022319A1 (en) | 2016-05-06 | 2017-11-09 | Tod M. Woolf | Improved methods for genome editing with and without programmable nucleases |
| WO2017197128A1 (en) | 2016-05-11 | 2017-11-16 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
| AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
| EP3469083A1 (en) | 2016-06-10 | 2019-04-17 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
| EP4163396A1 (en) | 2016-06-15 | 2023-04-12 | Streck LLC | Assays and methods for determining microbial resistance |
| US10337051B2 (en) | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
| ES2929047T3 (en) | 2016-06-24 | 2022-11-24 | Scripps Research Inst | Novel nucleoside triphosphate transporter and uses thereof |
| US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
| US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
| CA3029119A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
| JP2019525742A (en) | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス， インコーポレイテッド | Exon skipping oligomer for muscular dystrophy |
| JP2019520079A (en) | 2016-07-06 | 2019-07-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Substances and methods for treating pain related disorders |
| CA3029132A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
| WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| WO2018017814A1 (en) | 2016-07-20 | 2018-01-25 | President And Fellows Of Harvard College | Peptidoglycan glycosyltransferase inhibitors of sed proteins for treating bacterial infections |
| KR20190031306A (en) | 2016-07-21 | 2019-03-25 | 맥스시티 인코포레이티드 | Methods and compositions for altering genomic DNA |
| WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
| JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
| NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| UY37376A (en) | 2016-08-26 | 2018-03-23 | Amgen Inc | ARNI CONSTRUCTIONS TO INHIBIT EXPRESSION OF ASGR1 AND METHODS FOR USE |
| CN109789216B (en) | 2016-08-29 | 2023-05-23 | 加利福尼亚大学董事会 | Topical skin treatment formulations based on ionic species |
| SG10201607303YA (en) | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| US11202818B2 (en) | 2016-09-14 | 2021-12-21 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| KR102468174B1 (en) | 2016-09-15 | 2022-11-17 | 에프. 호프만-라 로슈 아게 | How to perform multiplex PCR |
| KR20190053905A (en) | 2016-09-16 | 2019-05-20 | 바이오-패쓰 홀딩스 인크. | Combination therapy with liposomal antisense oligonucleotides |
| EP3519578B1 (en) | 2016-10-03 | 2021-12-22 | Precision Nanosystems Inc | Compositions for transfecting resistant cell types |
| SG10201609048RA (en) | 2016-10-28 | 2018-05-30 | Agency Science Tech & Res | Antisense oligonucleotides |
| US11459568B2 (en) | 2016-10-31 | 2022-10-04 | University Of Massachusetts | Targeting microRNA-101-3p in cancer therapy |
| TWI788312B (en) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
| AU2017378153B2 (en) | 2016-12-13 | 2024-03-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
| SG10201913552UA (en) | 2016-12-16 | 2020-03-30 | Alnylam Pharmaceuticals Inc | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
| WO2018112470A1 (en) | 2016-12-16 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes |
| BR112019012647A2 (en) | 2016-12-19 | 2019-11-19 | Sarepta Therapeutics Inc | exon jump oligomer conjugates for muscular dystrophy |
| AU2017382773A1 (en) | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2018118759A1 (en) | 2016-12-19 | 2018-06-28 | Ventana Medical Systems, Inc. | Peptide nucleic acid conjugates |
| WO2018118627A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| BR112019014282A2 (en) | 2017-01-10 | 2020-03-03 | Arrowhead Pharmaceuticals, Inc. | ANTITHRIPSIN RNAI AGENTS (AAT) ALPHA-1, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE |
| ES2874143T3 (en) | 2017-01-10 | 2021-11-04 | Paragon Genomics Inc | Methods and compositions to reduce redundant, molecular barcodes created in primer extension reactions |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US11197928B2 (en) | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
| MX2019008675A (en) | 2017-01-23 | 2019-09-18 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof. |
| WO2018154439A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
| US20200216857A1 (en) | 2017-02-22 | 2020-07-09 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| JP2020508056A (en) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ | Compositions and methods for gene editing |
| WO2018154459A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
| US20180284123A1 (en) | 2017-03-30 | 2018-10-04 | California Institute Of Technology | Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform |
| US20200113821A1 (en) | 2017-04-04 | 2020-04-16 | Yale University | Compositions and methods for in utero delivery |
| CA3059446A1 (en) | 2017-04-18 | 2018-10-25 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| JP2020517638A (en) | 2017-04-20 | 2020-06-18 | エータイアー ファーマ， インコーポレイテッド | Compositions and methods for treating lung inflammation |
| EP3612232A1 (en) | 2017-04-21 | 2020-02-26 | The Broad Institute, Inc. | Targeted delivery to beta cells |
| CA3062595A1 (en) | 2017-05-10 | 2018-11-15 | The Regents Of The University Of California | Directed editing of cellular rna via nuclear delivery of crispr/cas9 |
| JP7356354B2 (en) | 2017-05-12 | 2023-10-04 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Materials and methods for the manipulation of cells and their use in immuno-oncology |
| JP7325341B2 (en) | 2017-07-11 | 2023-08-14 | シンソークス，インク． | Incorporation of non-natural nucleotides and method thereof |
| AU2018301477A1 (en) | 2017-07-13 | 2020-02-27 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof |
| KR20200028997A (en) | 2017-07-13 | 2020-03-17 | 노오쓰웨스턴 유니버시티 | General and direct method of preparing oligonucleotide-functionalized metal-organic framework nanoparticles |
| NZ761430A (en) | 2017-08-03 | 2024-03-22 | Synthorx Inc | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| WO2019032827A1 (en) | 2017-08-09 | 2019-02-14 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| WO2019036225A1 (en) | 2017-08-17 | 2019-02-21 | Elitechgroup, Inc. | Duplex stabilizing fluorescence quenchers for nucleic acid probes |
| US11306312B2 (en) | 2017-09-01 | 2022-04-19 | Thomas Jefferson University | Compositions and methods for MYC messenger RNA inhibitors |
| MA50267A (en) | 2017-09-19 | 2020-07-29 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF TREATMENT OF TRANSTHYRETIN-MEDIA AMYLOSIS (TTR) |
| EA201991450A1 (en) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
| WO2019067981A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP2020536060A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | Combination therapy to treat muscular dystrophy |
| EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US20220080055A9 (en) | 2017-10-17 | 2022-03-17 | Crispr Therapeutics Ag | Compositions and methods for gene editing for hemophilia a |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| US20210180091A1 (en) | 2017-10-26 | 2021-06-17 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| WO2019089922A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| MA50579A (en) | 2017-11-09 | 2020-09-16 | Crispr Therapeutics Ag | AUTO-INACTIVATION (INS) CRISPR / CAS OR CRISPR / CPF1 SYSTEMS AND THEIR USES |
| US20200385719A1 (en) | 2017-11-16 | 2020-12-10 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| US10953036B2 (en) | 2017-11-20 | 2021-03-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods of modulating HIF-2A to improve muscle generation and repair |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| CA3082450A1 (en) | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| CN111629747A (en) | 2017-12-05 | 2020-09-04 | 沃泰克斯药物股份有限公司 | CRISPR-CAS9 modified CD34+ human pigment stem cells and progenitor cells and application thereof |
| AR113490A1 (en) | 2017-12-12 | 2020-05-06 | Amgen Inc | RNAi CONSTRUCTIONS TO INHIBIT THE EXPRESSION OF PNPLA3 AND METHODS OF USE OF THE SAME |
| CA3084825A1 (en) | 2017-12-14 | 2019-06-20 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
| US20200308588A1 (en) | 2017-12-18 | 2020-10-01 | Alnylam Pharmaceuticals, Inc. | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof |
| CN111491667A (en) | 2017-12-18 | 2020-08-04 | 文塔纳医疗系统公司 | Peptide nucleic acid conjugates |
| EP3728595A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| AU2018393050A1 (en) | 2017-12-21 | 2020-06-18 | Bayer Healthcare Llc | Materials and methods for treatment of Usher Syndrome Type 2A |
| WO2019139997A1 (en) | 2018-01-09 | 2019-07-18 | Trucode Gene Repair, Inc. | Polymer-based nanoparticles, related formulation methods, and apparatus |
| CA3088180A1 (en) | 2018-01-12 | 2019-07-18 | Crispr Therapeutics Ag | Compositions and methods for gene editing by targeting transferrin |
| WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| EP3749767A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| US11268077B2 (en) | 2018-02-05 | 2022-03-08 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
| MA51869A (en) | 2018-02-16 | 2020-12-23 | Bayer Healthcare Llc | COMPOSITIONS AND METHODS FOR TARGETING GENE EDITING OF FIBRINOGEN-ALPHA |
| JP2021514974A (en) | 2018-02-26 | 2021-06-17 | シンソークス， インコーポレイテッド | IL-15 conjugate and its use |
| AU2019239957A1 (en) | 2018-03-19 | 2020-09-10 | Bayer Healthcare Llc | Novel RNA-programmable endonuclease systems and uses thereof |
| EP4051799A2 (en) | 2018-03-30 | 2022-09-07 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers for targeted activaton of t cell-mediated immunity |
| US20210155959A1 (en) | 2018-04-06 | 2021-05-27 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
| WO2019204668A1 (en) | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
| TW202016304A (en) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | Angiotensinogen (agt) irna compositions and methods of use thereof |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| US11155713B2 (en) | 2018-05-29 | 2021-10-26 | Elitechgroup, Inc. | Carborhodamine compounds and methods of preparation thereof |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| TW202020153A (en) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | Exon skipping oligomers for muscular dystrophy |
| WO2020028133A1 (en) | 2018-07-30 | 2020-02-06 | Trucode Gene Repair, Inc. | Lipid nanoparticle formulations comprising nucleic acid mimics |
| WO2020028729A1 (en) | 2018-08-01 | 2020-02-06 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
| US11939593B2 (en) | 2018-08-01 | 2024-03-26 | University Of Georgia Research Foundation, Inc. | Compositions and methods for improving embryo development |
| US20210189431A1 (en) | 2018-08-10 | 2021-06-24 | Yale University | Compositions and methods for embryonic gene editing in vitro |
| JP2021533767A (en) | 2018-08-13 | 2021-12-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA substance composition and its usage |
| US20210348162A1 (en) | 2018-08-16 | 2021-11-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| CN112912502A (en) | 2018-08-31 | 2021-06-04 | 耶鲁大学 | Compositions and methods for enhancing triplex and nuclease-based gene editing |
| US11273137B2 (en) | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
| AU2019340388A1 (en) | 2018-09-11 | 2021-03-18 | Amgen Inc. | Purification methods for guanine-rich oligonucleotides |
| CN112912422A (en) | 2018-09-14 | 2021-06-04 | 西北大学 | Programming protein polymerization with DNA |
| CN112424355A (en) | 2018-09-18 | 2021-02-26 | 阿尔尼拉姆医药品有限公司 | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| JP2022505173A (en) | 2018-10-17 | 2022-01-14 | クリスパー・セラピューティクス・アクチェンゲゼルシャフト | Compositions and Methods for Delivering Transgenes |
| US20210395721A1 (en) | 2018-10-24 | 2021-12-23 | Codiak Biosciences, Inc. | Methods to improve potency of electroporation |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| WO2020112195A1 (en) | 2018-11-30 | 2020-06-04 | Yale University | Compositions, technologies and methods of using plerixafor to enhance gene editing |
| US20210332495A1 (en) | 2018-12-06 | 2021-10-28 | Northwestern University | Protein Crystal Engineering Through DNA Hybridization Interactions |
| EA202191630A1 (en) | 2018-12-10 | 2021-11-29 | Эмджен Инк. | CHEMICALLY MODIFIED CONSTRUCTIONS FOR RNAi AND WAYS OF THEIR APPLICATION |
| US20220017906A1 (en) | 2018-12-10 | 2022-01-20 | Amgen Inc. | Rnai constructs for inhibiting pnpla3 expression and methods of use thereof |
| KR20210104759A (en) | 2018-12-13 | 2021-08-25 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Exon skipping oligomer conjugates for muscular dystrophy |
| CN113631709A (en) | 2018-12-20 | 2021-11-09 | 普拉克西斯精密药物股份有限公司 | Compositions and methods for treating KCNT 1-related disorders |
| CN113543791A (en) | 2018-12-20 | 2021-10-22 | 维尔生物科技有限公司 | Combination HBV therapy |
| EP3899035A1 (en) | 2018-12-20 | 2021-10-27 | F. Hoffmann-La Roche AG | Detection of target nucleic acid by solid-phase molography |
| EP3931313A2 (en) | 2019-01-04 | 2022-01-05 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
| SG11202107669WA (en) | 2019-01-16 | 2021-08-30 | Genzyme Corp | Serpinc1 irna compositions and methods of use thereof |
| BR112021014415A2 (en) | 2019-02-06 | 2021-09-21 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USING THEM |
| WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
| EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
| MX2021010559A (en) | 2019-03-07 | 2021-12-15 | Univ California | Crispr-cas effector polypeptides and methods of use thereof. |
| JP2022523779A (en) | 2019-03-12 | 2022-04-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Methods and compositions for treating cancer |
| US20220145274A1 (en) | 2019-03-12 | 2022-05-12 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
| WO2020214763A1 (en) | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
| SG11202112240VA (en) | 2019-05-13 | 2021-12-30 | Vir Biotechnology Inc | Compositions and methods for treating hepatitis b virus (hbv) infection |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| KR20220016138A (en) | 2019-05-30 | 2022-02-08 | 암젠 인크 | RNAI constructs for inhibiting SCAP expression and methods of use thereof |
| CA3140112A1 (en) | 2019-05-31 | 2020-12-03 | Streck, Inc. | Detection of antibiotic resistance genes |
| US20220249660A1 (en) | 2019-06-06 | 2022-08-11 | Sitokine Limited | Compositions and methods for treating lung, colorectal and breast cancer |
| WO2020252257A1 (en) | 2019-06-12 | 2020-12-17 | President And Fellows Of Harvard College | Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism |
| TW202113078A (en) | 2019-06-14 | 2021-04-01 | 美商史基普研究協會 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
| EP3986456A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| JP2022536945A (en) | 2019-06-18 | 2022-08-22 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | Combination of hepatitis B virus (HBV) vaccine and RNAi targeting HBV |
| WO2020257779A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof |
| WO2020257776A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof |
| EP3990465A1 (en) | 2019-06-25 | 2022-05-04 | Amgen Inc. | Purification methods for carbohydrate-linked oligonucleotides |
| CN114096683A (en) | 2019-07-03 | 2022-02-25 | 简·探针公司 | Oligonucleotides for determining the presence of Trichomonas vaginalis in a sample |
| WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
| WO2021022161A1 (en) | 2019-07-31 | 2021-02-04 | Yale University | Compositions and methods for treating sickle cell disease |
| WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021028469A1 (en) | 2019-08-12 | 2021-02-18 | Sitokine Limited | Compositions and methods for treating cytokine release syndrome and neurotoxicity |
| JP2022544238A (en) | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | RNAi constructs for inhibiting SLC30A8 expression and methods of use thereof |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| MX2022001776A (en) | 2019-08-15 | 2022-03-17 | Synthorx Inc | Immuno oncology combination therapies with il-2 conjugates. |
| MX2022002053A (en) | 2019-08-23 | 2022-03-17 | Synthorx Inc | Il-15 conjugates and uses thereof. |
| CA3149421A1 (en) | 2019-08-30 | 2021-03-04 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| CN114616331A (en) | 2019-09-03 | 2022-06-10 | 阿尔尼拉姆医药品有限公司 | Compositions and methods for inhibiting expression of LECT2 gene |
| US20210070827A1 (en) | 2019-09-10 | 2021-03-11 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
| CN115176004A (en) | 2019-10-22 | 2022-10-11 | 阿尔尼拉姆医药品有限公司 | Complement component C3 iRNA compositions and methods of use thereof |
| US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| AR120341A1 (en) | 2019-11-01 | 2022-02-09 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE |
| TW202131952A (en) | 2019-11-04 | 2021-09-01 | 美商欣爍克斯公司 | Interleukin 10 conjugates and uses thereof |
| BR112022009216A2 (en) | 2019-11-13 | 2022-08-02 | Alnylam Pharmaceuticals Inc | METHODS AND COMPOSITIONS TO TREAT AN ANGIOTENSINOGEN-ASSOCIATED DISORDER (AGT) |
| EP4061943A1 (en) | 2019-11-19 | 2022-09-28 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Antisense oligonucleotides and their use for the treatment of cancer |
| US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
| CA3159501A1 (en) | 2019-11-27 | 2021-06-03 | Brian Joseph CAFFERTY | Methods of synthesizing rna molecules |
| EP4073252A1 (en) | 2019-12-09 | 2022-10-19 | Amgen Inc. | Rnai constructs and methods for inhibiting lpa expression |
| BR112022011417A2 (en) | 2019-12-13 | 2022-08-30 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF THE IRNA AGENT OF THE OPEN READING PHASE 72 OF HUMAN CHROMOSOME 9 (C9ORF72) AND METHODS OF USE THEREOF |
| TW202138559A (en) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2021122944A1 (en) | 2019-12-18 | 2021-06-24 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
| WO2021154705A1 (en) | 2020-01-27 | 2021-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
| WO2021154933A1 (en) | 2020-01-30 | 2021-08-05 | Aat Bioquest, Inc. | Uv excitable polyfluorene based conjugates and their use in methods of analyte detection |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| KR20220140593A (en) | 2020-02-10 | 2022-10-18 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for silencing VEGF-A expression |
| IL295496A (en) | 2020-02-18 | 2022-10-01 | Alnylam Pharmaceuticals Inc | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| US11965161B2 (en) | 2020-03-04 | 2024-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
| WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| AU2021232014A1 (en) | 2020-03-06 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) IRNA compositions and methods of use thereof |
| WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| MX2022011801A (en) | 2020-03-23 | 2022-10-07 | Amgen Inc | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof. |
| JP2023519274A (en) | 2020-03-26 | 2023-05-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | CORONAVIRUS iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230190785A1 (en) | 2020-03-30 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| US20230295622A1 (en) | 2020-04-06 | 2023-09-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
| WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
| JP2023521094A (en) | 2020-04-07 | 2023-05-23 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Compositions and methods for silencing SCN9A expression |
| WO2021205013A1 (en) | 2020-04-09 | 2021-10-14 | Sitokine Limited | Compositions and methods for treating covid-19 |
| JP2023523993A (en) | 2020-04-27 | 2023-06-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Apolipoprotein E (ApoE) iRNA agent compositions and methods of use thereof |
| CN116096381A (en) | 2020-04-30 | 2023-05-09 | 阿尔尼拉姆医药品有限公司 | Complement Factor B (CFB) iRNA compositions and methods of use thereof |
| EP4150086A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
| EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
| WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
| WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
| WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
| EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
| US10941453B1 (en) | 2020-05-20 | 2021-03-09 | Paragon Genomics, Inc. | High throughput detection of pathogen RNA in clinical specimens |
| EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| EP4157264A1 (en) | 2020-05-27 | 2023-04-05 | The Regents of the University of California | Compositions and methods for transdifferentiating cells |
| JP2023528608A (en) | 2020-06-01 | 2023-07-05 | アムジエン・インコーポレーテツド | RNAi constructs for inhibiting HSD17B13 expression and methods of use thereof |
| US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| JP2023530234A (en) | 2020-06-05 | 2023-07-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | Compositions and methods for treating neoplasms |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| CA3184289A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| US20230233693A1 (en) | 2020-06-19 | 2023-07-27 | Yale University | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
| CA3182458A1 (en) | 2020-06-24 | 2021-12-30 | Laura ROSEN | Engineered hepatitis b virus neutralizing antibodies and uses thereof |
| KR20230027235A (en) | 2020-06-25 | 2023-02-27 | 신톡스, 인크. | Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies |
| US20230235315A1 (en) | 2020-07-10 | 2023-07-27 | Horizon Discovery Limited | Method for producing genetically modified cells |
| JP2023540429A (en) | 2020-07-10 | 2023-09-25 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Methods and compositions for treating epilepsy |
| IL300360A (en) | 2020-08-13 | 2023-04-01 | Amgen Inc | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION |
| EP4204002A1 (en) | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
| WO2022056454A2 (en) | 2020-09-14 | 2022-03-17 | President And Fellows Of Harvard College | Methods and compositions for treating hpv-positive cancers |
| US20230340124A1 (en) | 2020-09-16 | 2023-10-26 | President And Fellows Of Harvard College | Methods of treating an individual that has failed an anti-pd-1/anti-pd-l1 therapy |
| TW202227102A (en) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | Method of treating fatty liver disease |
| EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| US20230392134A1 (en) | 2020-09-30 | 2023-12-07 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis |
| WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| AU2021356610A1 (en) | 2020-10-09 | 2023-06-15 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
| MX2023004029A (en) | 2020-10-09 | 2023-04-27 | Synthorx Inc | Immuno oncology combination therapy with il-2 conjugates and pembrolizumab. |
| EP4228637A1 (en) | 2020-10-15 | 2023-08-23 | Yeda Research and Development Co. Ltd | Method of treating myeloid malignancies |
| AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| IL302330A (en) | 2020-11-05 | 2023-06-01 | Amgen Inc | METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS |
| IL302709A (en) | 2020-11-13 | 2023-07-01 | Alnylam Pharmaceuticals Inc | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CA3201452A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| EP4267764A1 (en) | 2020-12-22 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for performing multiplexed real-time pcr with the use of large stokes shift fluorescent dyes |
| WO2022140702A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
| WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022174102A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
| WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| WO2022174101A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
| WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
| AU2022226098A1 (en) | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| IL305418A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
| WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| WO2022192038A1 (en) | 2021-03-12 | 2022-09-15 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
| AR125230A1 (en) | 2021-03-29 | 2023-06-28 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE |
| EP4314293A1 (en) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
| EP4330392A1 (en) | 2021-04-26 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
| WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| WO2022235537A1 (en) | 2021-05-03 | 2022-11-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
| WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
| EP4341405A1 (en) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
| WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
| TW202317762A (en) | 2021-06-02 | 2023-05-01 | 美商艾拉倫製藥股份有限公司 | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2022256538A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab |
| IL308743A (en) | 2021-06-04 | 2024-01-01 | Alnylam Pharmaceuticals Inc | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| AR126070A1 (en) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) |
| EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
| IL308896A (en) | 2021-06-11 | 2024-01-01 | Bayer Ag | Type v rna programmable endonuclease systems |
| WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
| US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
| KR20240026203A (en) | 2021-06-30 | 2024-02-27 | 알닐람 파마슈티칼스 인코포레이티드 | Methods and compositions for treating angiotensinogen (AGT)-related disorders |
| WO2023285431A1 (en) | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
| TW202333748A (en) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| IL309905A (en) | 2021-07-23 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
| WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
| WO2023014677A1 (en) | 2021-08-03 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
| TW202337474A (en) | 2021-08-04 | 2023-10-01 | 美商艾拉倫製藥股份有限公司 | Irna compositions and methods for silencing angiotensinogen (agt) |
| TW202334413A (en) | 2021-08-13 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Factor xii (f12) irna compositions and methods of use thereof |
| EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
| WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
| WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
| CA3233242A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023055879A1 (en) | 2021-09-30 | 2023-04-06 | Amgen Inc. | Methods for separating molecular species of guanine-rich oligonucleotides |
| WO2023059629A1 (en) | 2021-10-05 | 2023-04-13 | Amgen Inc. | Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| AU2022370883A1 (en) | 2021-10-22 | 2024-04-18 | Amgen Inc. | Rnai constructs for inhibiting gpam expression and methods of use thereof |
| CA3234835A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| TW202333749A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Complement factor b (cfb) irna compositions and methods of use thereof |
| WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2023091704A1 (en) | 2021-11-18 | 2023-05-25 | Circularis Biotechnologies, Inc. | Compositions and methods for production of circular nucleic acid molecules |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| WO2023118349A1 (en) | 2021-12-21 | 2023-06-29 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
| WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| WO2023150181A1 (en) | 2022-02-01 | 2023-08-10 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2023159189A1 (en) | 2022-02-18 | 2023-08-24 | Yale University | Branched poly(amine-co-ester) polymers for more efficient nucleic expression |
| WO2023164631A1 (en) | 2022-02-25 | 2023-08-31 | Amgen Inc. | Methods of preparing high concentration liquid drug substances |
| WO2023194359A1 (en) | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
| US11680293B1 (en) | 2022-04-21 | 2023-06-20 | Paragon Genomics, Inc. | Methods and compositions for amplifying DNA and generating DNA sequencing results from target-enriched DNA molecules |
| WO2023233290A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Sciences Ireland Unlimited Company | Rnai agents targeting pd-l1 |
| WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
| WO2024002924A2 (en) | 2022-06-28 | 2024-01-04 | F. Hoffmann-La Roche Ag | Fluorescent dyes with large stokes shift |
| WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
| WO2024026258A2 (en) | 2022-07-25 | 2024-02-01 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
| WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| EP4311579A1 (en) | 2022-07-29 | 2024-01-31 | Association Française contre les Myopathies | B cell-specific mab-sirna conjugates improve myasthenia |
| WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
| WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
| WO2024056880A2 (en) | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | Enqp type ii cas proteins and applications thereof |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0215942B1 (en) * | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US5134066A (en) * | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| DK51092D0 (en) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
| MX9207334A (en) * | 1991-12-18 | 1993-08-01 | Glaxo Inc | NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM |
| DE4331012A1 (en) * | 1993-09-13 | 1995-03-16 | Bayer Ag | Nucleic acid-binding oligomers with N-branching for therapy and diagnostics |
-
1993
- 1993-04-26 US US08/054,363 patent/US5539082A/en not_active Expired - Lifetime
-
1994
- 1994-04-25 JP JP52408494A patent/JP3210672B2/en not_active Expired - Lifetime
- 1994-04-25 AU AU67604/94A patent/AU680253B2/en not_active Ceased
- 1994-04-25 WO PCT/IB1994/000142 patent/WO1994025477A2/en not_active Application Discontinuation
- 1994-04-25 KR KR1019950704643A patent/KR100195290B1/en not_active IP Right Cessation
- 1994-04-25 EP EP94915682A patent/EP0699208A1/en not_active Ceased
- 1994-04-25 EP EP03075412A patent/EP1310507A3/en not_active Withdrawn
- 1994-04-25 CA CA002161230A patent/CA2161230A1/en not_active Abandoned
-
1996
- 1996-02-01 US US08/595,387 patent/US5773571A/en not_active Expired - Fee Related
-
1998
- 1998-12-01 JP JP34158298A patent/JP3273135B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU6760494A (en) | 1994-11-21 |
| EP1310507A2 (en) | 2003-05-14 |
| JPH10501121A (en) | 1998-02-03 |
| WO1994025477A2 (en) | 1994-11-10 |
| US5773571A (en) | 1998-06-30 |
| JP3273135B2 (en) | 2002-04-08 |
| KR100195290B1 (en) | 1999-06-15 |
| JP3210672B2 (en) | 2001-09-17 |
| EP0699208A1 (en) | 1996-03-06 |
| US5539082A (en) | 1996-07-23 |
| KR960701888A (en) | 1996-03-28 |
| WO1994025477A3 (en) | 1994-12-22 |
| JPH11310593A (en) | 1999-11-09 |
| AU680253B2 (en) | 1997-07-24 |
| EP1310507A3 (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5773571A (en) | Peptide nucleic acids | |
| US5986053A (en) | Peptide nucleic acids complexes of two peptide nucleic acid strands and one nucleic acid strand | |
| EP0773950B1 (en) | Linked peptide nucleic acids | |
| US20030207804A1 (en) | Modified peptide nucleic acids | |
| US6441130B1 (en) | Linked peptide nucleic acids | |
| US7550582B2 (en) | Polyamide nucleic acid derivatives and agents, and processes for preparing them | |
| AU2001246536B2 (en) | Polyamide nucleic acid derivatives, agents and methods for producing the same | |
| US6770738B1 (en) | Higher order structure and binding of peptide nucleic acids | |
| US6872809B2 (en) | Nucleoside derivatives | |
| US20030105286A1 (en) | Linked peptide nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |